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ABSTRACT
Atherosclerotic cardiovascular disease is the principle cause of mortality in man in Western
society. Endothelial dysfunction caused by reactive oxidant species favours atherogenesis. The
trace element selenium is thought to contribute to the prevention of such damage through the
expression of intracellular or extracellular selenoproteins. Whilst the glutathione peroxidases
may have an antioxidant role in the endothelium, other selenoproteins may also be important.
In this thesis the selenoproteins expressed by endothelial cells (isolated from various vascular
beds and different species) and the modification of their expression through changes in
selenium supply and activation of second messenger pathways were studied. The ability of
sodium selenite and selenomethionine supplementation to prevent oxidative damage in cultured
endothelial cells was also examined.
The present study has confirmed the expression of cytoplasmic glutathione peroxidase (cyGPX)
and phospholipid hydroperoxide glutathione peroxidase (PHGPX) in human umbilical vein
endothelial cells (HUVEC). However, thioredoxin reductase (TR) was found to be the
predominant selenoprotein expressed, accounting for approximately 43% of the total intracellular
[75Se]-labelled proteins. No extracellular selenoproteins were synthesised by HUVEC.
The overall pattern of selenoprotein expression in endothelial cells isolated from different
species and from various human tissues showed considerable variation, though differences
were less pronounced when comparing the endothelial cells isolated from various human
vascular beds and the human endothelial cell line EAhy926. For example, human coronary
arterial endothelial cells which provide an ideal model to study atherosclerosis have a very
similar selenoprotein profile to that of HUVEC.
The expression of TR, cyGPX and PHGPX and other unidentified selenoproteins in HUVEC was
modified in response to the phorbol ester, phorbol-12-myristate 13-acetate (PMA). A 48 hr
incubation with PMA significantly decreased expression of both TR and PHGPX to
approximately half of that found in untreated cells. The expression of cyGPX was increased
approximately two-fold by PMA treatment. A brief exposure to PMA (one minute) produced
similar effects on the expression of these selenoproteins after a 48 hr lag-period. These effects
of PMA could be attenuated by the protein kinase C inhibitor, GF109203X. The calcium
ionophore A23187 also modified selenoprotein expression, in particular increasing the
expression of TR. However, these effects were only apparent after a 60 minute exposure,
becoming maximal after 35 hr, after which time cells began to detach. These observations
suggest that the A23187 effect may result from toxicity rather than activation of the calcium
signalling pathway. Endothelial cells isolated from the human coronary artery responded to PMA
in a similar manner to HUVEC. In contrast, bovine aortic endothelial cells showed no observable
changes in selenoprotein expression in the presence of PMA.
HUVEC grown in selenium-deficient culture medium and then supplemented with sodium
selenite for 48 hr were less susceptible to oxidative damage from tert-butylhydroperoxide (t-
BuOOH) compared to cells not supplemented with sodium selenite or cells in which sodium
selenite was introduced at the same time as t-BuOOH. It was also observed that sodium selenite
increased TR mass and TR, cyGPX and PHGPX activity at concentrations which protected
HUVEC from damage by t-BuOOH. These results are consistent with the protective effect of
selenium being due to the modification of selenoprotein expression and activity rather than a
direct effect of sodium selenite. Selenomethionine was much less potent than sodium selenite at
inducing protection from oxidative damage.
In conclusion, human endothelial cells express very high levels of TR, a selenoprotein whose
expression can be modified by selenium supply, PKC activation and oxidative stress. Since TR,
under certain circumstances is more potent than GPX's at detoxifying harmful peroxides, TR
maybe an important factor in the ability of selenium to protect endothelial cells from oxidative
damage, thereby limiting the development of atherosclerosis.
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Atherosclerosis (Gr. "porridge-like hardening") is a highly complex vascular disease process
which has been described as the principle cause of the pathogenesis of myocardial and cerebral
infarction, gangrene and loss of function of the extremities (Ross, 1993a). It is the leading cause
of morbidity and mortality in the United States, Europe, and much of Asia (Ross, 1999).
Extensive research over the past 20 years has aimed to elucidate the cellular and molecular
mechanisms involved in the formation, development and progression of the atheromatous lesion
with resultant clinical sequelae in order to establish therapeutic agents for the prevention and
treatment of atherosclerosis. Whilst a number of concepts prove controversial and many details
have not been clarified the mechanisms involved in the development of the atheromatous lesion
have been outlined.
1.1.2 'Response to injury' hypothesis
The most widely accepted model of atherogenesis is derived from the 'response-to-injury'
hypothesis which was originally formulated by Ross et at. (Ross and Glomset, 1973) and has
since been substantially tested and modified (Ross, 1993a; Ross, 1993b). The theory proposes
that injury to the endothelium (for example, by local disturbances of blood flow at certain branch
points of the arterial tree) coupled with major risk factors such as hypercholesterolemia,
hypertension, cigarette smoking, and microbal infections can provoke a protective, inflammatory-
fibroproliferative response. In excess this response results in a series of compensatory cellular
and molecular events leading to the formation and development of the atherosclerotic lesion.
This response is the result of multiple interactions of three different circulatory components-




1.1.3 The lesions of atherosclerosis
The lesions of atherosclerosis are principally found in large and medium-sized elastic and
muscular arteries such as the femoral artery, cerebral arteries, aorta and coronary arteries.
Lesions rarely occur in fine vessels (arterioles and capillaries) although the pathophysiological
consequences of atherosclerosis have been demonstrated in the human coronary
microcirculation (Zeiher eta/., 1991). In addition to the different theories concerning the etiology
of atherosclerosis different forms of classification of atherosclerotic lesions exist. The more
classical nomenclature of atherosclerosis; that is the fatty streak, intermediate lesion and fibrous
plaque (Ross, 1995) has been superseded by 'Stary's classification' (Yutani et al., 1999). The
'Stary classification' is a universally accepted classification which embraces the more recent
morphological and biochemical details of the processes involved in atherosclerosis.
a) Classical nomenclature
Under the classical nomenclature atherosclerotic lesions were arbitrarily divided into three
categories (Table 1.01). The initial lesion is the fatty streak which is characterized by the
presence of lipid laden foam cells together with T-lymphocytes in the arterial intima. In this early
stage of atherosclerosis there is an absence of gross morphological change within the vessel
wall. McGill et al. by 'mapping' lesions at different stages of development were able to
demonstrate that not all fatty streak lesions will progress to fibrous plaques (McGill, 1984). It
appears that within time some fatty streaks will develop into more advanced lesions whilst others
stabilise or alternatively regress. In the event of their progression, the inflammatory response
stimulates the proliferation and migration of smooth muscle cells into the area of inflammation
which, together with macrophages, form the intermediate lesion. This can progress to thickening
of the arterial wall which is compensated for by a gradual dilation referred to as 'remodelling' with
little effect on the lumen diameter (Ross, 1999). These lesions can develop into the fibrous
plaque referred to as a 'complicated' or 'advanced' lesion. At some point the artery can no longer
compensate by dilation, and remodelling leads to the occlusion of the artery. The fibrous
2
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comprises lipid laden macrophages
(foam cells) and T-lymphocytes
comprises lipid-filled macrophages
and T-lymphocytes
smooth muscle ceil migration into the
area of inflammation and smooth
muscle cell proliferation
comprises the fibrous cap (smooth
muscle cells and connective tissue)
and necrotic core (smooth muscle
cells, macrophages associated with
lipid and necrotic material)
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plaque consists of a fibrous cap made up of smooth muscle cells and dense connective tissue,
an underlying cellular layer, and a deeper necrotic core which comprises a mixture of
leukocytes, lipid and debris. Calcification, necrosis, haemorrhage, ulceration or thrombosis can
complicate the lesion further, producing the clinical manifestations of atherosclerosis sometimes
with fatal clinical consequences (Fuster et al., 1992). Each stage of atherosclerosis can
potentially be reversed either by removal of the injurious agent or by treatment of the
inflammatory and fibroproliferative processes (Ross, 1993a).
b) Stary's classification
Stary's classification characterises atherosclerotic lesions by categorising the process of lesion
progression into five phases each being defined by its histological characteristics (table 1.02)
(Stary et at., 1995). Briefly, the initial type I lesion consists of macrophage-derived foam cells
containing lipid droplets. The location of these and subsequent lesions is more evident in
locations such as branches, bifurcations and curvatures which are subject to alterations in blood
flow (Ross, 1999). These so-called 'adaptive thickenings' do not cause substantial
morphological alteration and are present at constant locations in everyone from birth. Type II
lesions (formerly designated 'fatty streaks') consist of layers of macrophage foam cells and
smooth muscle cells with intracellular lipid droplets. The type III lesion represents an
intermediate stage between the type II and type IV lesion. In addition to the lipid-laden cells
pertaining to the type II lesion diffuse collections of extracellular lipid pools occur which serve as
the immediate precursor to the core of extracellular lipid that characterises the type IV lesion.
Further lesion progression occurs generally around the fourth decade of life. The lipid core may
now also contain thick layers of fibrous connective tissue (type V lesion) and have the potential
to rupture. Surface defects, hematoma and thrombotic deposits are also evident (type VI lesion).
When type V lesions are largely calcified they are classified as typeVb whilst those which consist
mainly of fibrous connective tissue with little or no accumulated lipid or calcium are referred to as
4
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Table 1.02. Starys classification of atherosclerotic lesions. The flow diagram indicates the
progression of human atherosclerotic lesions. The Roman numerals represent the different
classification of lesion as defined in the left hand column and the direction of the arrows indicate






type I (initial lesion)
isolated macrophage
foam cells
type II (fatty streak lesion)
mainly intracellular
lipid accumulation
type III (intermediate) lesion
type II changes & small
extracellular lipid pools
type IV (atheroma) lesion
type II changes & core
of extracellular lipid
type V (fibroatheroma) lesion
lipid core & fibrotic layer, or
multiple lipid cores & fibrotic
layers, or mainly calcific, or
mainly fibrotic









type Vc lesions. Figure 1.01 illustrates the characteristic features that may occur at a constant
arterial location.
1.1.4 The cellular interactions of atherosclerosis
During the process of atherogenesis a complex series of interactions between different cells,
growth factors, cytokines, and other small molecules occur. Perhaps one of the earliest events in
atherogenesis is a change in the endothelial surface phenotype. At specific arterial sites the
expression of molecules on the endothelium, responsible for the adherence, accumulation and
migration of monocytes and T-lymphocytes, markedly increases. Adhesion molecules include
selectins (e.g. L- E- and P-selectin), intracellular adhesion molecules (e.g. intracellular adhesion
molecule-1 (ICAM-1)) and vascular-cell adhesion molecules (e.g. vascular cell adhesion
molecule-1 (VCAM-1)) (Gimbrone, 1995; Ross, 1999). The expression of some vascular
adhesion molecules such as ICAM-1 is in response to shear stress (Ross, 1999). The
endothelial adhesion molecules act as receptors for glyconjugates and integrins present on
monocytes and T-lymphocytes allowing the adherence of these leukocytes to the endothelial
surface. An increase in permeability in the endothelium follows, mediated by oxidised low density
lipoprotein (oxLDL), monocyte chemotactic protein-1 (MCP-1), interleukin-8, platelet derived
growth factor (PDGF), macrophage-colony stimulating factor (M-CSF) and osteopontin which
aids the transmigration of these inflammatory cells into the sub-endothelial intima by penetrating
the endothelial junctions. These factors work in conjunction with chemoattractant properties of
molecules such as MCP-1, oxLDL and osteopontin, which are synthesised by the endothelium,
smooth muscle and monocytes and attract leukocytes to the arterial wall.
The presence of macrophages and T lymphocytes in the intima may alter the gene expression of
several growth-regulatory molecules and cytokines which can potentially activate the
endothelium, smooth muscle and other components of the developing lesion. Fatty streak
6
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Figure 1.01. Schematic representation of cross-sections of identical, most proximal
part of six left anterior descending arteries showing the sequence of atherosclerotic
lesion types according to Starys classification. Identical morphologies may be found on




formation involves the migration of smooth muscle cells into the intima, mediated by PDGF,
fibroblast growth factor-2 (FGF-2) and transforming growth factor (3 (TGF[3). T lymphocyte
activation is stimulated by tumor necrosis factor alpha (TNFa), interleukin-2 (IL-2), granulocyte
macrophage-colony stimulating factor (GM-CSF) whilst foam cells develop through the action of
oxLDL, M-CSF, TNFa, and IL-2. Platelet adherence and aggregation is also a feature of the fatty
streak and is mediated by integrins, P-selectin, fibrin, thromboxane A2, tissue factor and the
factors which mediate leukocyte adherence and migration. Platelets adhere to the endothelium,
exposed collagen and macrophages where upon activation they release their granules
containing cytokines, growth factors and thrombin, all of which can mediate smooth muscle cell
and monocyte proliferation and migration.
The development of the fatty streak into more advanced complicated lesions of atherosclerosis
involves the formation of a fibrous plaque which forms as a result of the increase in PDGF,
TGF(3, IL-1, TNFa and osteopontin and a decrease in connective tissue degradation. Evidence
suggests that the smooth muscle cells present in the lesion have changed from a contractile
phenotype which responds to nitric oxide (NO) and prostacyclin (PGI2) to a synthetic phenotype
which responds in an autocrine manner to PDGF as well as other factors to enhance
proliferation and release extracellular matrix which progresses the lesion into a fibrous plaque.
The continued entry of macrophages mediated by M-CSF, MCP-1 and oxLDL causes the fibrous




1.2.1 Structure and function
Arterial vessels display a layered structure of tissues and cells (figure 1.02). The outermost layer
(tunica adventitia) comprises connective tissue rich in elastic and collagen fibres whilst the
middle layer (tunica media) consists of connective tissue and smooth muscle cells. Adjacent to
the lumen is the tunica intima consisting of lamina propria and a basement membrane upon
which lies the endothelium.
The vascular endothelium is a continuous monolayer of cells of mesoblastic origin that lines the
inner surface of all blood vessels providing a barrier between blood and the underlying vessel.
Once regarded as a quiescent layer of cells, research since the late 1970s has identified the
endothelium as a highly dynamic organ with numerous endocrine, paracrine and autocrine
functions. Resulting from its strategic positioning at the interface between the blood and tunica
intima the endothelium has a vital role in the maintenance of vascular homeostasis. It is involved
in the regulation of vascular tone, and growth as well as modulating inflammation and
coagulation. The principal functions of the endothelium are listed in table 1.03.
1.2.2 Endothelium-derived factors
The endothelium synthesises several factors including; nitric oxide (NO) (alternatively referred to
as endothelium-derived relaxing factor), prostacyclin (PGI2), endothelium-derived
hyperpolarizing factor (EDHF), endothelin-1, thromboxane A2 (TXA2), superoxide anion (02") and
possibly prostaglandin H2 (PGH2). These factors modulate the functions of adjacent cells
including smooth muscle cells and platelets as well as the endothelial cells from which they were
derived.
9
Figure 1.02. Structure of the arterial vessel wall. From Carola et al. (Carola etal., 1992).
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Table 1.03 Functions of the vascular endothelium. EDHF, endothelium-derived
hyperpolarizing factor; ET-1, endotheiin-1; NO, nitric oxide; 02~, superoxide anion; PDGF,
platelet-derived growth factor; PGH2, prostaglandin H2; PGI2, prostacyclin; TNFa, tissue necrosis
factor alpha.
Functions of the vascular endothelium
• Regulation of vascular tone through release of vasoactive compounds, e.g. NO, PGI2,
EDHF, ET-1, 02", PGH2
• Provision of a selective permeability barrier
• Provision of a non-adherent surface for leukocytes and platelets
• Formation and secretion of a variety of growth-regulatory molecules and cytokines, e.g.
PDGF and TNFa
• Modification of plasma-derived compounds e.g. oxidation of lipoprotein
• Formation and maintenance of the extracellular matrix e.g. basement membrane, collagen,
elastic fibres and proteoglycans
• Maintenance of a non-thrombogenic surface through the formation of molecules such as
ectoADPase, PGI2, thrombomodulin and heparin sulphate
• Provision of anticoagulant and procoagulant properties through the production of
molecules such as NO and PGI2
11
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Endothelium-derived factors are secreted from the endothelium in response to autonomic and
sensory nerves (e.g. acetylcholine (ACh), noradrenalin, adenosine triphosphate (ATP) and
substance P), circulating hormones (e.g. catecholamines, vaspressin, angiotensin II, insulin),
products of coagulation (e.g. serotonin, adenosine diphosphate (ADP), thrombin), autocoids
produced by endothelial or smooth muscle cells (e.g. bradykinin, ADP, ATP, angiotensins, ET-1)
and also to changes in shear stress.
NO, PGI2 and EDHF are the major endothelium-derived vasodilators (figure 1.03). NO is
discussed in detail in section 1.2.3c. Although primarily produced by the vascular endothelial
cell, the actions of PGI2 (a member of the prostaglandin family), are mainly detected through
specific receptors expressed on the vascular smooth muscle cell. PGI2-receptors are coupled to
adenylate cyclase to elevate cyclic AMP levels in vascular smooth muscle which in turn
stimulates ATP-sensitive K+ channels to cause hyperpolarization of the cell membrane and thus
inhibit contraction. The contractile machinery is further inhibited by the cAMP-induced extrusion
of Ca2+ from the smooth muscle cell cytosol. PGI2 can facilitate the release of NO from the
endothelium, whilst, NO potentiates the action of PGI2 indirectly through the action of cGMP
which inhibits cAMP-phosphodiesterase thus prolonging the half-life of cAMP (Mombouli and
Vanhoutte, 1999).
EDHF is a diffusible endothelium-dependent vasodilator the identity of which is presently
controversial. There is some evidence that it is synthesised through the cytochrome P-450
pathway (Campbell et at., 1996). Hyperpolarization results from the opening of K+ channels in
the smooth muscle which then inhibits vasoconstriction through several mechanisms which
includes closure of voltage-sensitive Ca2+-channels, impairment of receptor-dependent
activation of phospholipase C (PLC) and the subsequent Ca2+ release from intracellular stores
and a decrease in the Ca2+ sensitivity of the contractile proteins. It has not been possible to























Figure 1.03. A schematic representation summarising the release of endothelium-
derived relaxing factors and their effects on vascular smooth muscle cells. ACh,
acetylcholine; AA, arachidonic acid; A23187, calcium ionophore A23187; ATP, adenosine
triphosphate; BK, bradykinin; B2, bradykinin B2 receptor; cAMP, cyclic adenosine
monophosphate; cGMP, cyclic guanosine monophophate; EDHF, endothelium-derived
hyperpolarizing factor; GTP guanosine triphosphate K+, potassium channel; L-arg, L-
arginine; NO, nitric oxide; NOS, nitric oxide synthase; PGI2, prostacyclin; P450, cytochrome
P450 monoxygenase; SR, sarcoplasmic reticulum. The broken lines indicate the action of




Both PGH2 and TXA2 are products of arachidonic acid metabolism through the cyclooxygenase
pathway. Both act on the endoperoxide/ thromboxane receptors on the smooth muscle cell
surface to induce vasoconstriction. The major metabolite of arachidonic acid metabolism is PGI2
and therefore under normal circumstances vasoconstriction is masked by PGI2, NO and EDHF.
Reactive oxygen species (ROS) are released in response to shear stress and some agonists
e.g. bradykinin (Mombouli and Vanhoutte, 1999). These ROS can inactivate NO favouring
vasoconstriction. ROS may also mediate vasoconstriction by facilitating the mobilisation of Ca2+
in vascular smooth muscle cells and/or by enhancement of Ca2+ sensitivity of contractile
elements.
ET-1 is potent vasoconstrictor, secreted in response to thrombin, interleukin-1, TGFp, platelet
products and neurohormones such as catecholamines and vasopressin. However its synthesis
is inhibited by both the basal and stimulated production of NO through guanosine 3', 5'-cyclic
monophosphate (cGMP) (Boulanger and Luscher, 1991).
Endothelium-derived vasoactive substances also possess angiogenic and/or smooth muscle cell
growth modulating properties. Under physiological conditions the endothelium provides a non-
adhesive, anticoagulant and anti-thrombotic surface. For example EDHF prevents the deposition
of platelets on the endothelial cell surface whilst PGI2 and NO inhibit platelet aggregation thus
inhibiting the platelet aggregation induced by shear stress.
1.2.3 Second messenger systems in the endothelial cell
a) Introduction
The numerous functions of the endothelium are regulated by a variety of endogenous and
exogenous chemical stimuli, as well as mechanical stimuli. These bioactive substances or
mechanical forces transduce signals from the extracellular milieu through specific receptor-
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mediated processes and second messenger systems which transform extracellular signals into
intracellular effects. A number of bioactive compounds have been identified which interact with
endothelial cells initiating a second messenger response. The chemical stimuli include growth
factors, neurotransmitters, cytokines, kinins, inflammatory mediators and agonists such as
thrombin, adenine nucleotides, bradykinin (BK), ET-1, and histamine.
In the endothelial cell, several signal transduction pathways have been identified. Of the many
pathways described in the endothelium those relevant to this thesis include the phospholipase C
(PLC)/ inositol phosphate/ protein kinase C (PKC) pathway (Pollock, Wreggett and Irvine, 1988;
Tran, Proulx and Chan, 1994), the guanylate cyclase/ cyclic GMP pathway (Schmidt, Mayer and
Kukovetz, 1989), and the adenylate cyclase/ cyclic AMP pathway, all of which are coupled to G-
protein linked receptors.
b) The phospholipase C/ inositol phosphate/protein kinase C pathway
One of the principle signalling pathways of the endothelium is the PLC/ inositol phosphate/ PKC
pathway (Natarajan, 1995) (figure 1.04). The agonist-receptor interaction activates PLC via a G-
protein linked to the receptor. The activation of PLC in turn hydrolyses phosphatidylinositol 4,5
bisphosphate (PIP2) generating inositol (1,4,5) trisphosphate (IP3) and diacylglycerol (DAG). IP3
acting as a second messenger subsequently stimulates the release of Ca2+ from intracellular
calcium stores which in turn stimulates a number of cellular processes via Ca2+receptor proteins
(for example, calmodulin) or Ca2+-activated kinases. DAG activates PKC (Natarajan, 1995).
Mackie et at. concluded that PKC has a central role in endothelial cell function as endothelial
cells possess a large number of PKC substrates and exhibit high PKC activity (Mackie et at.,
1986). There are many reported functions which require the PLC/ inositol phosphate/ PKC
system in the endothelium. These include the release of NO, stimulated by BK (Freay et at.,









Figure 1.04. The phospholipase CI inositol phosphate/ protein kinase C pathway. CAM,
calmodulin; DAG, diacylglycerol, ER, endoplasmic reticulum; IP2, IP3, inositol (1, 4, 5)
triphosphate; R, receptor; Pf, phosphate; PIP2, phosphatidylinositol 4,5 bisphosphate; PKC,
protein kinase C; PLC, phospholipase C; PS, phosphatidylserine. Adapted from Voet and Voet
(Voet and Voet, 1990).
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anions (Matsubara and Ziff, 1986). a-Thrombin also stimulates an increase in PIP2 hydrolysis
and intracellular Ca2+ mobilisation in human endothelial cells (Garcia and Natarajan, 1992).
c) The guanylate cyclase/ cyclic GMP pathway
Second messenger signalling in the endothelium is also mediated through the guanylate
cyclase/ cyclic GMP pathway. The binding of various vasoactive substances (for example ACh,
BK, angiotensin II and histamine) activates specific G-protein-coupled cell surface receptors
which increases intracellular Ca2+ concentration via the PLC pathway in the manner described
above. The intracellular signalling pathway for NO is mediated through two different G-protein
linked pathways. The pertussis toxin-sensitive G-prolein (either referred to as Gaj or Gi2)
mediates one whilst the second is mediated by the toxin-insensitive G-protein (Gq) pathway
(figure 1.05). The increased cytosolic Ca2+ binds and activates calmodulin, which, in turn,
activates nitric oxide synthesis by stimulation of endothelial nitric oxide synthase (eNOS). eNOS
is expressed constitutively and exists in the membrane-bound particulate fraction of endothelial
cells. It uses L-arginine as a substrate and molecular oxygen as a co-substrate. The mechanism
of this reaction involves a five-electron oxidation of the terminal guanadine-nitrogen of L-arginine,
resulting in the production of NO and the co-product, L-citrulline. The cofactors required for this
reaction include flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), nicotinamide
adenine dinucleotide phosphate (NADPH) and 6(R)-5,6,7,8-tetrahydrobiopterin (BH4)
(Forstermann ef a/., 1994, Moncada, Palmer and Higgs, 1991). eNOS contains an oxidase and
reductase domain. Upon the Ca27 calmodulin binding, eNOS accepts electrons from NADPH at
the reductase domain, which are shuttled by the flavin moiety to the oxidised domain where they
are used to reduce molecular oxygen thereby providing a source of oxidation of L-arginine (Dart
and Chin-Dusting, 1999).
Even in the absence of an external stimulus the intracellular Ca2+ concentration is such that NO
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of LOL platelet adhesion cytokines
Figure 1.05. The intracellular signalling pathways for nitric oxide in the endothelium
and the anti-atherogeneic actions of nitric oxide, a.2, 012-adrenoreceptor, 5HT, serotonin;
5HT1B, 5HT1B-seretonergic receptor, ADP, adenosine diphosphate; BH4, tetrahydrobiopterin;
BK, bradykinin, CaM, calmodulin; ET, endothelin; LDL, low density lipoprotein; NE,
noradrenalin; NO, nitric oxide; 02, superoxide anion, P2y, p2y-purinergic receptor, ?,
mechanoreceptor to sense changes in shear stress. From Shimokawa (Shimokawa, 1999).
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the continuous, basal activation of eNOS which occurs at resting levels of intracellular Ca2+ is
thought to be provided by shear stress, which provides an effective and sensitive system for the
localised control of vascular tone.
NO has a half-life of milliseconds and activates soluble guanylate cyclase (sGC) present in the
endothelium and vascular smooth muscle. Due to its lipophilic nature NO can diffuse into the
underlying vascular smooth muscle to mediate vascular relaxation by the following mechanism
(Shimokawa, 1999). NO binds to the heme component of sGC to enhance the formation of
cGMP which through stimulation of cGMP-dependent protein kinase (PKG) inhibits vascular
contractility (Lincoln, Komalavilas and Cornwall, 1994). NO has also been shown to activate
charybdotoxin-sensitive, calcium-dependent potassium channels thereby inducing
hyperpolarization in vascular smooth muscle cells.
NO, in addition to regulating vascular tone also inhibits platelet aggregation and the expression
of adhesion molecules via the generation of cGMP. NO also impairs growth of smooth muscle
cells (Britten, Zeiher and Schachinger, 1999). The ability of NO to alter the expression of genes
which encode endothelial proteins has also been demonstrated (De Caterina et at., 1995).
Stimulants of NO release (ATP, A23187, and BK) have been shown to increase intracellular
cGMP in bovine aortic endothelial cells (Schmidt, Mayer and Kukovetz, 1989) probably by the
direct activation of sGC present in the endothelial cell. Endothelial cells possess particulate GO,
the activation of which by atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic
peptide produces cGMP which activates PKG and inhibits the synthesis of ET-1 (Inagami,
Naruse and Hoover, 1995).
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d) The adenylate cyclase/ cyclic AMP pathway
The mechanism of receptor-mediated activation/ inhibition of adenylate cyclase is shown in
figure 1.06.
In the endothelium, protein kinase A (PKA) mediates most of the effects of cAMP. The activation
of PKA subsequently regulates cell activity by specific protein phosphorylation of serine/
threonine residues, Adenylate cyclase in the endothelium regulates thrombomodulin and tissue
factor activity, the inhibition of endothelin through PGI2, the mediation of the effects of cyclic
strain, regulation of the plasma membrane calcium pump gene expression, endothelial cell
permeability and the regulation of tissue plasminogen activator and plasminogen activator
inhibitor expression (Manolopoulos, Samet and Lelkes, 1995). Receptors in the endothelium that
are linked to the adenylate cyclase pathway include the (3-adrenoreceptor, adenosine A2
purinoceptors, histamine and calcitonin gene-related peptide receptors (McKewan et at., 1990).
Forskolin directly activates adenylate cyclase in all endothelial cell types although its effects vary










Figure 1.06. The adenylate cyclase/ cyclic AMP pathway. The interaction of the agonist with
the stimulatory receptor stimulates the exchange of GDP for GTP on the a-subunit of inactive
heterotrimeric Gs protein. The G protein a-subunit: GTP complex, dissociates from the Gfiy
complex and activates adenylate cyclase (AC) to convert ATP to cAMP. The inherent GTPase
activity of the a-subunit hydrolyses GTP to GDP and Pj leading to the dissociation of the G
protein a subunit from AC and its reassociation with the G(3y complex reverting back to the
inactive state. cAMP activates protein kinase A (PKA) which catalyses the phosphorylation of
various cellular proteins. The binding of an agonist to the inhibitory receptor triggers an almost
identical chain of events with the exception that the association of GTP with the a-subunit of




1.3 ENDOTHELIAL DYSFUNCTION IN ATHEROSCLEROSIS
1.3.1 Introduction
Under physiological conditions the endothelium generally plays an inhibitory role; inhibiting
smooth muscle cell contraction, monocyte adhesion, oxidation of low density lipoproteins,
platelet aggregation and adherence, synthesis of inflammatory cytokines, vascular smooth
muscle proliferation and thrombosis (figure 1.05, pg 18) (Glasser, Selwyn and Ganz, 1996;
Shimokawa, 1999). However the endothelium plays an important role in the pathophysiology of
several vascular diseases. The proposal that endothelial denudation provides a primary step in
atherosclerosis was initially published by Ross and Glomset in 1973 following several
pathophysiological observations in humans and animals (Ross and Glomset, 1973). Endothelial
denudation is now more appropriately referred to as endothelial dysfunction i.e. 'the shut-down
or inactivation of certain intrinsic anti-atherogenic mechanisms' (Busse and Fleming, 1996).
There is considerable evidence that endothelial dysfunction is important in the etiology of
atherosclerosis by either initiating and/or sustaining atherogenesis.
Due to its anatomical position the endothelial surface provides a primary target for attack from
damaging stimuli. There are a number of risk factors which either alone or in combination can
cause 'endothelial dysfunction'. Fluid shear stress has been strongly implicated in the changes
to endothelial function, as atherosclerotic lesions are focal and localised to areas such as
branches, bifurcations and regions of arterial narrowing where there are disturbances in the
pattern of blood flow (Mano et a!., 1996). Changes in flow can alter the expression of genes
which have elements in their promoter regions which can respond to such variations. Low shear
stress for example has been shown to increase the expression of ICAM-1, PDGF-B chain, and
tissue factor which all promote endothelial dysfunction (Ross, 1999). Fluid shear stress may be
coupled to one or more other risk factors to promote endothelial dysfunction, such as elevated
and modified low density lipoprotein; free radicals caused by cigarette smoke; ageing;
menopause: hypertension; ischemia; diabetes meliitus; elevated plasma homocysteine
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levels and infectious organisms such as Herpes virus or Chlamydia pneumoniae (Ross, 1999;
Shimokawa, 1999).
1.3.2 Endothelial dysfunction as a primary event in atherosclerosis
Endothelial dysfunction is observed prior to the development of overt atheroma which may
suggest a principal role for endothelial dysfunction in the initiation of atherogenesis. There is
substantial evidence in support of this hypothesis. Several studies have demonstrated that
endothelial dysfunction precedes the detection of atherosclerosis using either angiography or
intravascular ultrasound (Ludmer et al., 1986; Mano et at., 1996). For example, in arterial
segments prone to atherogenesis, such as branching points, a paradoxical vasoconstriction in
response to acetylcholine is observed at a stage when there is no angiographic evidence of
atherosclerosis (McLenachan, Vita and Fish, 1990). However some controversy exists as to
whether the methods used in these studies are sensitive enough to detect the partial intimal
lesions that may only be observed microscopically at post-mortem (Mano et al., 1996).
Further evidence that endothelial dysfunction may culminate in the lesions of atherosclerosis has
been shown using experimental animal models with impairment of endothelial function. For
example, a chronic reduction of NO bioavailability through the inhibition of NOS was shown to
accelerate the progression of atherosclerosis, inducing neointimal formation (Cayette et al.,
1994). Also, eNOS knock-out mice have been shown to develop typical atherosclerotic lesions
following adventitial vessel wall injury, whereas wild-type mice do not (Moroi etal., 1998).
Clinical data shows that endothelial dysfunction is detectable in patients with a family history of
atherosclerosis prior to the manifestation of atherogenesis (Busse and Fleming, 1996). Also, the
impairment of endothelium-dependent vasodilatation is evident in isolated small arteries of the
microcirculation despite the absence of gross atherosclerotic lesions in these vessels (Dart and
Chin-Dusting, 1999; Selke, Armstrong and Harrison, 1990; Zeiher et al., 1991).
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Finally, the risk factors which promote atherogenesis are strongly associated with endothelial
dysfunction such that the removal or modification of the risk factor (for example, lowering
cholesterol, cessation of smoking, exercise, oestrogen replacement in menopausal women)
improves endothelial dysfunction and may prevent the further development of the disease
(Vogel, 1997).
1.3.3 Features of endothelial dysfunction
The endothelial dysfunction that results from injuries caused by one or more of the
aforementioned risk factors alters the normal homeostatic properties of the endothelium thus
promoting atherogenesis (Vogel, 1997). The endothelium serves a number of physiological roles
as summarised previously in table 1.03. Alterations of these functions associated with
'endothelial dysfunction' include; the increased expression of adhesion molecules on the
endothelial surface, the production of paracrine growth factors and chemoattractants, impaired
vascular tone, the ability to oxidise LDL and to respond to oxidised lipids and lipoproteins,
promotion of pro-coagulation and the modulation of plasma component levels within the vessel
wall through changes in permeability.
1.3.4 Mechanisms of endothelial dysfunction
There is considerable evidence to suggest that endothelial dysfunction is associated with the
loss of NO production and/or its bioavailability (Busse and Fleming, 1996; Harrison, 1997). For
example, it has been demonstrated that the inhibition of NO synthesis increases the expression
of genes associated with monocyte adhesion (Maxwell, Tsao and Cooke, 1998). A loss of
endothelial production and/or bioavailability of NO would be expected to diminish the normally
protective effects of the endothelium and predispose the vessel to atherogenesis. The
mechanisms which underlie the decreased production and bioavailability of NO appear to be
multifactoral and are dependent on the stage of atherosclerosis, the vascular bed and species
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under study and the agonist tested (Harrison, 1997) (figure 1.07). The mechanisms of
endothelial dysfunction particularly relevant to this thesis are discussed below.
Impairment of endothelial signal transduction through defects in either the membrane receptor
or signalling pathways may contribute to endothelial dysfunction. For example, oxidised LDL has
been shown to activate PKC (Ohgushi et at., 1993) which in turn can phosphorylate the Gai
protein and inhibit its function (Shimokawa, 1999).
eNOS, despite being constitutively expressed, is subject to regulation. For example, cultured
endothelial cells exposed to high concentrations of oxLDL have a decreased eNOS expression
(Busse and Fleming, 1996; Harrison, 1997). However several factors have been shown to
increase the expression of eNOS including shear stress, exposure to lysophosphatidycholine,
low concentrations of oxLDL and cGMP analogues (Harrison, 1997). Indeed there is evidence to
suggest that, despite a decrease in NO bioavailability, basal and stimulated NO levels are
enhanced in cholesterol-fed animals (Harrison and Ohara, 1995; Minor et at., 1990). These
differences may be accounted for by measurements having been taken at different stages of
atherogenesis.
Tetrahydropbiopterin (BH4) is an essential cofactor for eNOS activity and is hypothesised to
direct electron flow in the enzyme to L-arginine. In the absence of sufficient BH4 Pou et at.
reported that purified brain constitutive NOS transfers electrons to molecular oxygen, to produce
the powerful oxidant 02" (Pou et at., 1992). The addition of BH4 to recombinant eNOS increases
NO production whilst decreasing 02" production (Wever et at., 1998). BH4 has not been
measured under pathophysiological, conditions although in hypercholesterolemia patients
supplementation with BH4 has been shown to improve endothelium-dependent vasodilation






































Figure 1.07. Schematic representation of the possible mechanisms that underlie
endothelial dysfunction observed in hypercholesterolemia and atherosclerosis. AA,
arachidonic acid; ACh, acetylcholine; ADP, adenosine diphosphate; cAMP, cyclic
adenosine monophosphate; cGMP, cyclic guanosine monophosphate; EDHF,
endothelium-derived hyperpolarizing factor; NO, nitric oxide; eNOS, endothelial nitric oxide
synthase; 5HT, serotonin; PGI2, prostacyclin; M, muscarinic receptor; P2y, P2Y-purinergic
receptor; PDGF, platelet-derived growth factor; PGH2, prostaglandin H2; S, 5HT1B-
serotonergic receptor; T, thrombin receptor; TK, receptor for PDGF coupled to tyrosine
kinase, TXA2, thrmoboxane A2 From Shimokawa (Shimokawa, 1999).
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The concomitant release of endothelium-derived contracting factors such as 02", TXA2 ,
angiotensin II, ET-1, PGH2 may account for the changes in vascular tone. With the removal of
the negative feedback constraints of NO, it is suggested ET-1 production is increased which
may be of potential importance in atherosclerosis. Evidence consistent with this is the finding of
enhanced plasma levels of ET-1 in patients with advanced atherosclerosis (Lerman et al., 1991).
In addition, cultured human and porcine endothelial cells exposed to oxLDL stimulated the
release of ET-1 into the culture medium (Boulanger et al., 1992).
The reduction in bioavailability of NO is likely to be associated with its increased inactivation. 02"
is generated by the endothelium, smooth muscle and intimal macrophages in response to injury,
ischemia, oxLDL and activated leukocytes. Excess production of 02" has been reported in
hypercholesterolemia animals (Ohara, Peterson and Harrison, 1993) and there is also evidence
that NO levels may be enhanced in atherosclerotic lesions (Harrison and Ohara, 1995; Wever et
al., 1998). Because NO contains an unpaired electron it is paramagnetic and reacts rapidly with
02" at a rate of approximately 6.7 x 10"9 Ms"1 (as determined by flash photolysis) to form
peroxynitrite according to reaction 1 (Beckman, Wink and Crow, 1996; Beckmann et al., 1994;
Harrison, 1997; Kooy and Royall, 1994). This reaction is approximately three times faster than
the reaction of 02" with superoxide dismutase and nearly thirty times faster than the reaction of
NO with heme proteins.
NO + 02" ► ONOO" (1)
The presence of peroxynitrite in atherosclerotic lesions has been indirectly demonstrated
through nitrotyrosine immunostaining which serves as a marker of peroxynitrite-mediated protein
modification (Beckmann et al., 1994). This would suggest that under conditions of oxidative




At neutral pH the peroxynitrite radical is protonated and can form the cytotoxic peroxynitrous
acid which can then spontaneously yield the hydroxyl radical and nitrite (N02~) (Harrison and
Ohara, 1995; Wever et a/., 1998). The oxidation of LDL, protein fragmentation by nitration of
proteins, DNA damage, modification of iron-sulphur clusters, zinc-fingers, protein thiols and
membrane lipids have all been shown to be effects of peroxynitrite. These events might well be
important in the pathophysiology of atherosclerosis (Gross and Wolin, 1995; Harrison and
Ohara, 1995; Wever et a!., 1998). Peroxynitrite, as compared to NO is a relatively weak stimulus
for guanylate cyclase in vascular smooth muscle such that endothelium-dependent relaxation is
impaired (Villa etal., 1994).
In contrast, it is possible for peroxynitrite at low concentrations to nitrosylate sulfhydryl groups to
form S-nitrosothiols which are known to promote vasodilatation, inhibit platelet aggregation and
leukocyte adhesion (Maxwell, Tsao and Cooke, 1998; Stamler, Singal and Loscalzo, 1992).
Whilst the formation of peroxynitrite under physiological conditions, may not be toxic, under
pathological conditions where it is produced at much higher concentrations, the toxic effects of
peroxynitrite may become evident.
In conclusion, the findings from human and animal studies would suggest that the inactivation of
NO by 02" and other ROS observed under pathophysiological conditions contributes to
endothelial dysfunction (Harrison, 1997). The role of ROS in atherogenesis is discussed further
in section 1.3.5.
Finally, it should also be noted that the capacity of the endothelium to produce PGI2, (whose
functions include vasodilatation, the prevention of platelet aggregation, an increase in the activity
of enzymes which metabolise cholesterol esters by macrophage and the prevention of smooth
muscle cell proliferation) is decreased in atherosclerosis (Vane, Anggard and Botting, 1990).
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1.3.5 Reactive oxygen species and the endothelium
a) Reactive oxygen species and the endothelium
The endothelial cell in vivo is constantly exposed to the high partial pressure of molecular
oxygen in the blood as well as chemical derivatives of oxygen referred to as reactive oxygen
species (ROS) (Schuppe-Koistinen et at., 1994). Under normal cellular homeostasis there is a
balance between the rate and magnitude of oxidant formation and the rate of oxidant
elimination. The term 'oxidative stress' is used to describe the situation when the endothelial cell
is exposed to excessive levels of either molecular oxygen or ROS which overwhelm the cell's
antioxidant capacity.
b) Sources of reactive oxygen species
Metabolic trauma (e.g. hypercholesterolemia, diabetes mellitus, smoking, viral infection,
ischemia) and physical trauma (e.g. percutaneous transluminal coronary angioplasty,
hypertension) all increase vascular oxidative stress (McGorisk and Treasure, 1996). The ROS
relevant to vascular biology include 02* , hydrogen peroxide (H2O2) , the hydroxyl radical (OH"),
the hydroperoxy radicals, peroxynitrite (OONO") and lipid hydroperoxides (Kojda and Harrison,
1999). There are several enzymatic sources of ROS in the mammalian cell including,
mitochondrial electron transport chain, xanthine oxidase, cyclooxygenase, lipooxygenase,
eNOS, heme oxygenases, peroxides, hemeproteins and NADPH oxidases.
c) Reactive oxygen species and endothelial dysfunction
There is both indirect and direct evidence that there is an excess generation of 02" within
vessels from hypercholesterolemic subjects, that may lead to endothelial dysfunction and thus
serve as an early atherosclerotic event (Mugge et at., 1991; Ohara, Peterson and Harrison,
1993). In hypercholesterolemic rabbits a three-fold increase in aortic 02" production was
measured compared to that found in aorta from normal rabbits (Ohara, Peterson and Harrison,
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1993). This effect was abolished following endothelial denudation and was inhibited by
oxypurinol (a non-competitive inhibitor of xanthine oxidase) inferring that the endothelium
provides the major source of abnormal 02" production in early atherosclerosis through the
activation of xanthine oxidase. In the later stages of atherosclerosis activated macrophages in
the intima and smooth muscle ceils are also likely to contribute to the production of vascular 02"
as well as other ROS (Kojda and Harrison, 1999).
Damage to the endothelium by ROS, free radicals and oxidised lipids and lipoproteins has been
shown to favour atherogenesis (DiCorleto and Soyombo, 1993). Oxidative stress can disrupt
several physiological functions pertaining to the endothelium. These include regulation of blood
flow, inhibition of leukocyte adhesion and platelet aggregation and the control of cellular growth.
The role of NO in the modulation of monocyte adhesion and migration is associated with the
ability of NO to suppress the gene expression of adhesion molecules such as VCAM-1 and
chemokines such as MCP-1 by modulating an oxidant sensitive transcriptional signalling
pathway (Maxwell, Tsao and Cooke, 1998). It would appear that in hypercholesterolemia the
loss of NO bioavailability and the increased presence of 02" result in the activation of the NFkB
binding site present on the promoter region of the genes which regulate mechanisms such as
monocyte adhesion leading to the expression of these genes (Maxwell, Tsao and Cooke, 1998;
Ohara, Peterson and Harrison, 1993). Oxidative stress may also alter the expression of other
genes associated with atherogenesis such as eNOS, ICAM-1, E-selectin, PDGF and FGF-2.
The 02" has several pro-atherogenic features including, the oxidation of LDL and lipid
accumulation in the vessel wall. 02" can also provide a source of other ROS (H202, OH", singlet
oxygen, hypochlorous acid and ONOO") which may participate in lipid peroxidation and thereby
30
introduction chapter one
have an impact on endothelial function. The altered ratio of N0/02" production has been
proposed to diminish the intrinsic inhibition of the transcription factor NFkB leading to an
enhance expression of endothelial adhesion molecules and chemotactic factors (Busse and
Fleming, 1996).
d) Oxidised LDL - a promoter of atherosclerosis
LDL molecules are large spherical particles (diameter 19-25 nm) comprising of cholesterol ester
and triglycerides which form a central lipophilic core with a monolayer of amphipathic
phospholipids and free cholesterol in which is embedded a large glycosylated protein, apoprotein
B (apoB), which envelopes the LDL particle (figure 1.08). Several variants of apoB exist and LDL
is associated with the apoB100 form of the protein. LDL also contains several lipophilic
antioxidants such as a-tocopherol, y-tocopherol, carotenoids, oxycarotenoids and ubiquinol-10.
Variability in the chemical and structural composition of LDL may in part mediate the differences
in susceptibility between LDL samples to oxidation (Esterbauer et al., 1992). LDL particles
provide the major cholesterol-carrying lipoproteins in the blood. LDL-uptake into cells is via a
receptor-mediated pathway and non-specific endocytosis. Most cells contain the B/E receptor for
LDL uptake but the highest concentration is found in the liver where approximately three-
quarters of the LDL is removed from the blood stream (Esterbauer et al., 1992).
Oxidation of LDL is thought to be crucial to the initiation of atherogenesis (Tanner et al., 1991;
Witzum and Steinberg, 1991). In the plasma, LDL is generally protected against oxidation by
plasma antioxidants including vitamins C and E and (3-carotene. However, endothelial damage
may cause LDL to enter the intima where antioxidant levels are much lower and the
susceptibility of LDL to oxidation may be increased. Oxidative modification of LDL has been
demonstrated in vivo. LDL extracted from the intima includes oxLDL, characterized in terms of
its physical and biological properties, as well as by Western blotting using antibodies against









Figure 1.08. The lipoprotein particle. From Baynes and Dominiczak
(Baynes and Dominiczak, 1999).
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antibodies to epitopes of oxLDL are elevated in atherosclerotic patients (Esterbauer et al., 1992;
McGorisk and Treasure, 1996; Yla-Herttuala etal., 1989).
The mechanism by which LDL is oxidised in vivo is uncertain. In vitro studies suggest the
formation of oxLDL is mediated in part by the enhanced production of ROS by each of the cells
which constitute the arterial wall. The role of macrophage lipoxygenases, in particular 15-
lipoxygenase, has also been implicated in LDL oxidation (Esterbauer et at., 1992; Yla-Hertulala
et al., 1990). Chemical and physiochemical properties of oxLDL (some of which contribute to the
pro-atherogenic properties of this molecule) are summarised in table 1.04.
When LDL particles become trapped in the intima they can undergo progressive oxidation which
is a prerequisite for uptake of LDL into macrophages by means of the scavenger receptors.
These receptors present on the macrophage surface recognise and rapidly take up oxLDL in an
uncontrolled manner (Esterbauer et al., 1992). The majority of foam cells which develop in the
early stages of atherogenesis develop from monocytes/macrophages which have entered the
subendothelial space (Yla-Hertulala et al., 1990). The enhanced uptake of oxLDL and its
degradation by macrophages leads to the increased presence of cholesteryl ester thus
promoting the transition of macrophages into foam cells. The gene for the scavenger receptor
has been cloned and is found in macrophages and stimulated smooth muscle cells in vitro and
its presence in vivo has been demonstrated in arterial lesions (Dejager, Mietus-Synder and
Pitas, 1993). Scavenger receptor activity present in endothelial cells is encoded for by a different
gene. The importance of this receptor for atherogenesis has not been ascertained (Sawamura et
al., 1997).
Oxidised LDL affects numerous cellular functions each of which could contribute to each stage
of atherosclerosis. The more established pro-atherogenic properties of oxLDL are summarised
in Table 1.05, some of which are discussed in more detail below. In addition to oxLDL, minimally
modified LDL (MM-LDL) may also elicit biological responses implicated in the pathogenesis of
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Table 1.04. Summary of differences between oxidised LDL and native LDL. These altered
properties are characteristic of LDL oxidised in vitro either by Cu++ or cells for 24 hr.
Chemical and physiochemical properties
• Complete loss of antioxidants
• Entire or near complete loss of PUFAs
• Loss of phosphatidylcholine and cholesteryl ester
• Increase in lysophosphatidyicholine and oxysterol content
• Increase in hydroxy- and hydroperoxy-PUFA content
• Increase in conjugated dienne content
• Increase in aldehydes including MDA, hexanal, HNE
• Strong fluorescence at 430 nm with excitation at 360 nm
• Partial loss of free amino groups in apoB
• Fragmentation of apoB to smaller peptides
• MDA and FINE epitopes on apoB recognised by specific antibodies
• Increased electrophoretic mobility and increased density (1.06-1.08)
• Increased tendancy to aggregate, heterogeneity in size
• Conformational rearrangement of apoB structure and phospholipid monolayer
Adapted from (Esterbauer et al., 1992).
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Table 1.05. Summary of the pro-atherogenic properties of oxLDL. With the exception of
minimally modified LDL (MM-LDL) these properties are characteristic of LDL oxidised in vitro
either by Cu++ or endothelial cells for 24 hr.
Biological properties
• Increased uptake and degradation by macrophages
• Cytotoxic to several cell types e.g. endothelial, fibroblasts and smooth muscle cells
(Kosugi et al., 1987; Kuzuya et ai., 1991; Thomas, Geiger and Girotti, 1993).
• Chemotactic for monocytes and smooth muscle cells
• Inhibition of monocyte-macrophage motility
• Inhibition of NO activation of guanylate cyclase
• Inhibition of relaxation of isolated smooth muscle strips induced by ACh, NO
• Alteration of the vasoactive compounds released by the endothelium e.g. ET-1, EDHF
• Immunogenic and able to elicit an autoantibody response
• Suppression of protein C (which increases thromboresistance) activity in cultured
endothelial cells
• Suppression of the production of PDGF-mRNA and PDGF secretion by monocyte-
macrophages
• Increase in macrophage glutathione concentration (approximately two-fold)
• Systemic administration into hamsters causes an immediate leukocyte adhesion to
capillary endothelium
• Induction of DNA synthesis and enhancement of the proliferative response to M-CSF and
GM-CSF by macrophages (Hamilton et al., 1999)
• Treatment of cultured endothelial cells with MM-LDL stimulates the production of MCP-1,
endothelial-leukocyte-adhesion molecules (e.g. VCAM-1 and ICAM-1), M-CSF, G-CSF
and tissue factor required for coagulation (Drake et al., 1991)
• MM-LDL injected into mice increases MCP-1 and CSF levels in serum and tissue
• MM-LDL inhibits mitogenesis and stimulates (at low concentrations) or inhibits PGI2
synthesis in smooth muscle cells
• MM-LDL stimulates nuclear transcription factor (NFkB) to increase monocyte adherence
Adapted from (Esterbauer et al., 1992).
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atherosclerosis (Drake et at., 1991). Whereas oxLDL contains high levels of thiobarbituric
reactive substances (TBARS) and has major modification of apoB and is taken up by scavenger
receptors, MM-LDL has lower levels of TBARS and is taken up by specific LDL receptors. oxLDL
disrupts several other endothelial functions. For example, oxLDL has also been shown to
stimulate platelet aggregation (Aviram, 1989), procoagulant activity (for example, by an increase
in tissue thromboplastin activity on the surface of human macrophages) (Schuff-Werner et at.,
1989) and inhibit vasodilation induced by endothelium-derived NO (the mechanism for which has
been discussed previously) (Berliner and Haberland, 1993; Chin, Azhan and Hoffman, 1992;
Rosenfeld, 1991; Tanner et at., 1991).
1.3.5 Antioxidants and atherosclerosis
a) Enzymatic endothelial antioxidant defence systems
The endothelial cell possesses several intracellular enzymatic antioxidant systems. These
include the glutathione redox system, catalase and superoxide dismutases (figure 1.09). More
recently the role of the heme-oxygenases and the thioredoxin reductase/thioredoxin system
have also been implicated in antioxidant defence of the endothelial cell (Pohlman and Harlan,
2000).
Superoxide dismutases (SOD) accelerate the dismutation of 02" to H202 which is subsequently
reduced by either catalase or glutathione peroxidase (GPX). Two forms of SOD exist in the
endothelial cell: the copper/zinc-containing form is the predominant form and is expressed in the
cytoplasm whilst a manganese-containing SOD is found primarily in the mitochondria.
The role of the GPX selenoenzymes in the reduction and detoxification of H202 and other ROS
is discussed later in section 1.4.5a. Catalase is a ubiquitous enzyme that scavenges H202
exclusively. Whilst both GPX and catalase chemically reduce H202, catalase has a high Km for










Figure 1.09. The endogenous antioxidant system of the endothelial cell. CAT, catalase;
GPX, glutathione peroxidase; GR, glutathione reductase; GSH' reduced glutathione, GSSG,
glutathione disulphide; H202, hydrogen peroxide, L-Arg, L-Arginine; L-Cit, L-Citrulline; 02*",
superoxide anion; ONOO", peroxynitrite, NO, nitric oxide, NOS, nitric oxide synthase.
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exception of hepatocytes and erythrocytes (Asahi et al., 1995). Impairment of the glutathione
redox cycle, but not catalase, by pharmacologic manipulation increases the susceptibility of
pulmonary artery endothelial cells to damage by H202 (Suttorp, Toepfer and Roka, 1986).
b) Dietary antioxidants
There are several potential strategies for the treatment or prevention of atherosclerosis. These
include: lipid lowering diets, anti-thrombotic drugs, dietary supplementation with fish oil or L-
arginine, angiotensin-converting enzyme inhibitors, p-blockers, apheresis and gene therapy.
However much research attention has been focused on the ability of dietary antioxidant
treatment to inhibit the progression of atherosclerosis. The clinical importance of an altered
oxidation state in atherogenesis is attested to by the results of several case-control and cohort
studies in which treatment with antioxidants significantly improved prognosis of atherosclerosis.
However as yet randomised, double-blind, placebo controlled trials have not been able to assess
whether there is a direct causal effect of low antioxidant status on the pathogenesis of
atherosclerosis and other vascular diseases.
Laboratory data have demonstrated the beneficial effects of supplementation of SOD on
endothelium-dependent vasodilatation in pig coronary arteries (Brandes et al., 1997). In vivo
studies show that antioxidants such as probucol suppress lesion formation in animal models of
atherosclerosis (Witzum and Steinberg, 1991). Antioxidants have been shown to suppress LDL
oxidation ex vivo (Ross, 1999) and in hypercholesterolemia dogs and cholesterol-fed rabbits,
supplementation with vitamin E prevented the paradoxical vasoconstriction observed with
endothelial dysfunction (Britten, Zeiherand Schachinger, 1999).
Preliminary clinical trials has shown that vitamin E intake is inversely correlated with the
incidence of myocardial infarction and coronary heart disease whilst (3-carotene appears to show
no beneficial effects (Ross, 1999). Anderson et al. demonstrated that the combination of lipid-
lowering therapy (lovastatin) and an antioxidant therapy (probucol) was more effective in
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improving endothelium-dependent vasodilatation than the use of lipid lowering therapy alone
(Britten, Zeiherand Schachinger, 1999).
Dietary supplementation with a combination of ascorbic acid, organic selenium, D-a-tocopheryl
acetate and a-carotene was given in a randomised placebo-controlled double-blind small scale
clinical trial carried out over a three month period (Nyyssonene et at., 1994). The resistance of
very low-density lipoprotein and LDL to oxidation was significantly increased in the subjects
receiving the antioxidant supplements compared to the placebo group.
Despite these encouraging observations the evidence from case-control studies, prospective
cohort studies, and primary and secondary prevention trials (recently reviewed by Gaziano
(Gaziano, 1999)) attempting to link supplementation with the antioxidant vitamins C, E or (3-
carotene to a reduction in the risk of cardiovascular disease is equivocal. There are currently
three ongoing large-scale trials underway which aim to define a role for antioxidant
supplementation in the prevention of atherosclerotic disease. The Women's Health Study is
studying the effect of Vitamin E and low-dose aspirin in the prevention of primary cardiovascular
disease in 40,000 healthy health professionals. Secondary prevention trials such as the
Women's Antioxidant Cardiovascular Study and The Heart Outcomes Prevention Evaluation
Study have also been initiated. It is hoped that the results from these trials and several other
small-scale trials may provide a clearer insight into the role of antioxidants in the treatment and
prevention of cardiovascular disease in the near future.
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1.4 SELENIUM AND SELENOPROTEINS
Dietary selenium through the expression of selenoproteins is thought to prevent damage to the
endothelium caused by reactive oxygen species, thus protecting against atherogenesis.
1.4.1 Selenium - an introduction
The Swedish chemist, Jons Jacob Berzelius discovered the element selenium in 1817 as a red
deposit on the walls of a lead chamber used in the production of sulphuric acid (Reilly, 1993). It
was initially regarded as an element with high toxicity and no known beneficial biological role.
During the 1950s however Schwartz and Foltz demonstrated that selenium could prevent liver
necrosis in vitamin-E deficient rats and suggested that it was an essential nutrient (Schwartz and
Foltz, 1957). A functional role for selenium in mammals was not reported until 1973 (Rotruck et
al., 1973) when the element was shown to be a constituent of the antioxidant enzyme, cytosolic
glutathione peroxidase (cyGPX). Reports highlighting the importance of selenium in human
nutrition appeared in 1979 describing the selenium-responsive cardiomyopathy of Keshan
disease in China (Group, 1979). Since then a considerable amount of further research has
demonstrated that selenium is essential to human nutrition through the expression of a wide
range of selenoproteins which have multiple and diverse roles.
1.4.2 The chemistry of selenium
Selenium has an atomic weight of 78.96 and is classed as a metalloid by virtue of sharing
properties of both metal and non-metals (table 1.06). It lies between sulphur and tellurium in
Group VI of the Periodic Table of Elements. Chemical similarities exist between selenium and




Table 1.06. Some chemical and physical properties of selenium.
Properties Values
Relative atomic mass 78.96
Atomic number 34
Atomic radius (X2) 0.14 nm (2.02 A)





Oxidation states -2, 0, +2, +4, +6
Stable isotopes
mass 74 76 77 78 80 82
natural abundance (%) 0.87 9.02 7.85 23.52 49.82 9.19
From Foster and Sumar (Foster and Sumar, 1997)
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Selenium exists naturally in a range of oxidation states, combining with other elements to form
inorganic selenides, selenites and selenates (table 1.07). Selenium also forms organic
selenoamino acids, which include selenocysteine and selenomethionine.
1.4.3 Selenium metabolism and bioavailability
a) Introduction
Despite sharing some physical and chemical properties, selenium and sulphur are not
interchangeable in biological systems (Foster and Sumar, 1997). The metabolism of selenium in
animals and humans, i.e. its absorption, transport, distribution, excretion, retention and
transformation to an active selenide is dependent on its chemical form and the overall selenium
status of the individual. Animals normally receive dietary selenium as organic selenoamino acids
such as selenomethionine and selenocysteine and as methylated and non-methylated selenium,
though inorganic forms, such as sodium selenite and sodium selenate, are often used in
experimental diets and as supplements. Selenium is associated with tissue proteins throughout
the body. Proteins that incorporate selenium through a UGA codon are referred to as
selenoproteins and are metabolically active, whereas proteins that bind selenium non-specifically
have been termed selenium-containing proteins.
The only metabolic pathway for selenium that has been well characterized is that based on the
metabolism of most forms of selenium to selenite which is reduced to selenide. Figure 1.10
shows a hypothetical scheme of selenium metabolism (adapted from Foster and Sumar, 1997
and Sunde, 1990). The diagram shows the pathway through which most forms of selenium are




Table 1.07. Oxidation states of selenium.
Name Formula Oxidation state Properties and other information





Selenite SeO? +4 m.p.315°C
Readily oxidised to a +6 state:
alkali pH
Reduced to elemental selenium by
S02, ascorbic acid; reacts with o-
diamines
Binds to iron and aluminium





Different forms include trigonal, a-
monoclinic, (3-monoclinic, red
amphorous, black amphorous and
vitreous
Stable, insoluble: formed by +6 &
+4 reduction
Selenide H2Se m.p.-66°C, b.p.-41°C
a colourless flammable gas
From Foster and Sumar (Foster and Sumar, 1997).
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Se - specific selenoproteins
e.g. GPX, formate dehydrogenase, selenoprotein P
Figure 1.10. A diagram illustrating a hypothetical scheme of selenium metabolism. Adapted




It is generally accepted that selenium is well absorbed and under normal feeding conditions
absorption is not the limiting factor to bioavailability (Mutanen, 1986). Virtually complete
absorption occurs when selenium is supplied as selenomethionine (Swanson et al., 1991) and
other forms are generally well absorbed. Different forms of selenium are absorbed through
different mechanisms, although most forms of selenium are absorbed through the duodenum
(Thomson, 1998).
McConnell et al. demonstrated through the use of everted intestinal sacs prepared from hamster
small intestine, that L-selenomethionine is absorbed using the same active transport mechanism
as L-methionine (McConnell and Cho, 1965). Information on the absorption of selenocysteine is
limited though it is known its absorption does not follow the same metabolic pathway as
cysteine.
The details for the absorption of inorganic selenium are still unclear although the absorption of
these compounds is influenced by several luminal factors. It is generally accepted that selenite is
absorbed via a passive mechanism. McConnel et al. using the intestinal sac model showed no
net exchange of selenite across the intestinal mucosa when concentrations of selenium were
equal on both sides (McConnell and Cho, 1965). However further studies suggest that reduced
glutathione in bile may be important in the absorption of selenite. Selenate absorption is primarily
through the ileum and may share the same absorption pathway as sulphur (Daniels, 1996).
Tracer studies in humans have shown that selenium given as [75Se]-selenomethionine is
incorporated more efficiently into body tissues and has a longer half-life than selenium given as
[75Se]-selenite (Griffiths, Stewart and Robinson, 1976). There is considerable evidence to
suggest that selenomethionine increases the plasma, erythrocyte and whole blood selenium
more rapidly and to a greater degree than inorganic forms of selenium such as selenite and
selenate (Daniels, 1996). However in individuals with low selenium status it has been shown that
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organic and inorganic selenium supplementation were equally effective at raising blood
glutathione peroxidase (GPX) and selenate was more effective than selenomethionine at raising
platelet GPX levels (Daniels, 1996). After supplementation with inorganic selenium, blood levels
decline rapidly to baseline whereas in selenomethionine supplementation, selenium levels
remain elevated above baseline (Daniels, 1996). In a recent study, Brown et at. examined the
effects of dietary organic and inorganic selenium supplementation, over a 28 day period, on
GPX activities in blood cells taken from 45 men and women from a UK population (Brown et al.,
2000). The transient and acute changes in phospholipid GPX (PHGPX) activity observed during
selenite supplementation in lymphocytes, granulocytes and platelets were largely mirrored in
lymphocytes of the subjects given selenomethionine. Whereas, PHGPX activity in granulocytes
and platelets from subjects given selenomethionine increased gradually over the 28 day period.
Certain interacting factors may affect the absorption of different selenium compounds. For
example, in a study carried out on men, Greger and Marcus (Greger and Marcus, 1981) showed
that selenium was better absorbed (72%) from a high protein diet rather than a low protein diet
(44%). However supplementation of the low protein diet with cysteine and methionine so that
both diets had similar total amino acid levels partly overcame the differences in absorption.
However this study has been criticised, because in the high protein diet sodium selenite was
used to provide all the selenium (261 pg/day) whereas in the low protein diet it only provided 150
pg/day of the selenium. Therefore these findings are difficult to interpret due to this use of
different selenium compounds (Robinson and Thomson, 1983). Animal studies have shown that
vitamins A and C promote absorption of selenite (Robinson and Thomson, 1983). This is an
unexpected finding as ascorbic acid would be expected to reduce selenite to elemental
selenium, which is probably not absorbed (Robinson and Thomson, 1983).
c) Transport
Selenium is transported in plasma bound to protein, though the proteins involved vary between
species and have not been well defined in humans. Albumin seems to be the main plasma
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selenium carrier in mice, whereas in humans selenium has been shown to be associated with
selenoprotein P, a2 and (3-globulins and [^-lipoproteins (Burk and Hill, 1994, Daniels, 1996;
Robinson and Thomson, 1983).
Selenoprotein P has been identified in plasma of both rats and humans (Burk and Hill, 1994),
accounting for over one half of the selenium content of mammalian plasma. Selenoprotein P has
a postulated selenium transport function (Motsenbocker and Tappel, 1982), though the evidence
for this is equivocal. Selenium is incorporated into selenoprotein P during protein synthesis
rather than non-specifically bound, an energy consuming process that appears wasteful merely
for transportation purposes. (Arthur, 1992; Hill and Burk, 1994). The half-life of selenium in
selenoprotein P is not affected by the selenium status of the animal (Burk and Hill, 1993) and the
only tissue which takes up selenium incorporated into selenoprotein P in selenium-deficient rats
is the brain (Hill and Burk, 1994). These factors casts doubt on the role of selenoprotein P in
transportation.
d) Metabolism and distribution
The metabolism of selenium is a complex process and varies according to the form ingested.
Selenomethionine is readily and non-specifically incorporated in place of methionine residues
into a large number of proteins especially skeletal muscle protein. The function(s) of the proteins
which have a selenomethionine residue substituted for methionine appear unaltered. This non-
active selenium pool makes up a large proportion of the total body selenium and does not
appear to be under homeostatic control (Behne et at., 1991). However, its incorporation is
directly correlated with selenomethionine intake and inversely correlated to methionine intake
(Burk and Hill, 1993). Selenomethionine is not directly available for utilisation in specific
selenium pathways until it has been catabolized to selenide. Its metabolism to selenocysteine is
via the methionine transamination and transsulphuration pathways provided adequate
methionine is available (Burk, 1991; Daniels, 1996; Esaki et at., 1981; Sunde, 1990). The
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resulting selenocysteine does not accumulate, instead it is reduced to selenide to enable its
selenium to be made available for selenoprotein synthesis. Non-methylated forms of ingested
selenium are converted into methylated mono-, di- and tri-methylated selenium species in this
metabolic pathway (Foster and Sumar, 1997) (Figure 1.10).
Selenocysteine does not follow the same metabolic pathway as cysteine, instead selenocysteine
is rapidly converted to L-alanine by the selenocysteine-specific enzyme selenocysteine (3-lyase
which catalyses the p-elimination of L-selenocysteine (figure 1.10) (Esaki et al., 1981). The two
possible products from this mechanism are selenide, which is produced when the reaction is
carried out in the presence of dithiothreitol, and elemental selenium, which is formed when the
reaction is carried out anaerobically in the absence of any thiols. The action of selenocysteine p-
lyase has two main purposes. It allows for the rapid elimination of the reactive molecule
selenocysteine and it supplies the reduced form of selenium which is required for selenoprotein
synthesis.
Inorganic sources of selenium are not stored but are metabolised according to figure 1.10.
Erythrocytes rapidly take up and reduce selenite to selenodiglutathione which then undergoes a
two-stage reduction to selenide in the liver and erythrocytes by glutathione reductase (Foster
and Sumar, 1997).
There appear to be two distinct metabolic pools or compartments of selenium in animal tissues.
The first incorporates all forms of selenium derived from inorganic selenium, including
endogenously synthesised selenoproteins, the excretory trimethyl selenium and the intermediary
products from the metabolism of selenite to selenide. This pool provides the metabolically active
seleno-compounds. The second pool includes the proteins into which selenomethionine is non-
specifically incorporated. These selenium-containing proteins have no known function other than
possibly providing a selenium store. There is no evidence that the first pool contributes to the
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second, but the second can contribute to the first through cataboiism of selenomethionine as
described above (Janghorbani et al., 1990).
e) Excretion
The principle route of excretion of selenium is through the kidneys in urine as trimethyl selenium,
with some loss through faeces, which comprises mainly unabsorbed selenium. Homeostatic
balance of selenium in animals is primarily controlled through the regulation of its excretion
through urine. Urinary concentrations of selenium are closely correlated to plasma selenium and
dietary selenium within sample groups (Robinson and Thomson, 1983). Trimethyl selenium is
the only metabolite identified in urine, although five other unidentified metabolites have been
found.
Selenium is excreted to a small extent through dermal loss and normally only insignificant
amounts are lost through exhalation, except when selenium intake is toxic when dimethyl
selenium is exhaled (Diplock, 1976). This compound has a smell similar to garlic.
1.4.4 Selenoprotein synthesis
Selenium is incorporated specifically into selenoproteins as selenocysteine residues through a
co-translational event directed by the UGA codon (Heider, Baron and Bock, 1992). This UGA
codon was originally identified as a termination codon in the genetic code. However in
selenoprotein synthesis the UGA codon signals the site of selenocysteine incorporation. This
alternative interpretation of the UGA codon requires a mechanism which recognises the
appropriate UGA codon and distinguishes it from the termination codon.
The mechanism for the synthesis of selenoproteins was characterised in prokaryotes using E.
coli mutants (as reviewed in Bermano, Arthur and Hesketh, 1996; Heider, Baron and Bock,
1992). The synthesis of selenocysteine and its insertion into specific selenoproteins in
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prokaryotes involves the products of four genes (selA, selB, seIC, and selD) (Allan, Lacourciere
and Stadtman, 1999). The products are; a selenocysteine specific tRNA species (tRNASec)
(seIC) which carries the anticodon for UGA, the enzymes, selenocysteine synthase (selA) and
selenophosphate synthetase (selD) that are essential for the formation of selenocysteine-
tRNASec from seryl-tRNASec and the elongation factor that specifically recognises the
selenocysteine-tRNA (selB). The major steps of this co-translational event are illustrated in
figure 1.11.
The lack of a corresponding series of mutants has prevented a complete elucidation of the
mechanism of selenocysteine incorporation and selenoprotein synthesis in eukaryotes. However
two forms of the tRNASec have been isolated in eukayotes and both contain the UGA anticodon
which is functional in E. coli (Kollmus, Flohe, and McCarthy, 1996; Low and Berry, 1996). Like
bacterial tRNASec, in eukaryotes tRNASec is esterified with serine and is subsequently converted
to seryl-tRNAsec. However, the nature of the mRNA selenocysteine insertion sequence (SECIS)
elements which are responsible for the recognition of the UGA as a selenocysteine insertion
codon differs between prokaryotes and eukaryotes (Kollmus, Flohe, and McCarthy, 1996). In
prokaryotic selenoproteins these sequences form a stem-loop structure immediately
downstream (3') from the UGA codon in the open reading frame. The movement of this
sequence by more than one codon seriously compromises selenoprotein synthesis. In contrast
eukaryotic SECIS elements are located in the 3'-untranslated region of the mRNA (Berry, 1991).
They comprise a small number of conserved nucleotides which form a stem-loop structure (Low
and Berry, 1996). Studies by Berry et al. have shown these SECIS elements are functionally
interchangeable (Berry, 1991; Berry et al., 1993).
The selenocysteine residue in most selenoproteins is necessary for the full activity of that
enzyme. This has been demonstrated through the use of mutant cysteine analogues of
selenoproteins whereby the selenocysteine residue of the selenoprotein has been substituted
with a cysteine residue. A comparison of the enzyme activity of the selenocysteine-containing
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Figure 1.11 The synthesis of selenocysteine and its incorporation into selenoproteins in
prokaryotes. The selenocysteine specific tRNA (tRNA360) is initially esterified with l-serine
catalysed by seryl-tRNA synthetase [373], Once charged with l -serine the seryl-tRNASec can
bind to selenocysteine synthase. Selenocysteine synthase is a pyridoxyl 5-phosphate enzyme
which catalyses the exchange of the conversion of seryl-tRNASec to selenocysteyl-tRNAS6C. The
initial step involves a 2,3-elimination of a water molecule to form an aminoacrylyl-tRNASe°
intermediate. The second step involves the addition of a reactive selenium derivative across
the double bond of the aminoacrylyl residue. Monoselenophosphate acts as the selenium donor
in this reaction. It is produced from the selenide and ATP by the selD gene product
selenophosphate synthetase. The selenocysteyl-tRNAS6C (sec-tRNASec) is then released from
the selenocysteine synthase and binds to the elongation factor selB which delivers the sec-
tRNA360 complex to a stem loop structure on the mRNA. In order to recognize the UGA codon
as an insertion sequence for selenocysteine as opposed to a stop codon the stem loop structure
has a specific sequence, positioned downstream from the UGA codon. The stem loop structure
binds the se/B-tRNAS6C-selenocysteine complex aiding its interaction with the UGA codon and
the subsequent incorporation of selenocysteine into the protein. Adapted from Leinfelder
(Leinfelder et at., 1990).
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type I 5' deiodinase with its cysteine-containing mutant analogue showed that the mutant
enzyme was only 10-20% as active as the native selenocysteine-containing enzyme (Berry,
Banu and Larsen, 1991). More recently cysteine-containing mutants have been made for TR.
The NADPH-disulphide oxidoreductase activity of the purified TR mutant-enzyme was only 6-
11% of that of the wild type rat liver TR (Lee et a!., 2000).
For many years cytoplasmic GPX (cyGPX) was the only known selenoprotein. It is now known
that selenium exerts its effects through the expression of a number of different intracellular and
extracellular selenoproteins (Arthur and Beckett, 1994). At least 30 selenoproteins have been
identified by SDS-polyacrylamide electrophoresis (SDS-PAGE) of [75Se]-labelled tissue, but only
approximately 13 have been characterized by purification and cloning.
1.4.5 Mammalian selenoproteins and selenium-containing proteins
Table 1.08 lists the mammalian selenoproteins that have been characterized.
a) Glutathione peroxidases
i) Introduction
The family of glutathione peroxidases include four distinct selenoproteins. Each of these
peroxidases arise from distinct gene products which are homologous with one another but
structurally and phytogenetically unrelated to the selenium-containing bacterial oxidoreductases
and the other mammalian selenoproteins.
Cytoplasmic glutathione peroxidase (cyGPX) was first discovered by Mills in 1957 and was
shown to be important in the protection of red blood cells against hydrogen peroxide or
ascorbate-induced haemoglobin oxidation (Mills, 1957; Rotruck et al., 1973). Until the discovery
of further selenoproteins the biological functions of selenium, including its antioxidant role, were
attributed to this classic tetrameric selenoprotein cyGPX. However, in 1982 a second glutathione
52
Introduction chapter one








type I & type II
type I & III
Selenoprotein P
Thioredoxin reductase





intracellular antioxidant, selenium store?




catalyses the conversion of thyroxine (T4) to
3,5,3' triiodothyronine
catalyses the conversion of T4 to 3,3',5'
reverse triiodothyronine
transport? Antioxidant role?
multiple roles associated with its role as part
of a dithiol-disulphide oxidoreductase system
antioxidant role ?
catalyses the production of selenophosphate,
required for selenoprotein synthesis
linked with prostate cancer?
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peroxidase was identified and characterized as phospholipid hydroperoxide glutathione
peroxidase (PHGPX ) (Ursini efa/., 1982). This was followed four years later by the isolation and
characterization of a glycosylated extracellular selenoprotein isolated from the plasma and aptly
named plasma GPX (pIGPX) (Avissar et ai, 1989; Takahashi and Cohen, 1986). The
gastrointestinal tract yielded the fourth member of this family of selenoproteins appropriately
labelled gastrointestinal GPX (giGPX) (Chu, Doroshow and Esworthy, 1993). More recently
selenoproteins with structural similarities to the glutathione peoxidases, encoded by viral
genomes, have been identified (Burk and Hill, 1999). For example the human immunodeficiency
virus is thought to sequester selenium thus depriving infected cells (Taylor et ai, 1994).
As is common to most known selenoproteins, selenium is an essential requirement for the
synthesis of all the glutathione peroxidases. The elimination of the selenocysteine residue or
carboxymethylation of selenocysteines by iodoacetate inactivates the GPX (Ursini etal., 1995).
ii) Cytoplasmic glutathione peroxidase
The structure and function of the cyGPX has been extensively studied. cyGPX comprises four
identical subunits, each with a molecular weight reported to be between 19-25 kDa. Each
subunit contains a glutathione binding site and an active site comprising of a single
selenocysteine residue which is located at approximately the fortieth residue from the N-terminal
end; the exact location depends on the tissue and species (Sunde, 1994; Zachara, 1992).
Following the cloning of murine cyGPX from a mouse genomic DNA library, this enzyme has
since been cloned from several tissues and species (Sunde, 1994). cyGPX is expressed in
virtually all cells although its specific activity is known to vary between different species and
tissues.
The antioxidant function of the glutathione peroxidases is well documented. cyGPX, as well as
the other tetrameric glutathione peroxidases (pIGPX and giGPX) is able to catalyse the reduction
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of a variety of hydroperoxides, including hydrogen peroxide, cumene hydroperoxide, t-butyl
hydroperoxide and fatty acid hydroperoxides (Fiohe, 1989).
The reactions catalysed by each glutathione peroxidase (GPX) follow a similar mechanism in
which the GPX catalyses the reduction of either hydrogen peroxide (H202) or an organic
hydroperoxide (ROOH), using glutathione (GSH) as a reducing agent, to form water or the
corresponding alcohol and glutathione disulphide (GSSG) according the equation 1 and 2. Each
member of the GPX family uses a complex ter uni Ping-Pong mechanism for its actions (Ursini
et at., 1995; Ursini, Maiorino and Gregolin, 1985). Several different catalytic mechanisms have
been postulated for these reactions. Figure 1.12 illustrates the mechanism described below.
Ganther proposed that the first step involves the oxidation of the GPX active site selenol to
selenenic acid by the peroxide substrate (Ganther, 1999). This is followed by the reaction of
selenenic acid with the first GSH molecule to form water (or alcohol in the case of organic
hydroperoxides). The final step involves the cleavage of the sulfoselenide link by a second GSH
molecule, releasing oxidised glutathione and restoring GPX to its selenol form (Zachara, 1992).
GPX
H202 + 2GSH ► 2H20 + GSSG (1)
GPX
ROOH + 2GSH ► ROH + H20 + GSSG (2)
The importance of cyGPX in the physiological regulation of intracellular hydroperoxide
concentrations is in doubt as selenium deficiency resulting in a loss of cyGPX activity to less
than 1% of control values in the rat liver resulted in no obvious adverse clinical effects in the
short term (Arthur eta!., 1987; Burk and Hill, 1993). In addition cyGPX knock-out mice displayed





GSSG + H+ GSH
GSH^ E-Se-SG ^ ^ H2O
Figure 1.12. A diagram illustrating a hypothetical mechanism for the glutathione redox
cycle. The first step involves the oxidation of the glutathione peroxidase active site selenol (E-
Se") to selenenic acid (E-SeOH) by the peroxide substrate. E-SeOH then reacts with the first
reduced glutathione molecule (GSH) to form water (or alcohol in the case of organic
hydroperoxides). Finally the sulfoselenide (E-Se-SG) link is cleaved by a second GSH
molecule releasing oxidised glutathione (GSSG) and restoring GPX to its E-Se" form. Adapted
from Zachara (Zachara, 1992).
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the evidence for such a role is equivocal (Burk and Hill, 1994). The incorporation of selenium
into selenoprotein P and its subsequent release are energy consuming processes which appear
to be wasteful merely for transportation purposes (Arthur, 1992). The half-life of selenium in
selenoprotein P is not affected by the selenium status of the animal which also questions a
transportation role for selenoprotein P (Burk and Hill, 1993). Also, in the selenium-deficient rat
the only tissue to accumulate selenium from selenoprotein P is the brain (Hill and Burk, 1994).
Alternatively selenoprotein P may provide an important defence for endothelial cells against
oxidative damage (Burk et a/., 1997). The association of selenoprotein P with endothelial cells
has led to speculation that selenoprotein P can protect the endothelium against extracellular
reactive oxygen species such as peroxynitrite and superoxide produced in cardiovascular
disease (Burk et at., 1997). Burk et at. have described an in vivo model which links the
selenoprotein P with an antioxidant function (Burk et a!., 1995; Burk, Lawrence and Lane, 1980).
Selenium-deficient rats administered diquat (a compound which generates superoxide in the
hepatocyte) at concentrations well below the LD50 for selenium-sufficient rats die within hours
due to liver necrosis and lipid peroxidation (Burk, Lawrence and Lane, 1980). However if
selenium-deficient rats are injected with selenium 12 hr prior to diquat administration the rats
survive and the degree of protection correlates with selenoprotein P levels in plasma but not with
glutathione peroxidase activity (Burk eta!., 1995).
d) Thioredoxin reductase
i) Thioredoxin reductase - characteristics
Thioredoxin reductase (TR) is a member of the pyridine nucleotide-disulphide family of enzymes
which includes lipoamide dehydrogenase, mercuric reductase, trypanothione reductase and
glutathione reductase (Gasdaska et al., 1999b; Lee et at., 1999; Sun et at., 1999). However the
other members of this family lack the selenocysteine residue which characterizes TR as a
selenoprotein (Tamura and Stadtman, 1996; Gladyshev, Jeang and Stadtman, 1996).
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TR is a FAD-containing homodimeric selenoenzyme which, together with thioredoxin (Trx) as a
substrate and NADPH as a cofactor, forms a powerful dithiol-disulphide oxidoreductase system
referred to as the TRTTrx system. Each TR subunit has a molecular mass of between 54-65 kDa
and contains a tightly bound FADPH which mediates the transfer of reducing equivalents from
NADPH to the disulphide bond of Trx and other substrates (Holmgren, 1989). TR has a
conserved Cys-Val-Asn-Val-Gly-Cys active site sequence. A single selenocysteine encoded by a
UGA codon is also contained within each subunit within the sequence Cys-SeCys-Gly as the
penultimate carboxyl terminal residue (Gladyshev, Jeang and Stadtman, 1996a). The function of
the selenocysteine residue has not been clarified. Its presence is essential for enzyme function,
as substitution of the selenocysteine residue with cysteine (Berggren et at., 1997), or removal of
the selenocysteine residue by peptidase treatment (Zhong et at., 1998), by selective alkylation
(Nordberg et at., 1998) or by the removal of the selenocysteine insertion sequence (SECIS)
element (Fujiwara et at., 1999) abolishes TR activity. It is postulated that the selenocysteine
does not form part of the catalytic site but carries reducing equivalents from the active site to the
substrate (Gladyshev, Jeang and Stadtman, 1996b; Gromer etal., 1998).
ii) Thioredoxin reductase - substrates
Trx is a ubiquitous low molecular weight (10-12 kDa) multifunctional protein (Holmgren, 1985;
Holmgren, 1989; Holmgren and Bjornstedt, 1995). It consists of a redox-active disulphide (Trx-
S2)/dithiol (Trx-(SH)2 within the conserved active site sequence:- Cys-Gly-Pro-Cys-Lys
(Holmgren, 1989; Holmgren and Bjornstedt, 1995). The redox state and activity of Trx is
regulated by TR whereby TR converts oxidised Trx back to its reduced form (Holmgren and
Bjornstedt, 1995).
Mammalian TR can catalyse the reduction of a variety of substrates including Trx, protein
disulphide-isomerase, low molecular weight disulphides such as 5,5'-dithiobis (2-nitrobenzoic
acid) (DTNB), lipoic acid as well as non-disulphides such as selenite, selenodiglutathione,
vitamin K, alloxan and lipid hydroperoxides (Bjornstedt et al., 1995; Bjornstedt, Kumar and
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Holmgren, 1992; Lundstrom and Holmgren, 1990). The ability of TR to reduce dehydroascorbic
acid to ascorbic acid has also been reported (May eta/., 1997).
iii) Cellular functions
The reduction of Trx (Trx-S2) to Trx-(SH)2 catalysed by TR (reaction 1) provides a powerful
protein disulphide reductase (reaction 2), which has multiple roles.
TR
NADPH + H+ + Trx-S2 < * NADP+ + Trx-(SH)2 (1)
spontaneous
Trx-(SH)2 + protein-S2 < - Trx-S2 + protein-(SH)2 (2)
Interest in the TR/Trx system increased after the initial discovery that TR provides reduced Trx
which serves as a hydrogen donor for ribonucleotide reductase in the initial and rate limiting step
in DNA synthesis (Thelander and Reichard, 1979). The TR/ Trx system has subsequently been
associated with many diverse cellular functions including the regulation of cell growth in both
normal and cancer cells (possibly by increasing the sensitivity of the cell to endogenous growth
factors) (Berggren et at., 1996; Gallegos et at., 1996) and the inhibition of apoptosis via the
binding of oxidised Trx to the apoptosis signalling kinase-1 (Fujiwara et at., 1999). The
regeneration of proteins inactivated by oxidative stress including glyceraldehdye-3-phosphate
dehydrogenase (Fernando et al., 1992), phosphotyrosine phosphatase (McCarty, 1999) and
nitric oxide synthase (Patel, Zhang and Block, 1996) is also thought to involve the TRTTrx
system. In addition this system is believed to regulate the DNA-binding activity of transcription
factors (Berggren et al., 1996a; Bjornstedt et al., 1995; Gallegos et al., 1997a), including NF-kB
(Matthews et al., 1992; McCarty, 1999); the glucocorticoid receptor (Makino et al., 1996); TFIIIC
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(Cromlish and Roeder, 1989); BZLF1 (Bannister, Cook and Kouzarides, 1991) and the
modulation of activator protein 1 (fos/ Jun heterodimer) indirectly through a nuclear redox factor
ref-1/HAPE (Xanthoudakis etal., 1992).
The TRTTrx system can regulate the cellular redox state (Gasdaska et al., 1999a) and protect
against oxidative stress (Holmgren, 1985; Holmgren, 1989). For example, it can serve as a
redox regulator of cellular antioxidant systems by acting as an electron donor for methionine
sulfoxide reductase (Holmgren, 1985); 3-phosphoadenosine 5'-phosphosulphate reductase
(Holmgren, 1985); thioredoxin-dependent peroxidase (Chae et at., 1994); protein disulphide
isomerase (Holmgren and Bjornstedt, 1995); and vitamin K epoxide reductase (Maellaro et at.,
1994). Trx also facilitates the refolding of disulphide-containing protein [Lundstrom, 1990 #627],
Trx is a reactive oxygen species (ROS) scavenger and recombinant human Trx has been shown
to protect against hydrogen peroxide and TNFa-induced cytoxicity (Matsuda et at., 1992;
Nakamura et at., 1994). In a cell-free system TR has been shown to directly reduce and detoxify
hydrogen peroxides, organic hydroperoxides and lipid hydroperoxides (Bjornstedt et at., 1995)
and, serve as a electron donor to plasma glutathione peroxidase (Bjornstedt et at., 1994). Trx
will also act as a reducing agent for type 1 iodothyronine deiodinases (Sharifi and St Germain,
1992). More recently up-regulation of the thioredoxin system has been associated with the
development of cellular resistance to the chemotherapeutic agent c/s-diamminedichloroplatinum
(II) (Sasada etal., 1999).
iv) Thioredoxin reductase isoforms
Recently it has been shown that several isoforms of TR exist. Studies have shown that the
57kDa TR isolated from HeLa cells and from human lung adenocarcinoma cells can be further
dissociated according to their ability to bind to a heparin-agarose affinity column and their
reactivity with anti-rat liver TR polyclonal antibodies (Gorlatov and Stadtman, 1999; Liu and
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Stadtman, 1997). The cytosolic form of TR (classified by Gorlatov and Stadtman as TrxR1
(Gorlatov and Stadtman, 1999)) is not retained by the heparin column and shows cross-reactivity
with anti-rat liver polyclonal antibodies. In contrast, the mitochondrial isoform (TrxR2) binds
tightly to the heparin affinity column and shows only very weak cross-reactivity (Gorlatov and
Stadtman, 1999). These two different isoforms have been cloned and sequence data suggest
that they are closely related, including a conserved active site sequence (CVNVGC) and FAD-
binding and NADPH-binding domains (Miranda-Vizuete et al., 1999). Immunoblot analysis has
confirmed that TrxR1 is expressed in the cytosol and nucleus but is also secreted (Hirota et al.,
1997) whilst expression of TrxR2 as a fusion protein with green fluorescent protein showed that
TrxR2 is located in the mitochondria (Miranda-Vizuete et al., 1999). The TrxR2 initially
possesses a N-terminal extension which in the human adrenal gene product targets the enzyme
from the cytoplasm to the mitochondrial membrane (Lee et al., 1999; Miranda-Vizuete et al.,
1999). The postulated function of this alternative TR isoform is to provide a mitochondria-
specific defence against ROS produced by the mitochondrial respiratory chain thus maintaining
a redox balance critical for cell survival (Lee et al., 1999).
Gortalov and Stadtman have recently suggested that the differing abilities of these enzymes to
bind to the heparin reflect differences in conformational states determined by the redox state of
the enzyme (Gorlatov and Stadtman, 1999). Gasdaska et al. recently reported the identification
and characterization of a third human TR (TR-(3), differing in molecular mass (56.5 kDa) and
exhibiting a distinct pattern of tissue expression with high levels of TRp mRNA found in the
prostate, testis, liver, uterus and small intestine and only low levels in placenta, kidney,
pancreas, thymus and peripheral blood leukocytes (Gasdaska et al., 1999b). The cDNA
sequence of TR(3 is identical to that of TrxR2 from human adrenal with the exception that the
former possess a Met-Ala-Ala extension at its N-terminus (Gorlatov and Stadtman, 1999). Using
a polyclonal antibody made against synthetic TRp peptide, Western blot analysis identified TR(3
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in both the cytosolic and microsomal subcellular fractions of MCF-1 human breast cancer cells
(Gasdaska et al., 1999b).
e) Selenoprotein W
Selenoprotein W is a small intracellular selenoprotein comprising one selenocysteine residue
per polypeptide chain (Burk and Hill, 1999). Four different forms of selenoprotein W have been
isolated from rat muscle and a partial amino acid sequence has been determined (Allan,
Lacourciere and Stadtman, 1999). The molecular masses of these isoforms range from 9.5 -10
kDa. The brain, muscle, testis and spleen contain the greatest amounts of selenoprotein W
whilst the liver contains only small amounts (Burk and Hill, 1999). The catalytic activity of
selenoprotein W is at present unknown although an antioxidant role has been postulated (Burk
and Hill, 1999). Over-expression of selenoprotein W in cultured rat glial cells has been
associated with increased protection against free-radical damage which supports a postulated
antioxidant function (Sun, Gu and Whanger, 1998).
f) Selenophosphate synthetase
Selenoprotein synthetase (SPS), the Sel D gene product, is an essential component of
selenoprotein synthesis, catalysing the production of selenophosphate, the selenium donor
required for selenocysteine synthesis. Two homologues of human SPS have been identified.
The first human SPS was cloned by Low et al. and is referred to as SPS1 (Low, Harney and
Berry, 1995). The transfection of SPS1 cDNA into mammalian cells led to increased [75Se]-
labelling of type 1 iodothyronine deiodinase (Low, Harney and Berry, 1995). The following year a
second SPS was identified. Designated SPS2, the gene encoding its transcription exhibits an in-
frame TGA codon at the enzymes putative active site (Guimaraes et al., 1996). The
incorporation of [75Se] into the immunopurified SPS2 protein provide further evidence that SPS2
is a selenoprotein (Guimaraes et al., 1996). The requirement of SPS2 synthesis for selenium
would suggest that this protein is involved in the regulation of selenoprotein synthesis per se,
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such that selenium-deficiency would be reflected by a down-regulation of SPS2 expression with
a parallel decrease in the expression of other selenoproteins. Therefore, differential expression
of these SPS1 and SPS2 proteins in tissues may explain the differences between tissues in
sensitivity to selenium-deficiency (discussed later in section 1.46).
g) Other selenoproteins and selenium-containing proteins
Through the use of SDS-PAGE and two-dimensional electrophoresis of [75Se]-labelled animal
tissue approximately 35 selenium-containing proteins or protein subunits with molecular masses
ranging between 6 and 116 kDa could be distinguished (Behne et al., 1988; Behne et al., 1999).
Naturally some of these selenium-containing proteins may represent as yet uncharacterized
selenoproteins. For example a 15 kDa selenoprotein has recently been isolated and
characterized in human T ceils. Its function is as yet unknown but its high expression in prostate
tissue has been linked with a protective role against prostate cancer (Gladyshev et al., 1998).
Several selenium-containing proteins have been characterized. Fatty acid-binding proteins
(FABP) constitute a family of highly conserved 14-15 kDa cytosolic proteins which are involved
in the regulation of intracellular levels of long chain fatty acids (Masouye et al., 1997). Bansal et
al. have identified a 14 kDa mouse liver selenium-binding protein as a FABP (Bansal et al.,
1989). Liver FABP has been implicated in the regulation of cell growth and the presence of
selenium may provide a mechanism by which this occurs. To date no other members of the
FABP superfamily have been identified as selenium-containing proteins. Protein disulphide
isomerase (PDI) is also a selenium-containing protein, with approximate molecular weight of 58
kDa. Treatment of PDI with SDS has shown that selenium is tightly bound to PDI. However
cloning and sequencing have not identified a TGA codon in the nucleotide sequence of PDI and
therefore selenium is not incorporated as a selenocysteine residue (Sinha et al., 1993). The role
of selenium is this protein is unclear as supplementation of mouse epithelial cells with selenium
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appears to have no effect on the levels of PDI (Sinha et al., 1993). Also, PDI activity is not
regulated by selenium in either rats or cultured cells (Arthur et at., 1991; Sinha et at., 1993).
1.4.6 Regulation of selenoproteins
i) Hierarchy of selenium supply
Expression of all the selenoproteins characterized to date, namely the glutathione peroxidases,
thioredoxin reductases, iodothyronine deiodinases, selenoprotein P and selenoprotein W is
regulated by selenium supply. Selenium deficiency results in a fall in all selenoproteins, unlike
other modulators of selenoprotein expression which may be specific for particular
selenoproteins. The extent to which selenium availability affects selenoprotein expression differs
between tissues and between individual selenoproteins within a tissue. Several studies have
been performed which demonstrate this differential regulation (Behne et al., 1988; Bermano,
1995; Bermano, Arthur and Hesketh, 1996; Burk and Hill, 1993; Hill et al., 1997; Weitzel, Ursini
and Wendel, 1990). For example, Yang et al. studied the effect of changes in dietary selenium
on cyGPX and pIGPX activities and selenoprotein P expression, measured in rat liver and
plasma (Yang, Hill and Burk, 1989). They found that as selenium was supplemented into the
diet, selenoprotein P expression increased initially, followed by an increase in pIGPX levels.
Liver cyGPX was the last to respond to increased selenium supply. In a diet supplemented with
0.02 mg selenium/kg the selenoprotein P concentration was 48% of the control, whilst pIGPX
and cyGPX activities were only 12% and 1% of control values respectively.
There is a clear hierarchy in the selenium supply to different tissues (figure 1.13). Behne et al.
were the first to show that in the rat there is a differential loss of selenium from different tissues
in selenium-deficiency (Behne et al., 1988). It appears that regulatory mechanisms exist which
ensure that, in selenium deficiency, selenium levels are maintained in certain priority organs.
Selenium is generally retained where it is most needed such as the brain, endocrine and
reproductive organs thus indicating the relative importance of the element for the biological
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Figure 1.13. Schematically representation of the hierarchy of selenium retention by
different tissues in selenium-deficient rats. Tissues at the top of the hierarchy preferentially




functions of these organs. The differential regulation is not achieved by a decrease in the
turnover of selenium in deficient tissues alone, re-distribution of the metabolised element and
priority supply to these tissues are also involved. In selenium-deficiency, selenium supply is not
only preferentially diverted to certain tissues it is also directed to specific selenoproteins within
that tissue such that selenium supply to selenoproteins other than glutathione peroxidase had
priority (Behne et al., 1988).
Both organ-specific and selenoprotein-specific regulation are demonstrated in the study carried
out by Bermano et al. which examined the levels of cyGPX, PHGPX and type I iodothyronine
deiodinase (IDI) in the heart, liver and thyroid of rats fed a diet of varying selenium content
(Bermano, 1995). In selenium-deficient rats cyGPX, PHGPX and IDI activities in the liver
decreased 99%, 75% and 95% respectively. In the thyroid, cyGPX was decreased by 50%,
PHGPX was unaffected and IDI was increased by 15%. Therefore with inadequate selenium
intake selenium is preferentially retained by the thyroid and in this tissue the supply of selenium
to PHGPX has priority over cyGPX.
Selenium status does not affect the transcription rate of genes for any of the selenoproteins
studied (Burk and Hill, 1993; Wingler et al., 1999). However, changes in the expression and/or
the activity of selenoproteins in selenium deficiency are accompanied by changes in mRNA
levels which may result from alterations in mRNA translation and/ or stability (Bermano, 1995;
Bermano, Arthur and Hesketh, 1996; Gallegos et al., 1997a; Saedi et al., 1988; Sunde et al.,
1993). In addition selenium deficiency may also result in premature polypeptide chain
termination owing to the recognition of the UGA codon as a normal stop codon (Burk and Hill,
1993).
ii) Regulation of thioredoxin reductase
The biosynthesis of each TR isoform, as with other selenoproteins, is dependent on selenium
status (Gallegos et al., 1997b; Marcocci, Flohe, and Packer, 1997). For example, in vivo, rats
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fed a high selenium diet undergo a transitory increased expression of TR in the liver, lung and
kidney (Berggren et al., 1999).
The expression and activity of TR is also subject to the hierarchy of selenium supply. This was
demonstrated in a recent study by Hill et al. in which dietary selenium deficiency in rats caused a
decrease in TR activity to 4.5% of control in liver and 11% in kidney whilst TR activity in the brain
was unaffected (Hill et al., 1997). In cell culture studies carried out by Gallegos et al. both TR
expression and activity were shown to be dependent on selenium availability in the media which
proved to be partly due to enhanced stabilisation of mRNA by selenium (Gallegos et al., 1997).
Stabilisation of mRNA is not the only mechanism by which selenium status influences
selenoprotein synthesis. Selenophosphate synthetase, which provides selenophosphate for
selenoprotein synthesis, exists in two forms, one of which is a selenoprotein containing a UGA
codon with a requirement for a source of selenium. It follows that in selenium-deficiency those
tissues which preferentially retain selenium have an active selenium-dependent
selenophosphate synthetase but in tissues with an inadequate supply of selenium this protein
would not be active which may therefore limit selenoprotein synthesis.
The degree of change in TR activity and TR protein levels has been shown not to be directly
related (Berggren et al., 1999; Gallegos et al., 1997). Instead, in certain rat tissues increases in
TR activity were not directly correlated to increases in protein levels, instead they paralleled
increases in specific activity possibly due to an increased selenocysteine incorporation
(Berggren et al., 1999). These particular findings are consistent with the possibility that in
selenium-deficiency a truncated protein is formed in which translation is terminated at the UGA
codon where selenocysteine is normally inserted (Gladyshev, Jeang and Stadtman, 1996).
However without subjecting the proteins to complete amino acid analysis this is not confirmed. In
contrast, it has been shown that removal of the selenocysteine residue by proteolysis, specific
alkylation of the selenocysteine residue, or oxidation of the selenocysteine leads to total loss or a
marked reduction in TR activity (Lee et al., 2000). It has also been suggested that some
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methods used to measure TR activity and mass are not entirely satisfactory (personal
communication, Dr J. R. Arthur, Rowett Research Institute, Aberdeen, UK). For example,
Western blot analysis of TR mass expressed in tissues identifies two immunoreactive bands
close in molecular weight. The quantification of the band which represents cross-reactivity of an
immunogenic plasma component in tissue may explain the lack of correlation between
measurements of TR activity and TR mass. In a recent study by Berggren et al. selenium
supplementation of rats was shown to have no effect on TR protein levels measured in kidney,
liver and lung tissue as measured by Western blot analysis (Berggren et al., 1999). However in a
similar study carried out by Arthur et al. increased dietary selenium was shown to significantly
increase TR protein synthesis which correlated with changes in tissue TR activity (personal
communication from Dr John Arthur, Rowett Research Institute, UK).
iii) Other modulators of selenoprotein expression
Selenium status is not the only modulator of selenoprotein expression and activity. Other factors
have been shown to influence selenoprotein expression at the level of the individual
selenoprotein. For example copper-deficiency has been shown to down-regulate cyGPX activity
and its mRNA (Sunde, 1994). Also the expression of TR has been shown to be increased by
PMA, the calcium ionophore A23187 and reactive oxygen species (Howie et al., 1998; Kumar
and Holmgrem, 1999; Sun et al., 1999). Mitchell et al. demonstrated that iodine-deficiency in
adult rats which leads to increased H202 production increases thyroidal cyGPX activity (Mitchell
eta!., 1996).
1.4.7 Effect of low selenium status or selenium deficiency in humans
Low dietary selenium intake has been implicated in the development of numerous health
disorders in humans. These include, Kashin-Beck disease, cancer, cardiovascular disease
(including Keshan disease), muscular dystrophy, malaria, alopecia areata, pregnancy
hypertension syndrome, altered immune function, male infertility and even AIDS (Baum et al.,
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1997; Foster and Sumar, 1997; Gallegos et at., 1997; Levander, 1987; Ximin et at., 1998).
Patients on long-term parenteral nutrition without selenium-supplementation in their formulation
run the risk of selenium deficiency which has been linked with myopathy (Brown et at., 1986; van
Rij et at., 1979) and cardiomyopathy (Fleming et at., 1982; Johnson et at., 1981).
Kashin-Beck disease (osteoarthritis deformans endemica) is a selenium-responsive endemic
osteoarthritis affecting preadolescent and adolescent children living in northern China, North
Korea and eastern Siberia (Levander, 1987). The principle pathological feature of this disease is
the necrotic degeneration of the chondrocytes. Joint deformation and, in extreme cases,
dwarfism results from the cartilage abnormalities characteristic in the later stages of Kashin-
Beck. There is some evidence that low selenium status contributes to the development of
Keshin-Beck, though other etiological factors may be important, including poisoning by Fusarium
mycotoxins and nutritional mineral imbalances (Levander, 1987). Studies have shown a dose-
response relationship between urinary selenium levels and the incidence of this disease in
China. Results from an uncontrolled therapeutic trial showed that 80% of children with early
symptoms responded positively to treatment with sodium selenite and vitamin E (Luo, 1984. In
contrast, an intervention trial carried out over a five year period to test the prophylactic effect of
selenite against Kashin-Bech disease failed to demonstrate any preventative effect (Levander,
1987).
The evidence for an association between selenium status and incidence of cancer is primarily
based on epidemiological evidence and animal experiments. In 1965 Shamberger and Rudolph
demonstrated a significant reduction of skin cancer incidence in carcinogen-treated mice given a
topical application of sodium selenite (Shamberger and Rudolf, 1965). This initiated a great
number of subsequent studies, using animal models, which demonstrated the anticarcinogenic
nature of selenium. Conclusions drawn from epidemiological studies are conflicting, with some
showing a significant association between selenium and cancer risk (Fex, Petterson and
Akesson, 1987; Salonen et at., 1984; Virtamo et at., 1987) and others not (Nomura et at., 1987;
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Ringstadt et a/., 1988). The most convincing evidence for the inverse relationship between
selenium and certain forms of cancer comes from a randomised double blind, placebo-
controlled study carried out by Clark et at. (Clark et at., 1996). 1300 subjects (mean age at
enrolment 63 yrs) from the south-eastern region of the USA either received a daily high-
selenium yeast tablet containing 200 pg selenium or a placebo yeast tablet for approximately 5
years. Interim analysis of the data collected up to 1993 showed that, excluding non-melanoma
skin cancers, total cancer incidence was found to be 42% lower in the selenium supplemented
group compared to the placebo group with the most significant decreases in the incidence of
prostate and colorectoral cancer. The total cancer death rate was found to be 52% lower in the
subjects who received selenium supplementation.
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1.5 SELENIUM AND CARDIOVASCULAR DISEASE
1.5.1 Selenium deficiency and cardiovascular disease
The risk of developing atherosclerosis and heart disease may be higher in people who have a
low dietary selenium intake. Also, patients on parenteral nutrition without selenium
supplementation have been shown to develop cardiomyopathy (Fleming et al., 1982; Johnson et
al., 1981). The first reported link between cardiovascular disease in humans and selenium
deficiency was established in the late 1970s in China (Korpela, 1993). Keshan disease, an
endemic cardiomyopathy affecting mainly children and young peasant women, was shown to be
regionally distributed in an area of low soil selenium content extending from north-east China
down to the south-west. The acute form of the disease is characterized by the sudden onset of
heart failure, whereas individuals suffering from the chronic form of the disease exhibit moderate
or severe heart enlargement with varying degrees of heart failure (Ge et al., 1983). The
pathological features of this disease are quite distinct, differentiating this cardiomyopathy from
other myocardial diseases. They include; multifocal necrosis, fibrous replacement of the
myocardium and myocytolysis (Levander and Burk, 1992). The incidence of Keshan disease is
dependent on age, socioeconomic status, seasonal variation and an annual shift in the epidemic
foci (Foster and Sumar, 1997). Selenium deficiency appears to be the fundamental underlying
condition pre-disposing individuals to the development of Keshan disease in certain endemic
areas (Yang et al., 1984). However supplementation only works as a prophylactic and cannot
reverse cardiac failure once it occurs (Levander and Burk, 1992).
Certain features of the disease cannot be explained by selenium status alone, including the
seasonal variation in the number of cases, suggesting an infectious agent may be involved.
Beck and co-workers carried out animal studies in which mice given a low selenium diet were
then exposed to the Coxsackievirus B3 (a family of viruses thought to be responsible for Keshan
disease). These mice developed inflamed hearts within one week whereas mice fed a selenium-
adequate diet were unaffected (Beck et al., 1995). When the virus, recovered from the infected
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selenium-deficient mice, was inoculated into selenium-adequate mice, a cardiomyopathic
condition was induced. Thus it appears that in a selenium-deficient host the virus is able to
mutate into a virulent cardiotoxic genotype. The isolated virus was shown to have mutated at
seven sites.
The contribution of selenium deficiency to the pathogenesis of cardiovascular disease was
originally suggested from epidemiological studies that correlated low selenium content of forage
crops, drinking water and blood levels with regional mortality rates from cardiovascular disease
(Schamberger, Willis and McCormack, 1979). Such associations are difficult to interpret
because it is not possible to exclude the effects of other factors such as interactions of other
nutrients, exercise, smoking, alcohol and fat intake and genetics. Whilst epidemiological studies
have provided some evidence for the role of low selenium intake in the aetiology of
cardiovascular heart disease and ischaemic heart disease, the results of studies within
populations have often produced conflicting results.
Moore et at. observed an inverse correlation between low plasma selenium and the severity of
atherosclerosis in 91 subjects examined by coronary angioplasty (Moore, Noiva and Wells,
1984). In a similar study the ratio of selenium to polyunsaturated fatty acid levels in serum was
negatively correlated to the degree of atherosclerosis (Kok et at., 1991). However, Aro et at.
found no such correlation in a group of Finnish subjects (Aro et at., 1986).
Up until 1997 the results from eight prospective studies had been published, attempting to
correlate selenium status with the risk of coronary vascular disease and myocardial infarction
(table 1.09) (Kok et at., 1987; Miettinen et at., 1983; Ringstad et at., 1987; Salonen et at., 1982;
Salonen et at., 1985; Simonetta et at., 1995; Suadicani, Hein and Gyntelberg, 1992; Virtamo et
at., 1985). Again the results from these studies are inconsistent. From the prospective studies
carried out in the 1980s only one found an inverse correlation between selenium and the risk of
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Table 1.09. The association of cardiovascular disease mortality and incidence with low
serum selenium in prospective case-control studies. CAD, coronary artery disease; CHD,
coronary heart disease; CVD, cardiovascular disease; Ml, myocardial infarction.
















Case-control study with 283
cases, men and women
aged 35-59 yrs, 7 yr follow-
up
Case-control study of 33
middle-aged male patients
with 1 or more risk factors
for CHD
5-7 yr follow-up
Cohort study of 1110 male
subjects aged between 55-
74 yrs
5 yr follow-up
Case-control study of 92
subjects, men and women
aged 30-64 yrs
5 yr follow-up
Case-control study of 59
male subjects initially free
of disease, aged 28-54 yrs,
6 yr follow-up
Case-control study of 84
subjects, men and women
aged 37-87 yrs, 6-9 yr
follow-up
Case-control study of 107
males aged 53-74 yrs, 3 yr
follow-up
Case-control study on 251
male subjects aged
between 40-84 yrs, 4-6 yr
follow-up
Serum selenium below 45 pg /1 was
associated with the increased risk of
death by CHD and CVD, as well as
the risk of fatal and non-fatal Ml
Serum selenium (50-105 pg /I) was not
associated with the development of
clinical CHD
Serum selenium below 45 pg /I was
negatively correlated to CVD death
but not in subjects initially free of CHD
No significant association between low
serum selenium (< 45 pg /I) and the risk
of coronary death or Ml
No significant association between low
serum selenium (< 45 pg /I) and the risk
of death from CAD
Low serum selenium is not associated
with an excess risk of Ml
No significant association between low
serum selenium (< 105 pg /I) and the risk
of subsequent death from CVD or CHD
Individuals whose selenium level was
below 1 pmol/L had an increased risk in
ischemic heart disease
No association between serum selenium
and risk of myocardial infarction
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death from cardiovascular death and myocardial infarction, two were equivocal, and no
association was found in the other studies (Levander, 1987).
The results from two larger studies were published in the 1990s. In 1992 the results from the
Copenhagen Male Study found that, after adjustments to take into account age, cholesterol,
social class and smoking, individuals whose selenium level was below 1 pmol/L had an
increased risk of coronary heart disease (Suadicani, Hein and Gyntelberg, 1992). In contrast, the
study carried out by Simonetta et al. concluded that there was no association between serum
selenium and risk of myocardial infarction (Simonetta et al., 1995).
To date, therefore, the epidemiological studies linking selenium deficiency to cardiovascular
disease are inconclusive. Huttunen postulated that the conflicting data from these studies can be
explained by the threshold effect of selenium intake on the risk of cardiovascular disease
(Huttunen, 1997). That is, in populations with low selenium status, a correlation between serum
selenium and cardiovascular risk is observed, whilst populations with a high selenium intake
(serum selenium levels > 45 pg/l) would show no such correlation (Korpela, 1993).
The results of a study carried out by Kardinnal et al. support this 'threshold hypothesis'
(Kardinaal et al., 1997). From the ten centres across nine European countries only one
demonstrated a statistically significant association between toenail selenium levels and risk of
myocardial infarction. This centre (in Germany) also has the lowest mean selenium levels.
In 1984 Finland embarked on a nationwide selenium supplementation programme. Prior to the
supplementation of multimineral fertilizers with sodium selenate, dietary selenium was 40-50 pig/
day. After three years of supplementation the selenium intake plateaued at 110-120 pg/ day,
remaining constant until 1990 when the selenium supplementation of fertilizers was decreased.
During this time the incidences of several human pathological conditions were assessed,
including the mortalities from ischemic heart disease. During the 1980s the decline in mortality
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from ischemic events was almost linear and the selenium supplementation programme did not
change this. Thus the decrease in mortality rates from ischemic heart disease could not be
attributed to increased dietary selenium and is likely to be the result of several factors such as
increased exercise, reduction in smoking, better health care and improved diet (Vara et al.,
1994).
1.5.2 Selenium and endothelial dysfunction
a) Introduction
Endothelial dysfunction is a primary factor in the pathogenesis of atherosclerosis as discussed
previously (section 1.3). In addition to the evidence gathered from epidemiological studies
discussed previously, laboratory based research has provided evidence that selenium may help
prevent atherosclerotic disease.
Selenium-deficiency is associated with an increased severity of atherosclerosis in experimental
animals. For example, Wojcicki et al. reported that the percentage of the aortic intima covered
by atherosclerotic lesions in hypercholesterolemic rabbits given selenium supplementation alone
decreased by 37% compared to controls (Wokcicki et al., 1991). The combined effect of
selenium and vitamin E supplementation diminished the area of atherosclerotic regions by
approximately 48% (Wokcicki etal., 1991).
The ability of certain selenoproteins to protect against atherosclerosis centres around their
capacity to reduce and detoxify ROS. Initially, research focused on the glutathione peroxidases
and the glutathione redox cycle and their antioxidant roles are now well established. Harlan et al.
using pharmacologic manipulation, established a protective role against neutrophil-mediated
H202 induced lysis in cultured bovine aortic and pulmonary artery endothelial cells and human
umbilical vein endothelial cells (Harlan et al., 1984). For example, in endothelial cells pre-treated
with butathione sulfoximime, an inhibitor of glutathione synthesis, neutrophil-mediated H202
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induced lysis was significantly greater compared to control cells. Using similar techniques, Ochi
et at. confirmed the protective effects of the glutathione redox cycle in cultured bovine carotid
endothelial cells, this time against the cytotoxic effects of 15(S)-hydroperoxyeicosatetraenoic
acid (15-HPETE) (Ochi, Morita and Murota, 1992). They demonstrated that the stimulation of
intracellular GSH synthesis in endothelial cells by treatment with L-2-oxothiazolidine-4-
carboxylate decreased 15-HPETE-induced injury whilst treatment with buthionine sulfoximine,
enhanced the susceptibility of endothelial cells to 15-HPETE toxicity. Also, exposure of cultured
bovine endothelial cells to 15-HPETE, in addition to inducing toxicity, suppressed GPX activity.
However, GPX activity was increased and 15-HPETE-induced toxicity decreased by
supplementing the cells with either sodium selenite or ebselen (a synthetic organoselenium
compound with cyGPX-like activity).
Selenium supplementation of bovine endothelial cells in the form of sodium selenite has also
been shown to protect against oxidative damage resulting from oxLDL, cholesterol
hydroperoxide and tert-butylhydroperoxide (t-BuOOH). This protection has been attributed to the
antioxidant effects cyGPX and PHGPX (discussed in further detail in section five) (Thomas,
Geiger and Girotti, 1993). Further evidence that cyGPX protects against oxidative damage is the
observation that the susceptibility of HUVEC to oxLDL-induced injury is higher than that of the
human endothelial cell line EAhy926 (Claise et at., 1997). The lower antioxidant capacity of
EAhy926 cells, particularly with regard to cyGPX activity, has been suggested as the cause of
the increased susceptibility of EAhy926 cells to oxLDL toxicity.
In many of the previous studies concerning the role of selenium in the protection of endothelial
cells from oxidative stress, the contribution of the TR/Trx system was not considered. In fact, TR
may also mediate the protective effects of selenium against oxidative damage to the
endothelium. For example, the TRTTrx system can maintain NOS in a reduced configuration
potentially overcoming the oxidative deactivation of NOS (Patel, Zhang and Block, 1996). The
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TR/Trx system has also been shown to directly reduce lipid hydroperoxides, hydrogen peroxide
and organic hydroperoxides (Bjornstedt et al., 1995).
Peroxynitrite formation is believed to contribute to endothelial dysfunction (for further discussion
see section 1.3.4). Glutathione peroxidases and possibly other selenoproteins such as
selenoprotein P in human plasma have been shown to act as peroxynitrite reductases (Arteel et
al., 1998; Sies et al., 1997). Recently it has been argued that the TR/Trx system may also
contribute to peroxynitrite defence (Arteel, Briviba and Sies, 1999).
The prostaglandin-like peroxidation product of arachidonic acid, 8-isoprostane, has been
implicated in atherosclerotic disease. It is used as a marker of lipid peroxidation. In agreement
with the findings from Thomas's study, bovine endothelial cells cultured in selenium-deficient
medium were more susceptible to damage from t-BuOOH than selenium-sufficient cells (Hara,
1998; Thomas, Geiger and Girotti, 1993). Selenium-deficient bovine endothelial cells were also
found to have enhanced levels of 8-isoprostane (Hara, 1998).
Selenium supplementation has been reported to have beneficial effects on several different
aspects of endothelial dysfunction. For example, selenium supplementation (4.33 pmol.g"1
bodyweight.d"1 for 3 consecutive days) enhances endothelium-dependent relaxation in response
to acetylcholine in rat aortic rings (Lu, Liu and Man, 1994). The mechanism for this enhanced
response may be through increased NO production mediated either directly by selenium or
through the selenoprotein glutathione peroxidase. Endothelial dysfunction is also evident in HIV-
positive patients (Constans et al., 1998) and although pilot studies show that selenium
supplementation does not improve the prognosis in these patients it does improve some
markers of oxidative stress, including a decrease in serum malondialdehyde and an increase in
glutathione peroxidase (Constans et al., 1996). Also, in a preliminary study on a small number of
HIV-infected patients, selenium supplementation with 100 pg selenite daily for 12 months
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prevented the usual increase in serum concentrations of soluble thrombomodulin and von
Willebrand Factor which are associated with endothelial dysfunction.
Selenium may also exert other effects in the endothelium, including the regulation of prostacyclin
and platelet activating factor (PAF) (Hampel et al., 1989). In selenium-deficient human umbilical
vein endothelial cells, histamine-induced PGI2 release was inhibited through the depression of
cyclooxygenase activity of prostaglandin endoperoxide synthase (PGPI2 synthase) It has been
proposed that this effect is due to a decrease in glutathione peroxidase activity resulting from the
selenium-deficiency. This leads to the accumulation of intracellular peroxides which can in turn
inhibit the cyclooxygenase activity of PGH2 synthase (Hampel et al., 1989). The effects of
selenium deficiency on PGI2 production have been reported elsewhere in cultured porcine aortic
endothelial cells (Schiavon et al., 1984) as well as in the aorta of selenium-deficient rats
(Valentovic, Gairola and Lubaway, 1985). PGI2 normally suppresses PAF formation. However, in
selenium-deficient HUVEC with suppressed PGI2 levels histamine-induced PAF release was
stimulated (Hampel et al., 1989). In vivo these effects may alter platelet function thus
contributing to the pathogenesis of atherosclerosis.
The transmigration of leukocytes into the subendothelial space promotes a pro-inflammatory
response which is a key feature of endothelial dysfunction observed in early atherogenesis
(discussed previously in section 1.1.4). Recently, neutrophil adherence to bovine mammary
artery endothelial cells in response to TNFa was shown to be increased in cells cultured in
selenium-deficient media compared to those cultured in selenium-sufficient media (Maddox et
al., 1999). This effect was closely correlated to an increase in E-selectin and ICAM-1 mRNA in
selenium-deficient endothelial cells. The gene sequences of both these adhesion molecules
contain binding sites for NF-kB, a redox regulated transcription factor. Hydroperoxides and other
ROS have been implicated as second messengers of NF-kB activation induced by cytokines
such as TNF and IL-1. A mechanism by which selenoproteins such as cyGPX, PHGPX and TR
may protect the endothelium from the pro-inflammatory impact of TNF and IL-1 has been
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proposed (McCarty, 1999). It is hypothesised that the ability of selenoproteins to down-regulate
cytokine signalling may reflect the prevention or correction of ROS-induced inhibition of
phosphotyrosine phosphatase which in its active form down-regulates the cytokine signalling
pathway and therefore the transcription of the pro-atherogenic adhesion molecules. Indeed,
overexpression of cyGPX in T47D cells has been shown to depress TNF-induced NF-kB
activation (Kretz-Remy et al., 1996) whilst in ECV304 cells (a human bladder cancer cell line)
interleukin-1 induced NF-kB activation was inhibited in sodium selenite supplementation (50 nM)
(Brigelius-Flohe eta/., 1997).
Hyperhomocyst(e)inemia has been described as an independent risk factor for endothelial
dysfunction and the subsequent development of atherosclerosis (Upchurch et al., 1997).
Homocysteine can damage the endothelium through several mechanisms including the
generation of H202. Recently Upchurch and his colleagues raised the possibility that the
increased H202 accumulation resulted from the ability of homocyst(e)ine to down-regulate the
expression of cyGPX (Upchurch et al., 1997). Several other studies have linked decreased GPX
levels with an increased incidence of coronary artery disease. For example, Guidi et al. have
shown that platelet GPX activity is impaired in patients with coronary artery disease (Guidi et al.,
1986).
This review does not cite every study which have taken place over the past two decades
associating selenium and selenoprotein expression with endothelial dysfunction. However it
does reflect the substantial evidence which supports a protective role of selenium through the
expression of selenoproteins such as cyGPX, PHGPX and TR against endothelial dysfunction
and atherogenesis. The ability of these selenoproteins to act as antioxidants, detoxifying lipid
hydroperoxides and other ROS, appears to provide the mechanism by which these compounds
exert their effects. However, the relative importance of each identified intracellular selenoprotein
has yet to elucidated as does the contribution of selenium-deficiency to atherogenesis.
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1.6 AIMS OF THE THESIS
The pattern of selenoprotein expression in human endothelial cells has not been previously
studied. Therefore this thesis examined the selenoproteins expressed by human endothelial
cells (isolated from different vascular beds) and compared the pattern of expression with that
found for endothelial cells isolated from different species. The modification of selenoprotein
expression through second messenger pathways and selenium supply was also studied.
Previous investigations have shown that selenium supplementation, through the modification of
selenoprotein expression, confers resistance to bovine endothelial cells against the cytotoxic
effect of reactive oxygen species (Ochi, Morita and Murota, 1992; Thomas, Geiger and Girotti,
1993). These studies attributed the protective effect observed to the modification of intracellular
glutathione peroxidase expression. However the expression of other selenoproteins with
antioxidant properties such as extracellular glutathione peroxidase, selenoprotein P and TR was
not considered. Therefore the ability of sodium selenite and selenomethionine to protect against
damage from oxidative stress was investigated in human umbilical vein endothelial cells, human
coronary arterial endothelial cells and bovine aortic endothelial cells.
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CHAPTER TWO MATERIALS AND GENERAL METHODS
2.1 CHEMICAL SUPPLIERS
The following equipment and chemicals were purchased from the commercial suppliers listed
below.
Amersham International pic, Buckinghamshire, UK.
Bolton & Hunter reagent for protein iodination (18.5 MBq, 500 pCi); lodine-125 (37 MBq, 1 mCi,
specific radioactivity 16 MBq/ nmol).
Binding Sites, Birmingham, UK.
Antiserum to human cytoplasmic glutathione peroxidase.
Bio-Rad Laboratories, Hemel Hempstead, Hertfordshire, UK.
Glass plates (inner; 20 cm x 20 cm; outer 20 cm x 22.3 cm); low range molecular weight
markers; N,N,N,'N'-tetramethyl ethylenediamine (TEMED).
Biowhittaker UK Ltd., Wokingham, Berkshire, UK.
Bovine aortic endothelial cells; endothelial growth medium bullet kit (EGM); endothelial growth
medium-2 bulletkit (EGM-2); endothelial growth medium-2 supplements (i.e. ; HEPES buffered
saline solution; human coronary arterial endothelial cells; trypsin/EDTA solution; trypsin
neutralising solution.
Calbiochem Novobiochem, Beeston, Nottingham, UK.
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Dako Ltd. Buckinghamshire, UK.
FITC-conjugated swine anti-rabbit immunoglobulins; normal rabbit serum; rabbit anti-human
polyclonal antibody to von Willebrand factor.
European Collection of Cell Cultures, Salisbury, Wilts, UK.
HepG2 cells
Gibco, Life Technologies, Paisley, UK.
Amphotericin B solution; Dulbecco's modified Eagle's medium (DMEM) (25 mM HEPES) with
4500 mg/L/ glucose; Dulbecco's modified Eagle's medium (DMEM)/Ham's F-12 nutrient mix;
Earle's balanced salt solution (EBSS); foetal bovine serum (FBS); glutamine; Flank's balanced
salt solution (HBSS) (Ca2+- and Mg2+-free); hypoxanthine, aminopterin, thymidine (FIAT);
Medium 199 (M199); penicillin/streptomycin solution; plastics.
Lome Laboratories, Twyford, Berkshire, UK.
Collagenase (type VI).
MERCK, Leicester, UK.
Acetic acid; ammonia; cyclohexane; ethanol; ethylenediaminetetraacetic acid (EDTA); glycine;
hydrochloric acid; methanol; microcrystalline cellulose; orthophosphoric acid; nitric acid;
perchloric acid polyethylene glycol (PEG); selenious acid.
Reactor Center, Columbia, MO, USA.
[75Se] selenite (specific activity, 16 MBq/ nmol).
Scottish Antibody Production Unit, Carluke, Lanarkshire, UK.
Donkey anti-rabbit serum, normal rabbit serum.
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Sigma Aldrich Company Ltd, Poole, Dorset, UK.
A23187 calcium ionophore; ammonium persulphate, aurothioglucose; bovine serum albumin
powder (BSA); bradykinin; Brijj solution; Coomassie brilliant blue (R-250 and G-250);
cytoplasmic glutathione peroxidase purified from human erythrocytes; dithiothreitol (DTT);
lactate dehydrogenase (LDH) kit (Sigma Diagnostics); lauryl sulfate (sodium dodecylsulfate;
SDS); phorbol-12-myristate 13-acetate (PMA); radiographic film Kodak X-OMAT XAR-5; sodium
azide.
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2.2 SOURCES OF NON-COMMERCIAL MATERIAL
2.2.1 Cell lines
The human endothelial cell line, EAhy926 was kindly donated by Professor Cora-Jean Edgell of
the University of North Carolina, North Carolina, USA.
2.2.2 Antibodies
Antisera to both rat liver and human placental thioredoxin reductase (TR) were raised in rabbits
to cytosolic proteins purified to homogeneity. Rat TR antisera was kindly supplied by Dr John
Arthur, Rowett Research Institute, Bucksburn, Aberdeen, UK, whilst Dr Forbes Howie of this
department supplied the antisera to human TR.
Antisera to rat PHGPX were raised in rabbits against PHGPX purified from rat testis. Again this
antisera was kindly donated from Dr John Arthur and Mr Fergus Nicol of the Rowett Research
Institute.
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2.3 GENERAL METHODS
2.3.1 Introduction
The experimental methods described below are those used throughout this thesis. They include
primary cell culture, maintenance of cell lines, selenoprotein determination, and selenoprotein
expression and activity measurements. Where the methods diverge from those described here
the modifications are explained in the relevant chapters.
2.3.2 Isolation and culture of human umbilical vein endothelial cells
Human umbilical cords (>100 mm in length) were obtained at normal deliveries or Caesarean
section from non-smoking women. Immediately after delivery the cords were placed into sterile
EBSS containing penicillin (100 units/ml), streptomycin (100 pg/ml) and amphotercin B (2.5
pg/ml) at 4°C. Endothelial cells were isolated within 20 hr of delivery using a method adapted
from that described previously by Jaffe et at. (Jaffe et at., 1973). Briefly, the vein of the umbilical
cord was located and cannulated with a Venflon (gauge 17/ 45 mm), which was then clamped
into place. The vein was washed with 100 ml of EBSS (pre-warmed to 37°C) to remove any
blood clots and the outside wiped using sterile gauze. One end of the cord was clamped shut
and the opposite end infused with 0.07% collagenase in EBSS (5-15 ml). The cord was then
incubated at 37°C in an atmosphere of 5% C02, 95% air.
After 10 min the cord was removed and massaged gently. The contents of the cord were flushed
out with 30 ml of Ca 2+and Mg 2+- free HBSS. The resulting cell suspension was collected and
centrifuged at 450 g for 10 min and the cell pellet washed once with EGM-2 containing penicillin
(100 units/ml), streptomycin (100 pg/ml) and amphotercin B (2.5 pg/ml). The cells were
resuspended in 15 ml EGM-2 and plated out into one 75 cm2 flask. This flask was then
incubated at 37 °C in an atmosphere of 5% C02, 95% air.
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After approximately 5 hr the HUVEC were washed with 2 x 10 ml EGM-2 to remove any blood,
contaminant cells and cell debris. The medium was then changed and replaced with a further
15ml of EGM-2 on alternate days.
Cell reached confluence within 3-7 days. When the cells were approximately 90% confluent the
HUVEC were subcultured as required. To subculture the HUVEC the overlying medium was
aspirated from the flask and the flask rinsed with approximately 9 ml HBSS. The HBSS was then
aspirated from the flask and replaced with 9 ml 0.025% trypsin/ 0.01% EDTA solution. The flask
was then placed in the incubator at 37°C for approximately 1.5 min. The flask was then viewed
under a light microscope to assess the number of cells detached and if necessary the flask was
given a rap to detach any remaining cells still attached to the surface of the flask. The trypsin/
EDTA solution was then neutralised with a trypsin neutralising solution and the cell suspension
transferred to a centrifuge tube. The cells were pelleted by centrifugation at 450 g for 10 min.
The supernatant was then aspirated and the cells resuspended in 5 ml EGM-2. The number of
cells were counted using a haemocytometer and then diluted in the appropriate amount of
medium. Cells were seeded approximately 3000 cells /cm2 into a 75 cm2 flask.
All cells used in a given experiment were derived from a single umbilical cord unless otherwise
stated.
2.3.3 Characterization of human umbilical vein endothelial cells
Cells cultured from the human umbilical vein showed the morphology characteristic of
endothelial cells in culture previously described by Jaffe et al. (Jaffe efa/., 1973). Under the light
microscope endothelial cells were observed as non-overlapping large polygonal cells, which
after 3-7 days in culture became a confluent single monolayer of contact inhibited cells with a
cobblestone appearance. Non-endothelial cell contaminants, particularly smooth muscle cells
and fibroblasts were identified by light microscopy. They were distinguishable from endothelial
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cells because of their morphological differences; smooth muscle cells have a characteristic 'hill
and valley' morphology whilst fibroblasts are elongated cells which like smooth muscle cells form
overlapping layers. HUVEC preparations which had greater than 5% contamination were
discarded.
To confirm cultured HUVEC were of endothelial origin some cultures were examined for the
presence of von Willebrand Factor (former designation Factor Vlll-related antigen, vWF) using
an indirect immuno-fluorescent detection system reported to be characteristic of endothelial cells
in culture (Hoyer, De Lso Santos and Hoyer, 1973; Jaffe etal., 1973).
Briefly, HUVEC were grown to approximately 70% confluence on 22 x 22 cm sterile glass
coverslips in six well plates. The glass coverslips were then placed in a rack with the cell layer
facing towards the front. The rack was then immersed in phosphate buffered saline (PBS) and
the cells washed for 5 min. The rack was then immersed in acetone to fix the cells. After 5-10
min the cells were rinsed in fresh PBS and any excess liquid was wiped from the bottom of each
coverslip.
The primary vWF antibody used was a rabbit anti-human polyclonal antibody diluted 1:100 with
PBS. Prior to use the antibody was titred on human tonsil sections, which are known to be
positive for vWF and then on HUVEC monolayers. A 1:100 working dilution of this antibody gave
optimal staining in both human tonsil sections and HUVEC monolayers. 100 pi of the diluted
antibody was then placed onto an appropriately labelled microscope slide and then each
coverslip with the cells facing downwards was carefully lowered onto the microscope slide. The
slides were placed into a humidity chamber and the ceils were incubated at room temperature
for 30 min. The coverslips are then lifted from the slides and replaced in the rack as described
previously and washed twice for 5 min in PBS.
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The secondary antibody used were FITC-conjugated affinity isolated swine anti-rabbit
immunoglobulins (the cross reactivity of which with human immunoglobulins was low as
determined by ELISA). The 30 min staining procedure was repeated with a 1:400 dilution of the
secondary antibody in darkness at room temperature. After which the coverslips were washed
twice for 5 min in PBS.
The coverslips were mounted onto microscope slides using a small drop of Citiflouor and
examined under a Leitz Ortholux 2 microscope fitted with a Leica HBO 50W mercury vapour
lamp using a Kodak Wratten No. 47B excitation filter and a Kodak Wratten No.12 barrier filter.
The cells were photographed with a Leitz Vario Orthomat 2 camera using an Ektachrome 400
film.
Figure 2.01a shows positive staining with vWF which is granular in appearance and situated in
the cytoplasm of the cell. Of the three HUVEC cultures stained, each tested positive for the
presence of vWF. No immunofluorescent staining was observed when HACAT, a spontaneously
transformed human keratinocyte cell line kindly supplied by Miss Teresa Rafferty, Department of
Dermatology, University of Edinburgh, Edinburgh, UK, were incubated with vWF antigen (data
not shown). EAhy926 cells display the characteristic morphology of endothelial cells as
described above and have previously been shown to stain positive for vWF (Edgell, McDonald
and Graham, 1983). Therefore these cells were used as a positive control for the presence of
vWF. Figure 2.01 b shows a positive staining for the glycoprotein vWF.
Using Southern blotting techniques the presence of significant levels of endothelial nitric oxide
synthase (eNOS) mRNA were detected in HUVEC cultured in this laboratory (Jackson et al.,
1998). ENOS is expressed in endothelial cells in a constitutive manner bound to the endothelial
membrane (Dominiczak and Bohr, 1995).
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Figure 2.01a Immunofluorescence of the glycoprotein von Willebrand Factor in a non¬
confluent monolayer of human umbilical vein endothelial cells. x400 magnification.
Figure 2.01b Immunofluorescence of the glycoprotein von Willebrand Factor in a non¬
confluent monolayer of Eahy926 cells. x400 magnification.
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2.3.4 Maintenance of EAhy926 endothelial cell line
EAhy926 endothelial cells were maintained unless otherwise stated in high glucose (4.5 g/L)
DMEM containing 10% FBS, 5 mM hypoxanthine , 0.02 mM aminopterin, 0.8 mM thymidine,
penicillin (100 units/ml), streptomycin (100 pg/ml) and amphotericin B (2.5 pg/ml). The cells were
incubated at 37°C in an atmosphere of 5% C02, 95% air. The cells were passaged weekly using
0.25% trypsin- 0.02% EDTA solution.
EAhy926 cells display the characteristic morphology of endothelial cells in culture as described
above and have previously been shown to stain positive for vWF (Edgell, McDonald and
Graham, 1983). The presence of the glycoprotein vWF was confirmed in this laboratory (figure
2.01b).
2.3.5 Maintenance of human coronary arterial endothelial cells
Fluman coronary arterial endothelial cells (FICAEC) were maintained in endothelial growth
medium-2 bulletkit (EGM-2) containing penicillin (100 units/ml), streptomycin (100 pg/ml) and
amphotericin B (2.5pg/ml). The cells were incubated at 37 °C in an atmosphere of 5% C02, 95%
air. The cells were passaged every 7-9 days as described in section 2.3.2.
HCAEC were purchased from Biowhittaker UK Ltd. The certificate of analysis supplied with
these cells stated the HCAEC tested positive for the presence of vWF and acetylated LDL (an
alternative method for the specific identification of endothelial cells in culture) (Voyta et ah,
1984). HCAEC also displayed the characteristic morphology of endothelial cells as described
above and cultures where non-endothelial contaminants were observed were discarded.
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2.3.6 Isolation and culture of human umbilical artery endothelial cells
Human umbilical artery endothelial cells (HUAEC) were isolated and cultured by methods similar
to those described for HUVEC in section 2.3.2. The exception being that the umbilical artery was
cannulated which required a smaller Venflon (gauge 20 / 32 mm). Also due to the smaller
surface area of the umbilical artery, fewer cells were isolated and therefore they were
resuspended in 10 ml EGM-2 and then plated out into one T25 flask.
Cells were maintained in endothelial growth medium-2 bulletkit (EGM-2) containing penicillin
(100 units/ml), streptomycin (100 pg/ml) and amphotericin B (2.5p,g/ml). The cells were
incubated at 37 °C in an atmosphere of 5% C02, 95% air.
When the cells were approximately 90% confluent the HUAEC were subcultured in T75 flasks
as described in section 3.3.2.
HUAEC were confirmed as being of endothelial origin by virtue of the characteristic morphology
displayed as described above. Cultures that showed greater than 5% contamination from non-
endothelial cell types were discarded.
2.3.7 Isolation and culture of porcine aortic endothelial cells
Segments of porcine aorta were obtained within 5-10 min of slaughter from pigs aged under two
years old. Upon receipt the aorta was immediately placed into sterile EBSS containing penicillin
(100 units/ml), streptomycin (100 pg/ml) and amphotericin B (2.5 pg/ml) at 4°C. Endothelial cells
were isolated within 2-3 hr of dissection using a method adapted from that previously described
by Slater and Sloan (Slater and Sloan, 1975). Any fat or connective tissue was removed from the
dissected aorta. Segments of about 5-10 cm were cut and any minor vessels were ligated using
strong cotton. The segments were washed with approximately 25 ml EBSS (pre-warmed to
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37°C). One end of the aorta was then clamped shut and the opposite end infused with 0.1%
collagenase in EBSS (approximately 10 ml). This end was then clamped shut and the cord was
incubated at 37°C in an atmosphere of 5% C02, 95% air.
After 15 min the segment was removed and gently massaged. The contents of the aortic
segment were then collected into a sterile universal container. The vessel was then cut along its
longitudinal axis and the luminal surface gently scraped gently with a sterile stainless steel
scalpel blade angled at approximately 60° to the intimal surface.
The blade was then washed with EBSS and the wash was added to the cell suspension
previously collected. The sample was then centrifuged at 450 g for 10 min and the resulting cell
pellet was washed with M199 containing 20% FBS, penicillin (100 units/ml), streptomycin (100
pg/ml) and amphotercin B (2.5 pg/ml). The cells were resuspended into a 25 cm2 flask and
incubated at 37°C in an atmosphere of 5% C02, 95% air. The growth medium was changed and
replaced after 24 hr and then on alternate days.
Cells reached confluence within 5-9 days. When the cells were approximately 90% confluent the
porcine aortic endothelial cells (PAEC) were subcultured as required.
To subculture the PAEC the overlying medium was aspirated from the flask and the flask rinsed
with HBSS. The HBSS was aspirated from the flask and replaced with 2 ml 0.05% trypsin/
0.02% EDTA in Puck's modified saline, which was agitated gently over the cells. The flask was
incubated at 37°C in an atmosphere of 5% C02, 95% air for approximately 1.5 min. The flask
was then viewed under a light microscope to assess the number of cells detached and if
necessary the flask was given a rap to detach any remaining cells still attached to the surface of
the flask. The trypsin/ EDTA solution was then neutralised with growth medium and the cell
suspension transferred to a centrifuge tube. The cells were pelleted by centrifugation at 450 g for
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10 min. The supernatant was then aspirated and the cells resuspended in 5 ml growth medium.
The number of cells were counted using a haemocytometer and then diluted in the appropriate
amount of medium. Cells were seeded at approximately 9000 cells /cm2 into a 75 cm2 flask.
PAEC were not tested for the presence of vWF, however cultures of these cells displayed the
characteristic morphology of endothelial cells without the presence of non-endothelial
contaminants.
2.3.8 Maintenance of bovine aortic endothelial cells
Bovine aortic endothelial cells (BAEC) were maintained in endothelial growth medium bulletkit
(EGM) containing penicillin (100 units/ml), streptomycin (100 pg/ml) and amphotericin B
(2.5|ig/ml). The cells were incubated at 37 °C in an atmosphere of 5% C02, 95% air.
The cells were passaged every 7-9 days as described in section 2.3.2.
BAEC were purchased from Biowhittaker UK Ltd. The certificate of analysis supplied with this
product stated that the BAEC tested positive for acetylated LDL. Also in culture BAEC displayed
the characteristic morphology of endothelial cells as described above and cultures where non-
endothelial contaminants were observed were discarded.
2.3.9 Isolation and culture of human thyrocytes
Human thyrocytes were isolated as previously described using thyroid tissue which was surplus
to routine histopathological examination obtained from patients with Grave's disease (Beech et
a!., 1993; Rapoport, 1975). These cells were cultured and maintained in DMEM/ 10% CPSR-1
(FCS, treated to remove endotoxins and immunoglobulins). This procedure was carried out by
Dr Forbes Howie of this department.
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2.3.10 Maintenance ofHepG2 cells
HepG2 cells are a human foetal liver-derived cell line which were maintained in DMEM/ Ham's
F-12 nutrient mix containing L-glutamine and 15mM Hepes to which 5% (v/v) foetal bovine
serum was added. The cells were cultured in 75cm2 culture flasks and incubated at 37°C in an
atmosphere of 5% C02 and 95% air.
2.3.11 Measurement of selenium content of culture medium
The method used to measure the selenium content of the different culture media used in this
study was based on the formation of a piazselenol between selenium and 2,3-
diaminonaphthalene followed by extraction and fluorometry.
This assay was carried out by Mr Fergus Nicol of the Rowett Research Institute, Aberdeen and
has been previously described by Olsen et al. (Olsen, Palmer and Carey, 1975). 10 ml of each
medium sample was boiled down to 1 ml before being digested overnight in 2 ml concentrated
nitric acid in a 75ml glass boiling tube. The following day samples were heated slowly up to
boiling point and boiled until the loss of brown fumes (approximately 5 min). 2 ml concentrated
perchloric acid was then added dropwise and the sample was boiled until the appearance of
white fumes. After 30 min boiling, hydrochloric acid was added dropwise to drive off excess nitric
oxide and to convert selenium as selenate to selenite.
When cooled, 5 ml hydroxylamine/ EDTA solution (25 g hydroxylamine and 9.24 g EDTA per
litre distilled water) was added to each sample. Five drops of a cresol red solution (0.05 g cresol
red in 250 ml distilled water containing 1 ml of 40% (v/v) ammonia. A 40% ammonia solution (v/v
in distilled water) was added to each sample until the sample turned green, then 10% HCI (v/v)
was added until the solution turned orange. The pH range of the sample at this stage was
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between 1.5 and 2.5 suitable for the formation of the diaminonaphthaline-selenium complex. The
samples were then diluted to 50 ml with distilled water.
Diaminonaphthalene solution (5 ml) was added to each sample and incubated for 30 min at
50°C in a covered water bath. After cooling the samples to room temperature, 6 ml cyclohexane
was added to each sample. Each tube was covered with a glass stopper and shaken vigorously
for 20 sec to extract the diaminonapthalene/ selenium complex. The sample was left for 10 min
to allow the diaminonapthalene layer to separate. 2.5 ml of the top layer was removed and
fluorescence was measured. The samples were read form a standard curve, prepared from
selenious acid supplied at 1 mg/ml. The standards were as follows:- 0 pg/ml, 25 pg/ml, 50 pg/ml
and 100 pg/ml. A dried blood standard was used as a control.
2.3.12 Determination of protein concentration
The protein concentration of cell lysates and extracellular proteins was determined using the
Bradford dye-binding method (Bradford, 1976) adapted for the Cobas Fara centrifugal analyser
(Roche Diagnositcs, Welwyn Garden City, UK).
The Bradford reagent was prepared by dissolving 100 mg Coomassie Brilliant Blue G-250 in 50
ml 95% ethanol. To this solution is added 100 ml of 85% (w/v) phosphoric acid and stirred for 30
min. The resulting solution is diluted with distilled H20 to a final volume of 1000 ml, filtered
through Whatman, grade 1 filter paper and stored at room temperature in a closed bottle.
Bradford reagent (256 pi) was added to each cuvette and incubated for 100 sec at 37°C. The
initial absorbance reading (595 nm), was taken at 95 sec. Sample (25 pi) and H20 diluent (50 pi)
were then added to the cuvettes and incubated at 37°C for 180 sec when a final absorbance
reading (595 nm) was taken.
98
Materials and general methods chapter two
Bovine serum albumin (BSA) standards were used at a concentration range of between 0-100
mg/L. Unless otherwise stated BSA standards were dissolved in distilled H20. The change in
absorbance reading resulting from the addition of the standard was used to construct a standard
curve. Samples with unknown protein concentrations were then interpolated from this curve.
Samples with a protein concentration greater than 100 mg/L were diluted in distilled H20 until
they fell within the range of the standard curve (0-100 mg/L).
2.3.13 Sodium-dodecyl sulphate-polyacrylamide gel electrophoresis
The [75Se]-selenoproteins in cell lysates and culture medium was separated by sodium-dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Samples were prepared for
electrophoresis by diluting each sample to a common protein concentration with 60 mM Tris
buffer, pH 7.8 at room temperature, containing 1 mM EDTA and 1 mM dithiothreitol. The diluted
samples were then further diluted 2:1 (sample: "boiling mix") with "boiling mix" (SDS 35 mM,
glycerol 1.4 mM, 2-mercaptoethanol 0.3 mM and bromophenol blue 15 mM) and heat-treated at
90°C for 10 min.
Electrophoresis was carried out at room temperature using a Protean II electrophoresis system
(Bio-Rad Laboratories Ltd, Watford, Herts, UK). The discontinuous gel (dimensions 0.1 cm x
16.5 cm x 18 cm) is cast as two separate gels sandwiched between two glass plates set in a
casting stand. The lower 12% resolving gel (14 cm long) was made up of 17 ml distilled H20; 32
ml acrylamide solution (30% acrylamide, 0.8% bis-acrylamide); 30 ml 1M Tris/ HCI, pH 8.85; 0.8
ml 10% SDS; 0.15 ml N,N,N',N'-tetramethylethylene diamine (TEMED); 0.15 ml 0.1%
ammonium persulphate. The upper stacking gel (approximately 4 cm long) consisted of 32 ml
distilled H20; 7.2 ml acrylamide; 20 ml 0.375M Tris/ HCI, pH 6.8; 0.6 ml 10% SDS; 0.2 ml
TEMED; 0.2 ml 0.1% ammonium persulphate. The gel sandwiches were removed from the
casting stand once set and transferred to the buffer chamber. The upper and lower buffer
chambers were filled with SDS-electrophoresis buffer (0.3% (w/v) Tris; 1.44% glycine; 0.1%
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SDS). Low range molecular weight markers (14.4 kDa - 97.4 kDa) and samples were loaded
into the wells. The gel was run at 200 volts (V), 35 milliamperes (mA), 50 Watts through the
stacking gel until the bromophenol blue tracking dye entered the resolving gel when the voltage
and current was increased to 300 V and 50 mA respectively. The power supply was
disconnected once the tracking dye had reached the bottom of the resolving gel.
The gels were stained in 0.2% (w/v) Coomassie Brilliant Blue R in a methanol: acetic acid:
distilled H20 solution (50: 7: 50 ratio) for 30 min and then destained in two changes of a
methanol: acetic acid: distilled H20 solution (5: 7: 88 ratio) overnight.
The gels were then dried under vacuum sandwiched between two layers of pre-soaked
cellophane support using a Bio-Rad gel drier (model 583) set at 80°C for 2 hr.
2.3.14 Autoradiography of SDS-PAGE gels
[75Se]-labelled selenoproteins were visualised by autoradiography using Kodak X-OMAT XAR-5
film. The dried gels were placed in close contact with the film within an exposure cassette at -
70°C for between 12 hr and 4 days. The staff of the Department of Radiology, The Royal
Infirmary of Edinburgh kindly developed the films.
The molecular weights of the standard protein molecular weight markers were plotted against
the distance travelled and a curve fitted using Fig P (produced by Fig P Software Incorporation,
Durham, NC, USA), which was used to determine the molecular weights of unknown
selenoproteins.
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2.3.15 Phosphoimage analysis
Two types of phosphoimage analysis were used in this study.
To quantify the expression of the major [75Se]-selenoproteins in HUVEC as a percentage of the
total intracellular [75Se]-selenoprotein labelling, Coomassie Blue gels were scanned using a Bio-
Rad model GS-525 Molecular Imager System to create a digitised image. The radioactivity in
each band was quantified by means of radioactive band densitometry using the Bio-Rad
Molecular Imager Analyst/ PC image-analysis software. The data was presented as a
percentage of the total intracellular [75Se]-labelled proteins expressed.
Quantification of TR expression from Western blots and changes in the [75Se]-labelling of the
major selenoproteins after PMA and A23187 treatment was carried out by Mr Fergus Nicol of the
Rowett Research Institute, Bucksburn, Aberdeen, UK. Autoradiographs were scanned and the
digitised image analysed by means of radioactive band densitometry, using an EpsonGT - 9500
scanner with Phoretix software.
2.3.16 Western blot analysis
Thioredoxin reductase (TR) and phospholipid hydroperoxide glutathione peroxidase (PHGPX)
were identified in HUVEC using Western blot analysis. The identification of TR and PHGPX was
carried out by Mr Fergus Nicol of the Rowett Research Institute, Bucksburn, Aberdeen, UK.
For the Western blot analysis of TR, proteins resolved by SDS-PAGE (section 2.3.13) were
transferred to Immobilon P membranes which were then blocked using a 10% (v/v) horse serum
with 0.025 M Tris buffer/0.5 M sodium chloride (pH 7.5) and 0.05% Tween. The membranes
were then probed with affinity-purified anti-rat TR antibody at a final dilution of 1:500. Enhanced
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chemiluminescence was used as a detection method to visualise the immunoreactive proteins
as described previously by McLeod ef a/(McLeod eta!., 1997).
Previous studies performed by Dr Forbes Howie of this department with the antiserum to TR and
the purified 58 kDa selenoprotein from [75Se]-labelled HepG2 confirmed that the antiserum
reacts only with TR and not another selenoprotein with a similar molecular mass (Howie et a/.,
1998).
PHGPX expression was analysed by Western blotting using a protocol based on that described
for TR. The PHGPX antibody was raised against rat testes PHGPX and was used at a final
dilution of 1:500.
2.3.17 Radioimmunoassay of thioredoxin reductase
Thioredoxin reductase (TR) was measured using an 'in-house' radioimmunoassay developed in
this laboratory by Dr. Forbes Howie (unpublished).
a) Purification of thioredoxin reductase
TR was purified from normal 40 week full-term human placentas obtained within two hours of
delivery. The method used for purification was based on that of Holmgren and Bjornstedt
(Holmgren and Bjomstedt, 1995). This procedure was kindly carried out by Dr Forbes Howie.
b) Details of antibodies
The primary antibody used was a kind gift from Dr Forbes Howie of this department. It was
raised by subcutaneous injection of purified human placental TR emulsified with an equal
volume of Freund's complete adjuvant into New Zealand White rabbits. Six weeks after the
primary immunisation each rabbit was given a booster injection of the protein-containing
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emulsion. After two further weeks, the animals were anaesthetised and the blood recovered by
cardiac puncture. The blood was centrifuged at 3000 g for 30 min, and the serum removed and
stored at -70°C at a dilution of 1:100 in 0.05 M phosphate buffer, pH 7.4, containing 0.1% BSA
and 0.02% sodium azide. To determine the titre of primary antibody required for the
radioimmunoassay an antibody dilution curve was performed. The antibody dilution used was
that which gave approximately 60% of the maximum total binding. This was determined for each
batch of tracer used. The primary antibody titre used was in the region of 1:30000
(approximately 15% binding).
The secondary antibody reagent was made by adding 25 ml of donkey anti-rabbit serum to 1.5
ml normal rabbit serum and mixing overnight at room temperature to precipitate out the
immunoglobulins. After centrifugation (230 g for 5 min) the supernatant was discarded and the
precipitate washed four times using 0.05 M phosphate buffer, pH 7.4, containing 0.1% BSA and
0.02% sodium azide. After the final wash the supernatant was removed and the pellet was
resuspended in the same 0.05 M phosphate buffer as described above, to give a final volume of
100 ml
c) Preparation of the assay diluent
The assay diluent used for both the antibody and the tracer was a 0.05 M phosphate buffer, pH
7.4, containing 0.1% BSA and 0.02% sodium azide. Prior to use in the assay, dithiolthreitol
(DTT) was added to the buffer at a final concentration of 10 mM.
d) Preparation of 125I-TR tracer, standards, controls and samples
Purified human placental TR was iodinated by Dr Forbes Howie using the Bolton-Hunter
iodination procedure (Bolton and Hunter, 1973). The 125I-TR trace was immediately diluted 1:2
with FBS and stored at -20°C for up to three months. For use in the radioimmunoassay the 125l-
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TR trace was diluted with assay diluent containing DTT such that approximately 10000 cpm was
added to each tube (mass approximately 50-100 pg TR/ tube).
Standards were made up by diluting a stock solution of purified placental human TR (1 mg TR/L)
with FBS to give the following concentrations: 0.5, 1, 2, 5, 10, 25, 50pg TR/ L. Two controls were
made by diluting a stock solution of human placental cytosol with FBS to values of approximately
5 and 25 pg TR/ L. Both standards and controls were dispensed into aliquots which were frozen
at -70°C.
Cell pellets were stored at -70°C immediately after harvesting. Prior to being assayed samples
were removed from the freezer and kept on ice at 4°C until required. Each sample was diluted
with radioimmunoassay buffer (without the added DTT) between 1:50 and 1:200.
e) TR radioimmunoassay
Antibodies, trace, standards, controls and samples were all brought to room temperature prior to
setting up the assay. All samples, standards and controls were performed in duplicate. The
radioimmunoassay was performed as follows: 100 pi of standard, control or sample was added
with 100 pi 125I-TR tracer. Primary antibody (100 pi) was then added to each tube with the
exception of the total counts tubes. The tubes were then mixed by vortexing for 30 sec and then
incubated overnight at 4°C.
Following the over night incubation, 100 pi of the secondary antibody (at room temperature) was
added to each tube with the exception of the total count tubes. The tubes were vortexed and
incubated for a further hour at room temperature with shaking. 1.5 ml of wash solution (0.05%
Brij solution containing approximately 200 mg microcrystalline cellulose) was added to each tube
(with the exception of the total count tubes) and the tubes were centrifuged for 30 min at 1800 g
(4°C). The supernatant was decanted, the precipitate was washed with a further 1.5 ml wash
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solution, centrifuged and decanted as previously described. The resultant precipitate was
counted in the LKB 1261 Multigamma gamma counter and the data processing performed using
the LKB 1224-RIACalc RIA evaluation program.
Figure 2.02 shows a typical standard curve for the TR radioimmunoassay.
Controls were run as 9 replicates within a single assay to determine the intra-assay precision
data. To determine the inter-assay precision controls were included at the beginning and the end
of each assay for 12 consecutive assays.
f) Intra-assay precision data
The intra-assay precision data calculated from one assay (in which 9 duplicates of each pool (5
and 25 pg TR/ L) were read from a single standard curve, is shown in table 2.01.
Table 2.01. Intra-assay variation for two pools run in one assay for TR. (Coefficient of
variation is referred to as CV)
pools n mean SD CV (%)
5 pg TR/ L 9 5.062 0.733 14.473
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Figure 2.02. A typical standard curve for the thioredoxin reductase
radioimmunoassay. The standard curve is a scan from an original printout from the
LKB1224-RIA CalcRIA evaluation program.
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g) Inter-assay precision data
The inter-assay variation was determined by running the controls in each assay for 12
consecutive assays. The results are shown in table 2.02 .
Table 2.02. Inter-assay variation for two pools run in twelve consecutive assays for TR.
(Coefficient of variation is referred to as CV).
pools n mean SD CV (%)
5 pg TR/ L 12 5.569 0.446 8.009
25 pg TR/ L 12 25.151 2.811 11.176
h) Detection limit of the TR radioimmunoassay
To determine the functional sensitivity of the assay a precision profile was constructed,
calculated from 9 consecutive assays (figure 2.03). The minimal detection limit of the TR assay
(functional sensitivity) was calculated as 1.50 pg TR /L which represented the TR concentration
which had a CV of 22.5% (McConway et at., 1989). The working range of this assay was 3.50 -
50.0 pg TR/ L and was defined as the concentration range which had a CV of less than 10%.
2.3.18 Thioredoxin reductase activity assay
TR activity was measured in cell homogenates using a method adapted from that previously
described by Hill et at. (Hill, McCollum and Burk, 1997). Assays were performed by Miss
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TR concentration (log)
Figure 2.03. Plot showing the mean % coefficient of variation (CV) (mean ± SD, n=9) for
each standard. The minimum detection limit of the assay is the concentration of TR (p.g/L) with
a CV of 22.5%. The working range of the assay represents the concentration range which had a
CV of less than 10%.
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The TR activity assay follows the NADPH-dependent-reduction of the substrate 5,5'-dithiobis (2-
nitrobenzoic acid) (DTNB) to 5'-thionitrobenzoic acid (TNB) according to reaction (1).
TR
DTNB + NADPH + H+ ► 2TNB + NADP+ (1)
TR activity was determined by following the rate of DTNB reduction to TNB measured as a
increase in absorbance at 412 nm using a Cobas Fara Centrifugal Analyser (Roche Diagnostics,
Welwyn Garden City, UK). To correct for the reduction of DTNB by enzymes other than TR and
by endogenous thiols such as glutathione, the assay was performed in the presence of
aurothioglucose (720 nM) which inhibits TR activity (Hill, McCollum and Burk, 1997). The
aurothioglucose at a concentration of 720 nM, used in our assay, has been optimised to
selectively inhibit TR activity but does not significantly decrease the activity of any of cyGPX and
PHGPX (unpublished data, personal communication from Miss Michelle Lewin of this
department).
a) Preparation of reagents
The assay buffer consisted of 2.194 g potassium phosphate, 0.47 g potassium chloride, 0.47 g
EDTA and 0.025 g BSA made up to 100 ml with distilled water to give final concentrations of 0.1
M, 50 mM, 10 mM and 0.2 mg/ml respectively. The pH of the buffer was adjusted to pH 7.0
using orthophosphoric acid and NADPH was added to the mixture to give a final concentration of
0.48 mM. This buffer was stored at 4°C until required.
The reaction mixtures were made prior to the beginning of the assay. To make reagent A, 6 mg
NADPH was added to 25 ml of the assay buffer to give a final NADPH concentration of 0.48
mM. This solution was stored in the dark until use. To make reagent B 0.66 g DTNB was made
up to 25 ml in absolute ethanol.
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b) Preparation of samples
Cell pellets were stored at -70°C immediately after harvesting. Prior to the assay samples were
removed from the freezer and kept on ice at 4°C until required.
c) Thioredoxin reductase activity assay
Samples (180 pi) were aliquoted into Cobas cups in the presence of either aurothioglucose at a
final concentration of 720 nM or assay buffer to give a final volume of 200 pi.
Prior to each assay run a fresh reaction mixture was made which consisted of 4.6 ml reagent A
and 400 pi reagent B.
To start the reaction 190 pi reaction mixture was added to 30 pi sample in a final volume of 250
pi (made up with distilled water). The increase in absorbance at a wavelength of 412 nm (37°C)
was followed through thirty 10 sec intervals with the first reading taken at 0.5 sec. A blank
containing assay buffer in place of sample was run at the beginning and the end of each assay.
One unit of TR activity was defined as that which reduces 1 pmole of DTNB per minute at 37°C
and pH 7.0. The molar extinction coefficient for TNB is 13600 M"1 cm"1. The conversion factor
used to convert absorption units into units of activity for this assay when a sample volume of 30
pi was used is 612.7.
Both the blank activity and the activity measured in the aurothioglucose-inhibited sample was
subtracted from the activity measured in the respective sample. These activity measurements
were then corrected for protein to give TR activity measured in mil/ mg protein.
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2.3.19 Cytosolic glutathione peroxidase assay
Cell pellets were stored at -70°C immediately after harvesting. Samples were then transported
on dry ice to the Rowett Research Institute, Aberdeen, UK where cytosolic glutathione
peroxidase (cyGPX) activities were measured by Miss Karen Pickering of the Rowett Research
Institute using a method previously described by Beckett et al. (Beckett et a!., 1990). The
measurement of cyGPX employs an indirect, coupled method. Briefly, the oxidised glutathione
produced during the cyGPX enzyme activity (figure 1.12, section one) is reduced by NADPH and
glutathione reductase. cyGPX activity is thus determined by following the rate at which NADPH
is oxidised to NADP+ measured as a change in absorbance at 340 nm in the presence of the
substrate hydrogen peroxide using a Unicam UV/Vis spectrometer (UV4). The spectrometer was
linked to a computer installed with Vision software for the calculation of cyGPX activity.
a) Preparation of the samples and standards for the cyGPX activity assay
Cell pellets were resuspended in 0.2 ml 0.125 M phosphate buffer containing 1 mM EDTA and
0.1% Triton X-100.
b) Preparation of the reaction mix
A reaction mix was made up of the following: 5 mg NADPH2, 46 mg reduced glutathione, 3 ml
distilled water, 24 ml PBS (pH 7.6), 1 ml sodium azide (0.1125 M), 20 U glutathione reductase
and 0.1% peroxide free Triton X-100. The reaction mix was placed in a water bath at 37°C.
To measure cyGPX activity 990 pi reaction mix was added to 10 pi sample in a 1 ml glass
cuvette. The blank rate was followed for 5 cycles at 340 nm (30 seconds per cycle). To start the
reaction 20 pi of the substrate solution hydrogen peroxide (0.0022 M) was added and the
subsequent reaction rate was followed for a further five cycles (30 seconds per cycle) at 340 nm.
111
Materials and general methods chapter two
A unit of cyGPX is defined as that which oxidises 1 pmole of NADPH per min. The molar
extinction coefficient of NADPH is 6220 M"1 cm"1. The blank rate was subtracted from the rate
obtained after substrate addition. The conversion factor for the assay when a 20 pi sample was
used was 8.0385.
2.3.20 Phospholipid glutathione peroxidase assay
Cell pellets for measurement of phospholipid hydroperoxide glutathione peroxidase (PHGPX)
activities were stored and transported as described for cyGPX activity measurement (section
2.3.19). All measurements were carried out by Miss Karen Pickering of the Rowett Research
Institute.
The same protocol was used for the measurement of PHGPX activity as described in section
2.3.19 with the exception that an alternative substrate of phosphatidyl choline hydroperoxide was
used and purified PHGPX was used as a control to quantify this substrate. The conversion factor
for the calculation of the results was the same as that used in the cyGPX activity assay which
was 8.0385.
a) Preparation of substrate (phosphatidyl choline hydroperoxide) for the PHGPX activity
assay
The substrate phosphatidyl choline hydroperoxide was prepared by dissolving 10 mg
phosphatidyl choline in 4 ml of 3% deoxycholate. This mixture was diluted with 21 ml 0.2M
sodium borate, pH 9.0 to which 100 pi of lipoxidase was added. The solution was placed in a
water bath at 37°C for 1 hr with oxygen passed through the mixture every 15 min.
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After incubation the mixture was passed through a Sep pak C18 cartridge, that had been
previously washed with methanol and equilibrated with distilled water. Distilled water (100 ml)
was added to the column and the phosphatidyl choline hydroperoxide was eluted with 2 ml
methanol.
The substrate could be stored frozen for up to 2 months (-40°C).
2.3.21 Cell viability measurements (lactate dehydrogenase activity assay)
The viability of cells was measured by the cellular retention of lactate dehydrogenase (LDH).
Intracellular and extracellular LDH activity was determined by following the rate at which NADH
is converted to NAD+ measured as a decrease in absorbance at 340 nm in the presence of
pyruvate using a Sigma Diagnostics LDH kit adapted for the Cobas Fara centrifugal analyser
(Roche Diagnostics, Welwyn Garden City, UK). The rate of decrease in absorbance at 340 nm
measured at 37°C is directly proportional to LDH activity in the sample. The percentage LDH
activity retained was calculated as follows; intracellular LDH activity/ (extracellular LDH activity +
intracellular LDH activity) x 100.
a) Preparation of reagents
LDH reagent A contains NADH (0.194 mM) in phosphate buffer, pH7.5 (54 mM). LDH reagent B
is a solution of pyruvate (16.2 mM) to which non-reactive stabilisers and filler have been added.
Both reagents were reconstituted by the addition of deionized water as indicated on the vial.
After addition of water, the vial was sealed and then gently inverted several times.
b) Sample preparation
All cells for cell viability studies were plated into 12 well plates at a density of 10000 cells/cm2.
Immediately after treatment with tert-butylhydroperoxide the medium (1 ml) was removed from
the cells into labelled eppendorf tubes. Cells were then washed with 2 x 1 ml phosphate
113
Materials and general methods chapter two
minutes the cell lysates were collected into labelled eppendorf tube and the wells were washed
in a further 0.5 ml PBS and the contents added to the respective eppendorf tube. Cell debris
which may interfere with the assay was removed by micro-centrifugation of all samples at
11500g.
c) LDH activity assay
Samples (200 pi) were transferred into Cobas cups for LDH activity analysis. The change in
absorbance at a wavelength of 340 nm was measured in 25 pi of sample in a final volume of
290 pi (200 pi reagent A and 25 pi reagent B). The reaction mixture was maintained at 37°C and
the LDH activity expressed as units per litre (U/L) was determined by kinetic analysis.
LDH activity was also measured in culture media which had not been in contact with cells as a
measure of background absorbance which was subsequently subtracted from each extracellular
LDH activity. The LDH activity in both the medium and cell lysates was then calculated as
described above.
2.3.22 Statistical analysis
The statistical analyses in this thesis were carried out using the computer statistics package
GraphPad InStat version 3 for Windows 95.
To test whether the means from two groups differed significantly the unpaired't' test was used.
This test assumes that the standard deviations of the two populations do not differ significantly.
In cases where there was found to be a significant difference the Welch correction was used.
One-way analysis of variance (ANOVA) was used when differences where suspected between
the means of a number of groups of data. In the cases where the difference was significant
(p>0.05) a Tukey-Kramer multiple comparison was used which compares all columns of data.
114
Selenoprotein expression in endothelial cells chapter three
CHAPTER THREE SELENOPROTEIN EXPRESSION
IN ENDOTHELIAL CELLS
3.1 INTRODUCTION
3.1.1 Antioxidant enzymes in plasma and endothelial cells
Selenium is found in all human tissues at an average concentration of 0.2 pg per gram in
association with tissue protein, either loosely bound or as selenium analogues of sulphur amino
acids forming selenoproteins (Reilly, 1993). Selenium is thought to exert its effects through the
expression of both intracellular and extracellular selenoproteins (Arthur and Beckett, 1994).
Since the identification of cytoplasmic glutathione peroxidase (cyGPX) in 1973, approximately 30
different selenoproteins in mammals have been identified by SDS-PAGE of [75Se]-labelled
tissue. Of these 30 selenoproteins, only about 13 have been characterized using purification and
sequencing of the protein and/ or cloning and sequencing of the cDNAs. The biochemical roles
of these 13 selenoproteins have been elucidated in all but three of the selenoproteins identified;
however the precise characterisation and detailed mechanisms of action of some have still to be
determined.
The intracellular selenoproteins identified to date consist of cyGPX, phospholipid hydroperoxide
glutathione peroxidase (PHGPX), gastrointestinal glutathione peroxide, three different forms of
both thioredoxin reductase (TR) and iodothyronine 5'-deiodinase (IDI), selenoprotein W and the
58, 56 and 14 kDa selenium-binding proteins.
Labelling with [75Se]-selenite provides a reliable, precise and sensitive method for assessing the
expression of selenoproteins which require insertion of selenocysteine residues at specific sites.
However, since equilibration of exogenous [75Se]-selenite with the endogenous pool of selenium
and selenoproteins can take within excess of 27 hr (Beech et a/., 1994), labelling experiments to
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detect specific selenoproteins are usually carried out over at least a 24-36 hr period. The use of
[75Se]-labelling to study the effects of selenium on selenoenzyme induction is potentially
problematic. Isotope dilution with added selenium would be likely to obscure any real changes in
selenoenzyme expression.
The [75Se]-labelling of endothelial cells has not been previously reported. However the presence
of specific selenoproteins in endothelial cells has been demonstrated. Thomas et at., (Thomas,
Geiger and Girotti, 1993), and Claise et at., (Claise et at., 1997) have measured cyGPX and
PHGPX activity in cultured bovine and human endothelial cells respectively, whilst cyGPX mRNA
has been detected using Northern blot analysis in human umbilical vein endothelial cells
(HUVEC) (Jornot and Junod, 1995; Ricetti etat., 1994).
Human plasma contains several antioxidant enzymes including superoxide dismutase, catalase
and the extracellular selenoproteins, extracellular glutathione peroxidase (EGPX) (Takahashi et
at., 1987) and selenoprotein P (Arteel et at., 1998; Burk and Hill, 1994; Mostert, Lombeck and
Abel, 1998). Whilst, endothelial cells are reported to be the main source of extracellular
superoxide dismutase (Marklund, 1984), Avissar et at. were unable to detect EGPX in the media
of HUVEC using immunoprecipitation. They concluded that either endothelial cells do not
synthesise and secrete EGPX or the levels were below the detection limit of their
immunopurification method (Avissar et at., 1989). Selenoprotein P was the second extracellular
selenoprotein to be identified and comprises of approximately 65% of the plasma selenium in
rats (Burk and Hill, 1994). Immunohistochemical techniques have shown that selenoprotein P is
associated with endothelial cells in brain, capillary endothelial cells of the renal glomeruli and the
endothelial cells of the liver (Burk et at., 1997). However the synthesis of selenoprotein P by
HUVEC or other endothelial cells has not been previously reported.
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Selenium status can modify selenoprotein expression. In studies where rats received selenium-
deficient diets substantial decreases in hepatic IDI and cyGPX activities and mRNA levels,
compared to selenium-adequate controls, were observed (Bermano, 1995; Mitchell et at., 1996).
In cell culture studies, selenium supplementation of approximately 174 nM and 520 nM
significantly increased cyGPX activity in HUVEC (Ricetti et at., 1994). The selenium
concentration of different culture media can vary significantly and this factor should be
considered when comparing selenoprotein expression and activities of cells cultured using
different media.
3.1.2 Model systems of endothelial cell function
The use of cell culture has allowed the study of homogeneous cell populations without being
complicated by the confounding factors of other tissues. Large vessel endothelial cell culture is a
well-established model for the study of the endothelium. The human umbilical vein is often the
chosen vessel for the study of human endothelial function as it has several advantages as a
source of endothelial cells, it is a non-branching vessel, with a large intimal surface area, making
it technically very easy to isolate cells. However there are many variables which can affect the
viability of the isolated cells, including foetal stress, maternal anaesthesia and smoking. The use
of HUVEC is also complicated by the genetic variability between preparations, limited population
doublings, difficulty in culture and the requirement for specialised growth factors.
An alternative to the use of HUVEC is to use human transformed cell lines such as EAhy926.
EAhy926 is an endothelial cell line established by hybridising primary HUVEC with A549 human
lung tumor cells (Edgell, McDonald and Graham, 1983). Cells in primary culture have a limited
replication potential and tend to senesce in culture (Ager et at., 1982), whilst EAhy926 cells
retain many of the differentiated functions common to primary endothelial cells beyond 100
passages. These functions include; the expression of von Willebrand Factor (Edgell,
McDonaldand Graham, 1983), prostacyclin formation (Suggs et at., 1986) and expression of
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endothelin-1 (Saijonmaa et at., 1991). The selenoprotein profile of EAhy926 cells has not been
previously determined, which is essential in order to establish whether this more convenient cell
line would provide a suitable model for future studies of selenoprotein expression in endothelial
cells.
Endothelial cells isolated from a number of different species have been used as model systems
to investigate human pathologies. For example bovine aortic endothelial cells (BAEC) were used
in the earliest studies due to their ease of isolation and subcultivation. Porcine aortic endothelial
cells (PAEC) were initially isolated and characterised by Slater and Sloan (Slater and Sloan,
1975) and were thought to provide a suitable alternative to HUVEC based on similarities of the
porcine cardiovascular system with that in man. In addition porcine aorta is subject to atheroma
formation and should provide a useful model for the study of atherosclerosis (Rosenthal and
Gotleib, 1990). However variation between endothelial cells isolated from different species has
been acknowledged; for example PAEC unlike HUVEC and BAEC do not have Factor VIII-
related antigen immunoreactivity (Rosenthal and Gotleib, 1990).
As well as species differences in the properties of endothelial cells it has also been shown that
endothelial cells isolated from different sites in the vasculature exhibit different properties.
Arterial and venous endothelial cells show differences in the production of angiotensin-
converting enzyme (Johnson, 1980) and their response to cytokine stimulation (Hauser, Johnson
and Madri, 1993). These observations have led to the suggestion that HUVEC, despite being
used by a number of researchers in the field of vascular disease [Milner, 1990; Jornot, 1997;
Zhao, 1998] may not be the most suitable model in the study of human cardiovascular disease.
Indeed a more suitable model to study vascular disease may be endothelial cells isolated from
arterial vascular beds as opposed to venous. Thus, human coronary arterial endothelial cells
may provide a good model as the coronary artery in particular is one of the main vascular beds
affected by the formation of atherosclerotic lesions.
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Furthermore if the efficacious effect of selenium on endothelial cell function is to be studied it is
essential that a model system is chosen which reflects the selenoprotein expression and
function of endothelial cells which line vessels prone to developing vascular disease.
The experiments reported here aim to:
• determine the labelling conditions required to study selenoprotein expression in endothelial
cells using [75Se]-selenite
• examine the expression of extracellular and intracellular selenoproteins in [75Se]-labelled
HUVEC
• compare the selenoprotein profile of HUVEC with that of the endothelial cell line, EAhy926
• compare the selenoprotein profile of HUVEC with those of endothelial cells isolated from
human umbilical artery and human coronary artery
• compare the pattern of selenoprotein expression observed in HUVEC with that of endothelial
cells isolated from alternative species
• to arrive at an appropriate model to investigate the role of selenium on endothelial cells.
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3.2 METHODS
3.2.1 Time-course of [75Se]-labelling in HUVEC
HUVEC were isolated and maintained as described in section 2.3.2. Cells were grown to
confluence and the culture medium was changed and replaced with fresh medium. [75Se]-
selenite (0.02 MBq/ml) was added to the culture medium of duplicate T75 flasks at time 0, 12,
24, 48, 72 and 96 hr. After 96 hr the medium was removed from all the flasks and the cells were
washed three times with EBSS (4°C). The cells were harvested into 20 ml of EBSS by scraping
and centrifuged at 2000 g for 10 min at 4°C. The supernatant was aspirated off and the cell
pellet resuspended in 200 pi of 60 mM Tris buffer, pH 7.8, containing 1 mM EDTA and 1 mM
dithiothreitol (Tris buffer). The cells were then lysed by sonication on ice using the Soniprep 150.
Protein concentrations were measured using the Bradford assay (section 2.3.12) and the
samples were diluted to a common protein concentration with Tris buffer. The cell lysates were
prepared for separation by SDS-PAGE (section 2.3.13) and the [75Se]-labelled proteins present
in 25 pg of protein were separated by SDS-PAGE (section 2.3.13). The resulting gel was dried
and the [75Se]-labelled selenoproteins were visualised by autoradiography using Kodak X-OMAT
XAR-5 film (section 2.3.14).
3.2.2 The intracellular and extracellular selenoproteins expressed by HUVEC
In experiments where only the intracellular selenoproteins were monitored the following protocol
was used. HUVEC were isolated and maintained as described in section 2.3.2. Cells were grown
to confluence and the culture medium was changed and replaced with fresh medium. [75Se]-
selenite (0.02MBq/ml) was added to a T75 flask of HUVEC and incubated for 48 hr to allow a
steady state of labelling to be achieved (as ascertained in the experiment described in section
3.2.1). After a 48 hr labelling period the cells were harvested and lysed in Tris buffer as
described above in section 3.2.1.
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3.2.1). After a 48 hr labelling period the cells were harvested and lysed in Tris buffer as
described above in section 3.2.1.
To monitor both the intracellular and extracellular selenoprotein expression, duplicate T75 flasks
containing confluent cultures of HUVEC were incubated with [75Se]-selenite (0.02 MBq/ml) for 48
hr. After 30 hr the EGM-2 culture medium was removed and the cells washed. Cells were then
incubated in protein-free culture medium EBM-2 containing [75Se]-selenite (0.02 MBq/ml). After a
further 18 hr this culture medium was removed, centrifuged at 2000 g for 20 min and then
dialysed over two days to remove any unbound [75Se]-selenite. Dialysis was against 2 litres of
Tris buffer at 4°C (which was changed four times over the two day period). The dialysed solution
was then concentrated by placing the dialysis sack into a saturated solution of poly(ethylene
glycol) prepared in dialysis buffer. Meanwhile the cells were harvested and lysed in Tris buffer
(section 3.2.1).
Protein concentrations of both the HUVEC lysate and the dialysed medium were measured
using the Bradford assay (section 2.3.12). The samples were prepared for separation by SDS-
PAGE (section 2.3.13) and the 75Se-labelled proteins present in 25 pg of protein in the HUVEC
and in 12.5 pg protein in the culture medium were separated by SDS-PAGE (section 2.3.13).
The resulting gel was dried and the [75Se]-labelled selenoproteins were visualised by
autoradiography using Kodak X-OMAT XAR-5 film (section 2.3.14).
Some of the gels were scanned using a Bio-Rad model GS-525 Molecular Imager System to
create a digitilized image (section 2.3.15). The radioactivity in each band was quantified using
the Bio-Rad Molecular Analyst/ PC image-analysis software. This method was used to assess
the relative amounts of each selenoprotein in a given selenoprotein profile.
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3.2.3 Identification of intracellular selenoproteins expressed by HUVEC
Thioredoxin reductase (TR), cytosolic glutathione peroxidase (cyGPX) and phospholipid
hydroperoxide glutathione peroxidase (PHGPX) were identified in HUVEC using Western blot
analysis. The methodology used is described in section 2.3.16 and was carried out by Mr Fergus
Nicol of the Rowett Research Institute, Bucksburn, Aberdeen, UK and Dr. Forbes Howie of the
Department of Clinical Biochemistry, The University of Edinburgh, Edinburgh, UK.
3.2.4 The effect of passage number on [75Se]-labelling in HUVEC
The intracellular [75Se]-selenoprotein profiles of eight passages of a single preparation of
HUVEC isolated from a single umbilical vein were compared. HUVEC were isolated and
maintained as described in section 2.3.2. The HUVEC from the primary isolate (passage zero)
were grown to confluence and passaged into at least three T75 flasks (passage one). At
confluence, two of the T75 flasks were labelled with [75Se]-selenite (0.02MBq/ml) for 48 hr, whilst
the third was sub-cultured to provide passage two HUVEC. This procedure was continued until
cells had reached passage eight, at which point distinct morphological changes were observed,
such as significant cell enlargement and a partial loss of the characteristic cobblestone
appearance.
After a 48 hr labelling period HUVEC of each passage were harvested and stored at -21 °C until
HUVEC had been collected for each passage number.
Samples were thawed, lysed and prepared for separation on an SDS-PAGE as described in
section 3.2.1. The [75Se]-labelled selenoproteins present in 25 pg of protein of each sample of
HUVEC were then separated on a single SDS-PAGE gel (section 2.3.13) to allow a direct
comparison between HUVEC of a number of passages. The resulting gel was dried and the
[75Se]-labelled selenoproteins were visualised by autoradiography using Kodak X-OMAT XAR-5
film (section 2.3.14).
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3.2.5 The [75Se]-labelling of endothelial cells isolated from different vasculature
The intracellular selenoprotein profile of the cell line EAhy926 cells, human coronary artery
endothelial cells (HCAEC), human umbilical artery endothelial cells (HUAEC) and bovine aortic
endothelial cells (BAEC) were each compared to that of HUVEC. Each cell type were isolated
and/or maintained as previously described (sections 2.3.4, 2.3.5, 2.3.6, 2.3.8 and 2.3.2).
Duplicate flasks of both HUVEC and the comparative endothelial cell type were seeded and
maintained in their respective growth media. At confluence the cells were labelled with [75Se]-
selenite (0.02MBq/ml). After 48 hr incubation the cells were harvested as described in section
3.2.1.
Cell lysates were then prepared for and the [75Se]-labelled proteins separated by SDS-PAGE
(section 3.2.1). The resulting gel was dried and the [75Se]-labelled selenoproteins were
visualised by autoradiography using Kodak X-OMAT XAR-5 film (section 2.3.14). The [75Se]-
labelled selenoproteins of the HUVEC and the comparative endothelial cell type were separated
on a single SDS-PAGE gel to allow a direct comparison between the two cell types.
The intracellular selenoprotein profile of porcine aortic endothelial cells (PAEC) was established
using the same protocol as described above in this section except that HUVEC were not labelled
in parallel with PAEC and therefore their intracellular selenoprotein profiles were not directly
compared on a single SDS-PAGE gel. (PAEC were isolated and maintained as described in
section 2.3.7).
3.2.6 Intracellular selenoprotein expression and activity of endothelial cells
isolated from different vasculature
HUVEC, EAhy926 cells, HCAEC and BAEC were isolated and/or maintained as previously
described (see sections 2.3.2, 2.3.4, 2.3.5 and 2.3.6).
123
Selenoprotein expression in endothelial cells chapter three
For measurement of TR mass and activity, cyGPX activity and PHGPX activity (sections 2.3.17,
2.3.18, 2.3.19 and 2.3.20), triplicate T75 flasks of each cell types were grown and maintained as
previously described (3.2.2, 2.3.4, 2.3.5 and 2.3.8). At confluence the cells were harvested,
lysed in 0.125 M potassium phosphate buffer, pH 7.4, and sonicated on ice (section 3.2.1). The
cell lysates were subsequently frozen at -70°C until assayed. All the samples for each
measurement were analysed in the same assay to avoid any between assay variation. All the TR
activity assays described in this chapter were carried out by Miss Michelle Lewin of the
Department of Clinical Biochemistry, The University of Edinburgh, Edinburgh, UK whilst Miss
Karen Pickard and Mr Fergus Nicol both of the Rowett Research Institute, Bucksburn,
Aberdeen, UK carried out the GPX activity assays.
TR, cyGPX and PFIGPX activity were not measured in HCAEC, whilst TR mass was not
measured in BAEC due to a shortage of cells.
3.2.7 Comparison of [75Se]-labelling of cell types isolated from different human
tissues
Cells originating from different human tissues (HUVEC, human thyrocytes and a human foetal
liver-derived cell line, FlepG2) were isolated and maintained as described in sections 2.3.2, 2.3.9
and 2.3.10. FIUVEC, human thyrocytes and hepG2 cells were grown to confluence in T75 flasks
and then each was labelled for 48 hr with [75Se]-selenite (0.02 MBq/ml). Cells were then
harvested, lysed in Tris buffer and separated by SDS-PAGE (section 3.2.1). The resulting gels
were dried and the [75Se] labelled selenoproteins visualised by autoradiography using Kodak X-
OMAT XAR-5 film. The autoradiographs obtained for each of the different cell types were then
compared with each other.
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3.2.8 Measurement of the selenium content of various culture mediums
The selenium content of the following culture media was measured using the method described
in section 2.3.11: EGM-2, EBM-2, DMEM containing 10% FBS and 1% HAT, M199 containing
20% FCS and EGM.
3.2.9 The effect of increasing doses of sodium selenite on [75Se]-labelling of
HUVEC
T75 flasks of HUVEC were isolated and maintained as described in section 2.3.2. Cells were
grown to confluence at which point the culture medium was changed and replaced with fresh
medium containing one of the following concentrations of sodium selenite; 0 nM, 0.1 nM, 1.0 nM,
10 nM and 100 nM. [75Se]-selenite (0.02 MBq/ml, 1.25 nM selenite) was added to each flask.
After 48 hr the cells were harvested and lysed in Tris buffer and the intracellular selenoproteins
separated by SDS-PAGE as described in section 3.2.1.
3.2.10 Statistical analysis
An unpaired 't' test was used to test the significant difference between the levels of
selenoprotein expression or enzyme activity in the different endothelial cell types. The Students
't' test assumes that the standard deviations (SD) are equal. In cases where there was found to
be a significant difference in the SD the't' test was used with a Welch correction.
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3.3 RESULTS
3.3.1 [75Se]-labelling time-course of HUVEC
Figure 3.01 shows an autoradiograph of an SDS-PAGE gel demonstrating the changes in [75Se]-
labelling with increasing time. Selenoproteins were faintly labelled after a 12 hr exposure to
[75Se]-selenite. The intensity of labelling of all selenoproteins increased up until 48 hr at which
time a steady state of labelling was achieved and no further increase in labelling was observed.
3.3.2 The intracellular and extracellular selenoproteins expressed by HUVEC
Figure 3.02 shows an autoradiograph of an SDS-PAGE gel of the intracellular [75Se]-labelled
selenoproteins in HUVEC. Four major [75Se]-labelled selenoproteins were observed. A single
selenoprotein with a molecular mass of 58.1 ± 1.0 kDa (mean ± SEM, n=5) was the dominant
[75Se]-labelled band accounting for 42.9+1.4% (mean ± SEM, n=3) of the total intracellular
[75Se]-selenoproteins. Two other selenoproteins that showed pronounced [75Se]-labelling had
calculated molecular masses of 21.7+0.5 kDa (mean ± SEM, n=5) and 24.4±0.5 kDa (mean ±
SEM, n=5) and accounted for 14.6+1.0% (mean + SEM, n=3) and 15.1+2.8% (mean + SEM,
n=3) respectively of the total intracellular [75Se]-labelling. The fourth prominently [75Se]-labelled
selenoprotein ran slightly above the 14.4 kDa molecular weight marker and had a molecular
mass of approximately 15 kDa and accounted for 14.7±5.4% (mean ± SEM, n=3) of the total
intracellular [75Se]-selenoproteins. In addition to these four major bands a number of minor
labelled selenoproteins were observed, including a band which ran slightly above the 58 kDa
[75Se]-selenoprotein and a band with an approximate molecular mass of 72 kDa. No distinct
variations in the pattern of intracellular [75Se]-labelled selenoproteins between different
preparations of HUVEC were observed (figure 3.03). The variation in the intensities of
autoradiographic bands between preparations can be accounted for by differing exposures of
the SDS-PAGE gels to the autoradiographic film.
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No significant [75Se]-labelling was detected in the culture medium of HUVEC (figure 3.02).
3.3.3 Identification of intracellular selenoproteins expressed by HUVEC
Using antiserum to rat thioredoxin reductase (TR) and human TR, the 58 kDa [75Se]-labelled
band in HUVEC was identified by Western blotting as TR (refer to lane 4, figure 3.20).
The 22 kDa [75Se]-labelled band was identified as phospholipid hydroperoxide glutathione
peroxidase (PHGPX) using antisera to rat PHGPX by Western blot analysis (figure 3.04). The
molecular weight of crocodile and human PHGPX was higher than that of rat PHGPX.
Using antiserum to human cyGPX it was not possible to visualise an immunoreactive band in
HUVEC (data not shown). The purified cyGPX separated by SDS-PAGE revealed several bands
but only one band had an electrophoretic mobility of 24 kDa. This 24 kDa protein (observed on
the Coomassie Blue gel) was superimposable on the 24 kDa [75Se]-labelled protein band
observed on the SDS-PAGE gel autoradiograph (figure 3.05).
The 58 kDa, 22 kDa and 24 kDa bands observed on an autoradiograph of an SDS-PAGE gel
showing the [75Se]-selenoproteins expressed by HUVEC are thought to represent TR, PHGPX
and cyGPX respectively. Therefore, these bands, whether expressed by HUVEC or other
endothelial cells, are referred to as the selenoproteins they are believed to represent.
3.3.4 The effect of passage number on [75Se]-labelling in HUVEC
Figure 3.06 demonstrates that the pattern of intracellular [75Se]-labelled selenoproteins
expressed by HUVEC of eight passages from a single preparation did not show any distinct
alteration with increasing passage.
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3.3.5 The intracellular selenoproteins expressed by the human endothelial cell
line EAhy926
Figure 3.07 shows that the overall pattern of selenoprotein expression in EAhy926 cells
resembles that observed in HUVEC with some significant differences in the levels of expression
of a few selenoproteins. TR is dominantly labelled and to a similar extent in both HUVEC and
EAhy926 cells. Figure 3.08 compares the TR mass and activity of both ceil types and confirms
that there is no significant difference in the TR expression in these cell types.
The [75Se]-labelled selenoprotein with an approximate molecular weight of 64 kDa in HUVEC is
not apparent in EAhy926 cells whilst an unidentified selenoprotein with an estimated molecular
mass of approximately 18 kDa is more prominently labelled in EAhy926 cells as compared to
HUVEC.
A lower expression of cyGPX and PHGPX can be observed in figure 3.07 in EAhy926 cells
compared to HUVEC. Figure 3.09 confirms this observation showing that cyGPX activity in
EAhy926 cells (0.086 ±0.001 U/mg protein, mean ± SD, n=3) is 27% of that in HUVEC (0.023
±0.001 U/mg protein, mean ± SD, n=3, p<0.01). The PHGPX activity in the EAhy926 cells
tended towards being lower than that observed in HUVEC, although this difference was not
shown to be significant (figure 3.10).
3.3.6 The selenoproteins expressed by human coronary artery endothelial cells
Figure 3.11 shows that the pattern of [75Se]-labelled selenoproteins in HCAEC was very similar
to that observed in HUVEC. The autoradiograph shows little difference in the degree of labelling
and hence the expression of some of these selenoproteins. TR is more dominantly labelled in
HCAEC compared to HUVEC, whilst the selenoprotein with an approximate molecular mass of
22 kDa is labelled to a slightly lesser extent in HCAEC compared to HUVEC.
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Figure 3.12 compares the TR mass between HUVEC and HCAEC. The expression of TR is
1.89-fold higher in HCAEC compared to HUVEC.
3.3.7 The pattern of selenoprotein expression in human umbilical artery
endothelial cells
Figure 3.13 demonstrates that venous endothelial cells and arterial endothelial cells isolated
from the same umbilical cord differ very slightly. In HUVEC one extra selenoprotein with a
molecular mass of approximately 27 kDa is labelled which is not observed in HUAEC.
TR expression in HUAEC appears to be greater than in the HUVEC.
3.3.8 The pattern of selenoprotein expression in porcine aortic endothelial cells
Figure 3.14 shows the [75Se]-labelled selenoproteins in a preparation of PAEC. Compared to
HUVEC, PAEC show quite distinct differences in the pattern of [75Se]-labelled selenoproteins.
TR is no longer the most prominently labelled band. Instead a band with an approximate
molecular weight of 15 kDa predominates.
3.3.9 The selenoproteins expressed by bovine aortic endothelial cells
Figure 3.15 shows that the pattern of [75Se]-labelled selenoproteins varies considerably between
HUVEC and BAEC. The [75Se]-labelling of most selenoproteins was significantly lower in BAEC,
with the exception of PHGPX which was labelled more prominantly in BAEC. The [75Se]-labelled
band with an approximate molecular weight of 15 kDa migrated at a slightly higher molecular
weight in BAEC than that observed in HUVEC, but the selenoprotein was labelled to a similar
degree.
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TR activity measured in BAEC was approximately 6% of that measured in HUVEC (figure 3.16).
TR mass was not measured in BAEC as the antiserum to human TR did not cross-react with
bovine TR. There was no significant difference in the cyGPX and PHGPX activities between
HUVEC and BAEC (figures 3.17 and 3.18).
3.3.10 Comparison of [75Se]-labelling of cell types isolated from different human
tissues
Distinct differences in the ratios of the intracellular [75Se]-labelled selenoproteins were observed
between cells isolated from different human tissues (figure 3.19). In the human foetal liver-
derived cell line, HepG2, the band with an approximate molecular mass of 58 kDa is observed
as a doublet rather than the single band found in both HUVEC and human thyrocytes. The same
[75Se]-labelled 58 kDa band was much more prominent in the HUVEC compared to HepG2 cells
and human thyrocytes. (It should be noted that these cell types were labelled and separated on
different SDS-PAGE gels, therefore some of the differences may be due to variability in the
labelling and processing conditions).
The [75Se]-labelled 58 kDa band observed in both HUVEC and HepG2 cells was identified as TR
by Western blot analysis as previously described in section 2.3.16 (figure 3.20). Quantification of
Western blots showed HUVEC expressed high concentrations of TR under basal conditions
(4.36 ±0.63 pig/ mg, mean ± S.E.M., n=3). The concentration of TR expressed by HepG2 cells
was approximately one tenth of that expressed in HUVEC. The Western blot was insufficiently
sensitive to detect TR in human thyrocytes grown under basal conditions (figure 3.20).
3.3.11 Comparison of selenium content of various culture media
Figure 3.21 shows the measured selenium concentrations of the culture media used for the
growth and maintenance of some of the endothelial cells described in this chapter. The results
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show that there is no significant difference between the selenium content of the culture medium
used to grow the human endothelial cell line EAhy926 i.e. DMEM containing 10% FBS and 1%
HAT and the culture medium used for HUVEC, HCAEC and HUAEC i.e. EGM-2. The selenium
content of the culture medium used to maintain BAEC has a significantly higher selenium
concentration than the other two culture media.
The culture medium used to maintain human thyrocytes contained a selenium concentration of
5.4 nM as measured by Beech et al. in a previous study (Beech etal., 1995).
The main source of selenium in EGM and EGM-2 media is selenious acid which can be
metabolised by the cultured cells for incorporation into selenoproteins. In contrast, the selenium
contained in most culture media is incorporated into serum proteins within the FBS which is not
easily utilised by cultured cells (Brigelius-Flohe et al., 1996). Therefore the selenium content of
the EAhy926 culture media is unlikely to provide a bioavailable source of selenium. Thus the
absolute levels of selenium measured in this study do not necessarily correlate to the ability of
the selenium to increase selenoprotein expression.
The selenium concentration was not measured in the complete media used to maintain HepG2
cells or PAEC. The source of selenium in both types of media is from FBS as both DMEM/
Ham's F-12 nutrient mix containing L-glutamine and 15mM Hepes and M199 contain only
negligible levels of selenium (data not shown).
3.3.12 The effect of increasing doses of sodium selenite on [75Se]-labelling of
HUVEC
Figure 3.22 shows an autoradiograph of an SDS-PAGE demonstrating the effects of increasing
concentrations of sodium selenite on the [75Se]-labelling of HUVEC. An observable decrease in
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labelling was observed between 10 and 100 nM sodium selenite. Concentrations of sodium





Figure 3.01. Autoradiograph of an SDS-PAGE gel of human umbilical
vein endothelial cells (HUVEC) labelled with [^SeJ-selenite (0.02
MBq/ml) for stated lengths of time. Duplicate flasks of HUVEC were
labelled for each time point. Lanes 1 and 2, 12 hr; lanes 3 and 4, 24 hr;
lanes 5 and 6, 48 hr; lanes 7 and 8, 72 hr; lanes 9 and 10, 96 hr. Each lane
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Figure 3.02. Autoradiograph of an SDS-PAGE gel of human umbilical vein endothelial
cell (HUVEC) intracellular and extracellular selenoproteins labelled with [75Se]-
selenite (0.02 MBq/ ml) for 48 hr. Quadruple flasks of HUVEC from a single isolation were
used. Lanes 1-4, intracellular selenoproteins (each lane was loaded with 25 pg protein);




Figure 3.03. Autoradiographs of four SDS-PAGE gels showing the intracellular
selenoproteins from four different preparations of human umbilical vein
endothelial cells (HUVEC) labelled with [75Se]-selenite (0.02 MBq/ ml) for 48 hr.
Lane 1, HUVEC prep 7; lane 2, HUVEC prep 13; lane 3, HUVEC prep 29 and lane 4,
HUVEC prep 31. Each lane was loaded with 25 pg of protein.
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Figure 3.04. Western blot of human umbilical vein endothelial cells (HUVEC) and
crocodile phospholipid hydroperoxide glutathione peroxidase (PHGPX) using antiserum
to rat PHGPX. Lane 1, purified rat PHGPX standard (28 ng); lane 2, purified rat PHGPX
standard (14 ng); lane 3, purified rat PHGPX standard (7 ng); lane 4, HUVEC grown in EGM-2
culture medium (50 pg protein loaded); lane 5, HUVEC grown in M199 culture medium (50 pg)
protein loaded); lanes 6, 7 and 8, semi pure crocodile PHGPX.
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Figure 3.05. Autoradiograph of an SDS-PAGE gel of human umbilical vein endothelial
cell (HUVEC) intracellular selenoproteins labelled with [75Se]-selenite (0.02MBq/ml
superimposed onto a Coomassie Blue gel of purified human cytoplasmic glutathione
peroxidase (cyGPX). Lane 1, purified human cyGPX (10 pg); lanes 2 and 3 (Coomassie
Blue gel), intracellular proteins expressed by HUVEC (25 pg); lanes 2 and 3
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Figure 3.06. Autoradiograph of an SDS-PAGE gel of a single isolation of human
umbilical vein endothelial cells (HUVEC) at different passages each labelled with
[75Se]-selenite (0.02 MBq/ ml) for 48 hr. Lane 1, passage 1; lane 2, passage 2; lane 3,
passage 3; lane 4, passage 4; lane 5, passage 5; lane 6, passage 6; lane 7, passage 7 and










Figure 3.07. Autoradiograph of an SDS-PAGE gel of the intracellular selenoproteins of
human umbilical vein endothelial cells (HUVEC) and EAhy926 cells labelled with [75Se]-
selenite (0.02 MBq/ ml) for 48 hr. Lane 1, HUVEC; lane 2, EAhy926 cells. Both lanes were
loaded with 25 pg protein. TR, thioredoxin reductase; cyGPX, cytoplasmic glutathione



















Figure 3.08 Thioredoxin reductase (TR) activity (a) and mass (b) comparison in human
umbilical vein endothelial cells (HUVEC) cultured in EGM-2 compared with EAhy926
cells cultured in DMEM + 10% FBS + 1% HAT. Results shown are those of the mean of 4
flasks ± SD. No significant differences were calculated.
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Figure 3.09. Cytoplasmic glutathione peroxidase (cyGPX) activity comparison between
human umbilical vein endothelial cells (HUVEC) cultured in EGM-2 and EAhy926 cells






Figure 3.10. Phospholipid hydroperoxide glutathione peroxidase (PHGPX) activity
comparison between human umbilical vein endothelial cells (HUVEC) cultured in EGM-2
and EAhy926 cells cultured in DMEM + 10% FBS +1% HAT. Results shown are those of the






Figure 3.11. Autoradiograph of an SDS-PAGE gel of the intracellular selenoproteins of
human umbilical vein endothelial cells (HUVEC) and human coronary artery endothelial
cells (HCAEC) labelled with [75Se]-selenite (0.02 MBq/ ml) for 48 hr. Lane 1, HUVEC; lane





Figure 3.12. Thioredoxin reductase (TR) comparison between human umbilical vein
endothelial cells (HUVEC) and human coronary artery endothelial cells (HCAEC) both
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Figure 3.13. Autoradiogrpah of an SDS-PAGE gel of the intracellular selenoproteins of
human umbilical vein endothelial cells (HUVEC) and human umbilical artery endothelial
cells (HUAEC) labelled with [75Se]-selenite (0.02 MBq/ml) for 48 hr. Both HUVEC and
HUAEC were isolated from a single umbilical cord and samples were taken from duplicate
flasks. Lanes 1 and 2, HUVEC; lanes 3 and 4, HUAEC. Each lane were loaded with 25 pg
protein. TR, thioredoxin reductase; cyGPX, cytoplasmic glutathione peroxidase; PHGPX,




Figure 3.14. Autoradiograph of an SDS-PAGE gel of porcine aortic endothelial cells





Figure 3.15. Autoradiograph of an SDS-PAGE gel of the intracellular selenoproteins of
human umbilical vein endothelial cells (HUVEC) and bovine aortic endothelial cells
(BAEC) labelled with [75Se] selenite (0.02 MBq/ ml) for 48 hr. Lane 1, HUVEC; lane 2,
BAEC. Both lanes were loaded with 25 pg protein. TR, thioredoxin reductase; cyGPX,
























Figure 3.16. Thioredoxin reductase (TR) activity comparison between human umbilical
vein endothelial cells (HUVEC) and bovine aortic endothelial cells (BAEC). Results shown




Figure 3.17. Cytoplasmic glutathione peroxidase (cyGPX) activity comparison between
human umbilical vein endothelial cells (HUVEC) and bovine aortic endothelial cells
(BAEC). Results shown are those of the mean of three flasks ± SD. No significant difference
in cyGPX activity between cell types was found.
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Figure 3.18. Phospholipid hydroperoxide glutathione peroxidase (PHGPX) activity
comparison between human umbilical vein endothelial cells (HUVEC) and bovine aortic
endothelial cells (BAEC). Results shown are those of the mean of three flasks ± SD. No




Figure 3.19. Autoradiograph of an SDS-PAGE gel of the intracellular selenoproteins of
different human cells isolated from three types of human tissue labelled with [75Se]-
selenite (0.02 MBq/ml) for 48 hr. Lane 1, human umbilical vein endothelial cells; lane 2,
human thyrocytes; lane 3, HepG2 cells. Each lane was loaded with 25 pg of protein.
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58 kDa - 58 kDa
Figure 3.20. Western blot of human thyrocytes, HepG2 cells and human umbilical vein
endothelial cells (HUVEC) using antiserum to thioredoxin reductase. Lane 1, purified rat
thioredoxin reductase standard (5 ng); lane 2, untreated human thyrocytes (20 pg protein
loaded); lane 3, untreated HepG2 cells (20 pg protein loaded); lane 4, untreated HUVEC (20 pg






Figure 3.21. Comparison of selenium contents of various culture media used to grow
and maintain some of the endothelial cells described in this chapter. The results shown
are the means of triplicate measurements ± SD. p<0.01* from EGM-2. DMEM, Dulbecco's
modified Eagle medium; EGM, endothelial growth medium; EGM-2, endothelial growth
medium-2; FCS, foetal calf serum. The cell types associated with each particular culture
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Figure 3.22. Autoradiograph of an SDS-PAGE gel of human umbilical vein endothelial
cells (HUVEC) labelled with [75Se]-selenite (0.02MBq/ml) in the presence of increasing
doses of sodium selenite for 48 hr. Lane 1, control; lane 2, 0.1 nM sodium selenite; lane 3,
1.0 nM sodium selenite; lane 4, 10 nM sodium selenite: lane 5, 100 nM sodium selenite. Each
lane was loaded with 25 pg of protein. TR, thioredoxin reductase; cyGPX, cytoplasmic
glutathione peroxidase; PHGPX, phospholipid hydroperoxide glutathione peroxidase.
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3.4 DISCUSSION
Labelling with [75Se]-selenite in vivo provides a precise and sensitive method to assess
selenoprotein expression in tissues and cells. [75Se] is either specifically directed to and
incorporated into selenocysteine residues which are incorporated into selenoproteins such as in
glutathione peroxidase (GPX), or it covalently binds to proteins at undefined sites as is the case
with fatty-acid binding protein and protein disulphide isomerase. The time taken for the
incorporation of [75Se] to reach equilibrium with the endogenous pool of selenium can vary
between different cell types. For example, in human thyrocytes [75Se]-labelling reaches a steady
state in excess of 27 hr, determined by measuring [75Se]-counts at specific time points, (Beech
et at., 1994), whereas in HUVEC our data show that [75Se] incorporation, determined by [75Se]-
selenoprotein labelling, reached a steady state after 48 hr. This difference can probably be
ascribed to variability in selenoprotein turnover in different tissues or possibly to different rates of
[75Se]-selenite uptake between cells from different tissue types.
Through [75Se]-labelling of intracellular selenoproteins, we have shown that human umbilical
vein endothelial cells (HUVEC) show dominant expression of a selenoprotein with a molecular
mass of 58 kDa. Western blot analysis using an antiserum to thioredoxin reductase (TR),
characterised previously by Howie et al. (Howie et al., 1998) identified this 58 kDa selenoprotein
as TR. The presence of TR in porcine pulmonary arterial endothelial cells has been previously
reported (Zhang et al., 1998). However, until recently the identification of TR in endothelial cells
derived from human tissue had not been described (Anema etal., 1999).
Two other prominent [75Se]-selenoproteins expressed by HUVEC, though labelled to a lesser
extent than TR, had molecular masses of 22 kDa and 24 kDa. These two selenoproteins were
tentatively identified as being PHGPX and cyGPX, respectively. Western blot analysis of HUVEC
using antiserum raised to rat liver phospholipid hydroperoxide glutathione peroxidase (PHGPX)
produced a single band with a slightly higher molecular mass than the rat standard used.
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(PHGPX purified from rat testis was used as a standard because no human PHGPX standard
was available). The single immunoreactive band in HUVEC had the same electrophoretic
mobility as purified crocodile PHGPX. It is possible that the difference in electrophoretic mobility
between human, crocodile and rat PHGPX may reflect a species difference in the molecular
mass of PHGPX. Indeed small variations in the molecular mass and electrophoretic mobility of
iodothyronine deiodinase (IDI) have been previously reported (Schoenmakers, Pigmans and
Visser, 1992). HUVEC also had basal PHGPX activity. Although, the possibility that the 22 kDa
[75Se]-labelled selenoprotein does not represent PHGPX cannot be excluded.
It was not possible to visualise an immunoreactive band in HUVEC using human antiserum to
cytoplasmic glutathione peroxidase (cyGPX). Using a commercial preparation of purified human
cyGPX a protein band with a molecular weight of approximately 24 kDa was observed using
Coomassie Blue staining on an SDS-PAGE gel. This band was superimposable with the 24 kDa
[75Se]-labelled band on the autoradiograph suggesting that this 24 kDa band was cyGPX. The
Western blot was insufficiently sensitive to detect cyGPX in HUVEC lysates directly and
confirmation of the identity of this 24 kDa [75Se]-selenoprotein would be desirable. Other groups
have shown that HUVEC express cyGPX. For example Ricetti et al. and Jornot and Jornod
detected cyGPX mRNA through Northern blot analysis (Ricetti et al., 1994; Jornot and Junod,
1997), whilst others like ourselves have demonstrated cyGPX activity in endothelial cells
(Crosby, Wahle and Duthie, 1996; Ricetti et al., 1994; Thomas, Geiger and Girotti, 1993). The
molecular mass of cyGPX has been reported to be in the range of 19-26 kDa (Gladyshev et al.,
1999; Jornot and Junod, 1995; Sunde, 1994), a range which includes the 24 kDa selenoprotein
band labelled in HUVEC. This evidence suggests that the 24 kDa [75Se]-selenoprotein labelled in
HUVEC is cyGPX although the possibility that this band may represent an alternative
selenoprotein cannot not be excluded at this stage.
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Many of the [75Se]-selenoproteins labelled in HUVEC were unidentified. These include a [75Se]-
labelled protein with a molecular mass of approximately 15 kDa which could be either the
uncharacterised 15 kDa selenoprotein described by Gladyshev et al (Gladyshev et al., 1998) or
epidermal fatty acid-binding protein, which has been identified previously in cultured HUVEC
using immunohistochemistry (Masouye et al., 1997). Indeed, Masouye et al. have demonstrated
the presence of E-FABP in HUVEC (Masouye et al., 1997). Nevertheless it should be noted that
immunohistochemistry carried out on the endothelium of the umbilical vein from which the
endothelial cells were isolated was negative for the presence of E-FABP (Masouye et al., 1997).
This implies that the expression E-FABP may be induced by cell culture and therefore this in
vitro model may not reflect the in vivo E-FABP content.
In overexposed autoragiographs (figure 3.22) it was possible to visualise additional bands
compared to the less exposed autoradiographs (figure 3.01). These minor bands may result
from proteolysis or may be selenoprotein products of post-translational modification. However it
is possible that these minor bands, only visible on overexposed autoradiographs, may be of
biological importance.
The cyGPX/glutathione reductase system has been implicated in hydrogen peroxide metabolism
thus forming part of the multicomponent enzymatic antioxidant defence system expressed in
cultured endothelial cells which works in conjunction with SOD and catalase to maintain the
redox potential within endothelial cells (Michiels, Toussaint and Remacle, 1990; Vercellotti et al.,
1988). PHGPX can reduce and detoxify the membrane-associated lipid hydroperoxides such as
the cholesterol hydroperoxides which are inaccessible to cyGPX (Thomas et al., 1990). The
TRTTrx system has the ability to scavenge reactive oxygen species (Bjornstedt et al., 1995)
indicating that it may contribute to the conventional antioxidant enzyme systems already
described.
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confirm the observations made by Avissar et al that HUVEC do not synthesise and secrete
EGPX (Avissar et al., 1989).
HUVEC was the chosen model in this study and was compared to the endothelial cell line,
EAhy926 as well as endothelial cells isolated from different vascular beds and species.
However, HUVEC can show genetic variability between preparations and cells in primary culture
have a limited replication potential, tending to senesce in culture (Ager et al., 1982).
Consequently some enzyme activities can vary with the number of passages (Oberley et al.,
1995). We observed no differences in the [75Se]-selenoprotein labelling of HUVEC throughout
eight passages of the same preparation cultured using identical growth conditions. These
findings suggest that the expression of selenoproteins is not significantly altered over eight
passages. Throughout this thesis HUVEC were used at passage numbers below nine and most
often using cells between passage one and four.
The intracellular [75Se]-selenoprotein profiles from four different HUVEC preparations were also
compared and showed no significant differences in the ratios of the various selenoproteins
expressed. Thus it would appear that similar patterns of selenoprotein expression occur
between most HUVEC preparations and that this profile does not change throughout eight
passages.
The use of cell lines in studies of this nature is often the preferred alternative to primary cell
culture, which is often complicated by genetic variability between preparations, limited population
doublings and requirements for specialised growth factors. However it is possible for cell lines to
lose the differentiated functions characteristic of their primary cell type which may make the cell
line unsuitable as a model. For this reason, the [75Se]-selenoprotein profile of the endothelial cell
line, EAhy926 was compared to that of HUVEC. Differences in the intensities of labelling of
some of the [75Se]-selenoproteins were observed between the two cell types.
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The [75Se]-labelling of TR, TR mass and activity were not significantly different in HUVEC
compared to EAhy926 cells. However, the 24 kDa [75Se]-labelled band was less intensely
labelled in EAhy926 cells. We have provided evidence to suggest that this 24 kDa selenoprotein
is cyGPX and this is supported by the finding that cyGPX activity was shown also to be
significantly lower in EAhy926 cells. This observation confirms the findings of Claise et at. who
reported lower cyGPX activity in EAhy926 cell homogenates as compared to HUVEC (Claise et
at., 1997). The intensity of [75Se]-labelling of PHGPX was slightly lower in EAhy926 cells
compared to HUVEC. The measurement of PHGPX activity did not fully confirm this observation
as the difference in PHGPX activity measured in HUVEC and EAhy926 cells was not significant.
This disparity between the [75Se]-labelling results and the activity assay may be accounted for by
the poor sensitivity of the PHGPX assay.
HUVEC and EAhy926 cells were grown in culture media with a similar selenium content,
although the level of bioavailable selenium is likely to be different between the two media.
Therefore the possibility exists that the differences in selenoprotein expression and activity
between HUVEC and EAhy926 cells, are the consequence of this variability in bioavailable
selenium and may not reflect true differences between the two cell types.
Endothelial cells show functional differences according to the vascular bed from which they are
derived. Arterial endothelial cells differ from venous endothelial cells in a number of respects,
such as the production of angiotensin-converting enzyme, ability to form prostacyclin (Johnson,
1980) and their cell adhesion molecule response to cytokine stimulation (Hauser, Johnson and
Madri, 1993). The selenoproteins expressed by endothelial cells isolated from different vascular
beds were therefore compared. HUVEC and human coronary artery endothelial cells (HCAEC)
were grown in the same culture medium and the cells compared were at the same passage. The
[75Se]-selenoprotein profiles of both cell types were very similar. The only observable differences
were that in HCAEC the [75Se]-labelled TR was more prominent, whilst the PHGPX was labelled
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to a lesser extent. A comparison of the TR mass between the two cell types confirmed that TR
expression was significantly higher in the HCAEC. These differences are more likely to reflect
true differences between endothelial cells isolated from different vascular beds because as far
as possible the growth and labelling conditions were identical. However it should be noted that
this comparison was only carried out using one preparation of both cell types and would need to
be repeated using several different preparations before drawing a final conclusion as to the
extent of these differences.
Differences between the [75Se]-labelled selenoprotein profiles of endothelial cells isolated from
the human umbilical vein and human umbilical artery of the same umbilical cord were observed.
The extra [75Se]-selenoprotein in HUVEC not labelled in HUAEC, with an approximate molecular
weight of 27 kDa, was unidentified but has an electrophoretic mobility consistent with it being IDI.
TR mass or activity was not measured in HUAEC, though there was an increased [75Se]-
labelling of TR in these cells compared to HUVEC. Arterial and venous endothelial cells in vivo
would be subject to different oxygen tensions and therefore different redox states. The
expression of some selenoproteins has been shown to be regulated by oxygen tension
(Berggren et al., 1996b; Jornot and Junod, 1997; Das, Guo and White, 1999). The possibility
that an in vitro cell culture model in which cells are exposed to the same oxygen tensions
underestimates variations in selenoprotein expression, cannot be excluded.
The differences in [75Se]-labelling of selenoproteins between HUVEC and HUAEC could reflect
true differences in basal expression reflecting functional variations as both cell types were
isolated from the same umbilical cord, grown in the same culture medium and were exposed to
the same oxygen tension post-isolation.
Marked differences in the pattern of selenoprotein expression between human endothelial cells
and endothelial cells isolated from bovine and porcine vascular beds were observed. In HUVEC
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and other human endothelial cells studied, TR was the dominantly [75Se]-labelled band. Although
a [75Se]-labelled band with a molecular mass of 58 kDa thought to be TR was observed in
porcine aortic endothelial cells (PAEC), the predominant selenoprotein had an approximate
molecular mass of 15 kDa. This 15 kDa [75Se]-selenoprotein was also found in HUVEC but to a
lesser extent. The identity of the 15kDa selenoprotein was not established, although its
electrophoretic mobility is consistent with it being either the uncharacterised 15 kDa
selenoprotein described by Gladyshev et at. (Gladyshev et at., 1998) or the selenium-containing
protein, epidermal fatty acid-binding protein (E-FABP) (Masouye et at., 1997).
The interpretation of the differential selenoprotein expression between HUVEC and PAEC is
limited because the two cell types were grown in different culture media and were not directly
compared on a single SDS-PAGE. The HUVEC were grown in EGM-2, which has a selenium
concentration of approximately 29 nM, whilst PAEC were maintained in M199 supplemented with
20% FBS. The selenium content of the latter was not measured although M199 was shown to
contain only trace levels of selenium and, when supplemented with 20% FBS, probably contains
within the region of 25 nM selenium in total. Though the bioavailability of this selenium to PAEC
in culture is thought to be limited.
The effect of selenium-supplementation on [75Se]-selenoprotein labelling was studied in HUVEC
(figure 3.22). It was shown that a significant dilution of the [75Se]-label was observed between 10
and 100 nM sodium selenite but in HUVEC the relative band intensities of [75Se]-selenoproteins
remained constant. It is possible that the lower intensity of labelling of the [75Se]-seienoproteins
could be the result of an isotope dilution effect although this is only likely if there is a parallel
decrease in the intensity of [75Se]-labelling of all the selenoproteins. The band which runs at
approximately 15 kDa was more intensely labelled in PAEC than in HUVEC suggesting that its
expression is truly greater in PAEC. These are only preliminary findings as only one preparation
of PAEC was studied.
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The pattern of [75Se]-selenoprotein expression in bovine aortic endothelial cells (BAEC) differed
considerably from that observed in HUVEC. The [75Se]-labelling of the majority of selenoproteins
was significantly lower in BAEC compared to HUVEC. One exception was a band with an
approximate molecular mass of 22kDa, which was more intensely labelled in BAEC. Another
exception was a [75Se]-selenoprotein with an approximate molecular mass of 15kDa which in
both BAEC and HUVEC was [75Se]-labelled to a similar intensity. It is unknown whether this
band represents the same selenoprotein or a different one.
The selenoprotein profiles of HUVEC and BAEC are not strictly comparable because each cell
type required a different culture medium for optimal growth. The EGM culture medium (used to
maintain the BAEC) had a selenium content approximately 20 nM higher than the EGM-2 (used
to maintain HUVEC). Therefore it is possible that the lower intensity of labelling of the [75Se]-
selenoproteins in BAEC could be the result of an isotope dilution effect. However it is unlikely to
provide a complete explanation, since PHGPX was more intensely labelled in BAEC than
HUVEC and a 15 kDa selenoprotein was labelled to a similar intensity in both HUVEC and
BAEC. The cyGPX activity in BAEC and HUVEC was compared and showed no significant
difference. This suggests that the less intensely labelled 24 kDa band (cyGPX) is the result of an
isotope dilution effect. The TR activity of HUVEC and BAEC was also compared and the results
confirmed the [75Se]-labelling findings, i.e. that TR activity is lower in BAEC even under
conditions of higher selenium concentration which has been shown to significantly increase TR
activity in BAEC (see chapter 5). The SDS-PAGE gel shows that PHGPX is expressed to a
greater extent in BAEC than HUVEC. However this was not confirmed as PHGPX activity
measured in HUVEC was not significantly different from that measured in BAEC.
The comparison of the GPX activities between HUVEC and BAEC showed that both PHGPX
activity and cyGPX activity were not significantly different between the two cell types. The
apparent disparity between the results from the SDS-PAGE and the activity assays may be
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because there is a difference in turnover number between the same enzyme in different species.
This effect has been reported in the selenium-containing enzyme IDI where the rate of substrate
turnover per mole of protein is variable between different species (Vissar et al., 1988) (Foster,
Thoday and Beckett, 2000). Alternatively, the possibility that this disparity between the [75Se]-
labelling results and the activity results may be accounted for by the poor sensitivity of the
activity assays used, cannot be excluded.
The [75Se]-selenoprotein profiles of HUVEC exhibit a distinct pattern of selenoprotein expression
compared to human thyrocytes and the human foetal liver-derived cell line, HepG2. In HUVEC a
58 kDa [75Se]-selenoprotein, identified as TR, was the dominant selenoprotein expressed. In
HepG2 cells the expression of TR was one tenth of that found in HUVEC, whilst in human
thyrocytes, TR expression was too low to be detected by Western blotting; [75Se]-selenoprotein
labelling suggests that its expression is half of that seen in HepG2 cells. These different patterns
of selenoprotein expression are presumed to underlie the requirement for different
selenoproteins to contribute to the specific functions of the various cell types.
In conclusion, this study has confirmed the presence of cyGPX and PHGPX in HUVEC; however
TR was found to be the dominant intracellular selenoprotein expressed by HUVEC in culture. No
extracellular selenoproteins were synthesised by HUVEC. Distinct differences were observed in
selenoprotein expression and activity in cells originating from various human tissues and
endothelial cells isolated from different species. However these differences were less
pronounced when comparing endothelial cells from different human vascular beds and the
human endothelial cell line, EAhy926. These differences cannot be wholly explained by
differences in selenium content and selenium bioavailability of the various culture media which
were used.
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The most appropriate cell culture model for the study of selenoprotein expression in
atherosclerotic disease in man would be HCAEC. However the tissue from which these cells are
isolated was not readily available for this study. Therefore a number of different cell culture
models were investigated. Our studies have shown that endothelial cells isolated from bovine
and porcine aortae may not provide a suitable alternative to HCAEC. In contrast, a distinct
similarity in selenoprotein characteristics between HCAEC and HUVEC was observed.
Therefore HUVEC can be regarded as a suitable alternative to HCAEC and are used as the cell
culture model throughout this study.
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CHAPTER FOUR REGULATION OF THIOREDOXIN
REDUCTASE AND GLUTATHIONE PEROXIDASE EXPRESSION
THROUGH DIFFERENT SECOND MESSENGER PATHWAYS
4.1 INTRODUCTION
The diverse homeostatic functions of the endothelium are modulated by various endogenous
and exogenous biochemical and mechanical stimuli which act through a number of second
messenger pathways. The signalling pathways of the endothelium include adenylate cyclase
(AC), guanylate cyclase (GC) and phospholipase C (PLC) (see section 1.2.3).
The expression of some selenoenzymes has been shown to be regulated through second-
messenger systems. Howie et al. reported that in the human foetal liver cell line, HepG2 and
human thyrocytes, thioredoxin reductase (TR) expression was significantly increased by the
addition of the calcium ionophore A23187 (1 pM) and PMA (1 pM) (Howie et al., 1998). In
contrast, extracellular glutathione peroxidase (EGPX) secretion from human thyrocytes was
inhibited by A23187 (1 pM), whilst PMA (1 pM) had little or no effect (Howie et al., 1995).
Activation of the calcium-phosphoinositol pathway has been shown to down-regulate the
expression of type-1 iodothyronine deiodinase in human thyrocytes, whilst the activation of the
cyclic AMP (cAMP) pathway stimulates the expression of this selenoenzyme (Beech et al.,
1995). These observations suggest that activation of second messenger pathways may be
important in the regulation of selenoprotein expression.
A number of different compounds have been used to stimulate second messenger pathways
directly. PMA is a phorbol ester which activates protein kinase C (PKC) in vitro and in vivo at nM
concentrations (Anema et al., 1999; Hirata et al., 1995; Keaney et al., 1996; Wheeler-Jones,
Sayed and Persaud, 1995). The calcium ionophore A23187 has been extensively used in
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studies for increasing intracellular calcium (Corder et al., 1993; Howie et al., 1998; Kumar and
Holmgren, 1999). Bradykinin (BK), histamine, adenosine triphosphate (ATP) and several other
ligands have been shown to elevate intracellular calcium levels in cultured endothelial cells up to
high nanomolar concentrations (Schmidt, Mayer and Kukovetz, 1989; Warren, 1990). The
AC/cAMP pathway has been studied using 8-bromoadenosine 3' 5'-cyclic monophosphate which
is a cell-permeable cAMP analogue (Beech et al., 1995; Boyer and Thiery, 1993; Howie et al.,
1995) whilst, forskolin, directly activates AC which results in increased cAMP levels (Crutchley et
al., 1993).
Howie et al. observed a significant induction of TR expression after incubation of [75Se]-selenite
pre-labelled (24 hr) human thyrocytes with A23187 and PMA for 6 hr (Howie et al., 1998), with a
maximal induction of the enzyme occurring after 24 hr of treatment. Although TR expression
was not altered after a 2 hr incubation with PMA and A23187 it is possible that short-term
exposure to these agents could produce rapid effects on the signalling pathways in the cell,
which elicit subsequent changes in selenoprotein expression that may only be observable after
several hours.
The modification of selenoprotein expression through the activation of second messenger
pathways has not been studied extensively in cultured large vessel endothelial cells. However
Jornot and Jornod previously reported that treatment of human umbilical vein endothelial cells
(HUVEC) with the phorbol ester phorbol 12, 13-dibutyrate induced a 2-fold increase in
cytoplasmic glutathione peroxidase (cyGPX) mRNA levels which occurred 24-48 hr after
treatment (Jornot and Junod, 1997).
Differences and similarities in the basal expression of intracellular selenoproteins between
endothelial cells isolated from different vascular beds and different species were described in
the previous chapter. Since the signalling pathways which modify selenoprotein expression may
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also be dependent on species and the vascular bed used for the endothelial cell isolation, these
issues are addressed in this chapter.
This study aims to:
• examine the effects of the phorbol ester PMA and the calcium ionophore A23187 on
selenoprotein expression and activity in HUVEC
• examine the effects of alternative agents which stimulate the Ca2+-phosphoinositol signalling
pathway on selenoprotein expression in HUVEC
• examine the effect of activation of the adenylate cyclase pathway on selenoprotein
expression in HUVEC
• compare the effects of PMA on selenoprotein expression in human coronary arterial
endothelial cells and bovine aortic endothelial cells to those observed in HUVEC.
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4.2 METHODS
4.2.1 Introduction
For all the experiments described in this section human umbilical vein endothelial cells (HUVEC)
were isolated and maintained as described in section 2.3.2. Both PMA and A23187 were
dissolved in dimethylsulphoxide (DMSO). Unless otherwise stated, when PMA and/or A23187
were used, the effects of DMSO were controlled for by treating the cells with 0.05% DMSO.
4.2.2 Changes in selenoprotein expression in response to protein kinase C
activation in HUVEC
a) The effect of PMA on [75Se]-selenoprotein expression in HUVEC for different times.
The concentration of PMA (0.5 pM) used for this experiment was chosen as it was the optimal
dose of PMA to induce TR expression in human thyrocytes (personal communication with Dr.
Forbes Howie, of this department).
The effects of PMA on the second messenger pathways in HUVEC may be rapid but the
changes in selenoprotein expression may only be observable after several hours. The following
experiments were designed to i) determine the effect of continual exposure of HUVEC to PMA
on selenoprotein expression and ii) the influence of shorter 'pulsed' exposure times to PMA on
selenoprotein expression observed after a 48 hr 'lag-period'.
i) The effect of continued exposure of PMA on selenoprotein expression in HUVEC (figure 4.01)
Confluent cultures of HUVEC were pre-labelled to steady state for 48 hr with 0.02 MBq/ml [75Se]-
selenite. After 48 hr the culture medium was replaced with a further 15 ml of medium containing
0.02 MBq/ml [75Se]-selenite to ensure that the selenium supply was not exhausted. The effect of
PMA (0.5 pM) on the selenoprotein profile was studied by the inclusion of this compound in the
168
Regulation of tnioredoxin reductase and glutathione peroxidase chapter four
expression through different second pathways
culture medium for 1 min, 12 hr, 24 hr, 48 hr, 72 hr or 96 hr in the continuing presence of 0.02
MBq/ml [75Se]-selenite. The additions were timed to ensure that the cells for each data point
were harvested immediately after the defined incubation period with PMA but after the same
overall length of culture time, ensuring that all cells were cultured with [75Se]-selenite for a total
culture time of 144 hr which included the 48 hr pre-incubation period.
After incubation the cells were harvested into 20 ml EBSS by scraping and centrifuged at 2000 g
for 10 min at 4°C. The resulting cell pellet was resuspended in 200 pi 60 mM Tris buffer, pH 7.4
(4°C), containing 1 mM EDTA and 1 mM dithiothreitol (Tris buffer). The cells were lysed by
sonication on ice for 30 sec using the Soniprep 150.
Protein concentrations were measured using the Bradford assay (section 2.3.12) and the
samples were diluted to a common protein concentration with Tris buffer. The cell lysates were
prepared for separation by SDS-PAGE (section 2.3.13) and the [75Se]-labelled proteins present
in 25 pg of protein were separated by SDS-PAGE (section 2.3.13). The resulting gel was dried
and the [75Se]-labelled selenoproteins visualised by autoradiography using Kodak X-OMAT XAR-
5 film (section 2.3.14).
The SDS-gels were scanned using an EpsonGT-9500 to create a digitized image (section
2.3.15). The radioactivity in each band was quantified using the Phoretix software. The same
system was used to quantify TR expression in the Western blots.
ii) The effect of 'pulsed' exposure to PMA on selenoprotein expression in HUVEC (figure 4.02)
Confluent cultures of HUVEC were pre-labelied to a steady state for 48 hr with 0.02 MBq/ml
[75Se]-selenite. The addition of PMA (0.5 pM ) was made to these pre-labelled cells for 1 min, 10
min, 1 hr or 12 hr in the continued presence of 0.02 MBq/ml [75Se]-selenite. Each addition was
made at the same time and after each time of exposure the culture medium was removed from
169
Regulation of thioredoxin reductase and glutathione peroxidase chapter four
expression through different second pathways
the flask and the cells were washed to remove any residual PMA. Fresh culture medium
containing 0.02 MBq/ml [75Se]-selenite but without PMA, was added and the cells were
incubated for a further period such that the total length of incubation from when PMA was initially
added was 48 hr. This total incubation time of 48 hr was chosen because the time course
experiment (described in 'i' above) showed that at 48 hr in the continual presence of PMA
maximal changes in the expression of [75Se]-selenoproteins occurred. HUVEC were harvested
and the intracellular [75Se]-selenoproteins separated by SDS-PAGE, visualized by
autoradiography and analysed using densitometry as described in section 4.2.2ai).
b) The effect of PMA on thioredoxin reductase and glutathione peroxidase expression in
HUVEC
Triplicate T75 flasks of confluent cultures of HUVEC were incubated in the presence of PMA
(0.5 pM) for 48 hr. The cells were harvested as described in section 4.2.2a and lysed by
sonication in 0.125 M potassium phosphate buffer, pH 7.4, containing 1mM EDTA for 30 sec
using the Soniprep 150 (4°C).
The HUVEC lysates were then assayed for thioredoxin reductase (TR) mass and activity,
cytoplasmic glutathione peroxidase (cyGPX) activity and phospholipid hydroperoxide glutathione
peroxidase activity (PHGPX) activity as described in sections 2.3.17, 2.3.18, 2.3.19 and 2.3.20
respectively.
c) Effects of GF109203X and PMA on the expression of [75Se]-selenoproteins in HUVEC
Confluent cultures of HUVEC were pre-labelled to a steady state with 0.02 MBq/ml [75Se]-
selenite for 48 hr prior to investigating the effect of the specific PKC inhibitor GF109203X in the
presence and absence of PMA on [75Se]-selenoprotein expression in HUVEC (figure 4.03). After
the 48 hr pre-labeliing period, the culture medium was removed and replaced with fresh medium
containing 0.02 MBq/ml [75Se]-selenite. GF109203X at 3 different doses (5 pM, 1 pM, 0.5 pM)
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was added to the culture medium 1 hr prior to any PMA additions, (previous studies in HUVEC
have shown PKC activity is inhibited under these conditions (Villard et al., 1998)). After the
addition of PMA (0.5 pM), the HUVEC were incubated for a further 48 hr before the cells were
harvested and [75Se]-labelled selenoproteins separated by SDS-PAGE as described previously
(section 4.2.2a). The [75Se]-selenoproteins were visualized by autoradiography as described in
section 2.3.14.
d) The effects of prolonged exposure and cumulative doses of PMA on [75Se]-
selenoprotein expression in HUVEC
Confluent cultures of HUVEC were pre-labelled to a steady state with 0.02 MBq/ml [75Se]-
selenite for 48 hr prior to investigating the effects of cumulative doses of PMA on [75Se]-
selenoprotein expression (figure 4.04). The effect of PMA on the [75Se]-labelled selenoproteins
was studied by the inclusion of PMA (0.5 pM) in the culture medium for 1 min, 48 hr and 96 hr in
the continued presence of 0.02 MBq/ml [75Se]-selenite. The additions were timed so that the
cells for each data point were harvested at 96 hr after the initial pre-labelling period. For the 96
hr time point two flasks were incubated with PMA (0.5 pM). In one of these flasks after 48 hr in
the presence of PMA a further addition of PMA was made to give a final concentration of 1 pM
PMA.
HUVEC were harvested as described above and the intracellular [75Se]-selenoproteins were
separated by SDS-PAGE and visualized by autoradiography (section 4.2.2a).
4.2.3 The effects of PMA on the selenoprotein expression in human coronary
arterial endothelial cells
Human coronary arterial endothelial cells (HCAEC) were maintained as described in section
2.3.5. Confluent cultures of HCAEC were pre-labelled to steady state for 48 hr in the presence of
0.02 MBq/ml [75Se]-selenite. The cells were then incubated with PMA (0.5 pM) for 48 hr.
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HCAEC were harvested as described above and the intracellular [75Se]-selenoproteins were
separated by SDS-PAGE and visualized by autoradiography (sections 2.3.13 and 2.3.14).
For measurement of TR mass and cyGPX and PHGPX activity, triplicate T75 flasks of confluent
cultures HCAEC were incubated in the presence of PMA (0.5 pM) for 48 hr and cell lysates
prepared as described for HUVEC in section 4.2.2b.
The HCAEC lysates were then assayed for TR mass, cyGPX activity and PHGPX activity as
described in sections 2.3.17, 2.3.19 and 2.3.20. TR activity was not measured in HCAEC.
4.2.4 The effects of PMA on the selenoprotein expression in bovine aortic
endothelial cells
The effect of PMA (0.5 pM) on the [75Se]-selenoprotein expression in bovine aortic endothelial
cells (BAEC) was established using the same protocol as described above for HCAEC in section
4.2.3.
For measurement of TR activity triplicate T75 flasks of confluent cultures of BAEC were
incubated in the presence of PMA (0.5 pM) for 48 hr and cell lysates prepared and assayed for
TR activity as described for HUVEC in section 4.2.2b.
The BAEC cell lysates were not assayed for TR mass because there was a lack of cross-
reactivity between the anti-human TR antibody with bovine TR in the radioimmunoassay. cyGPX
and PHGPX activities were also not measured in BAEC.
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4.2.5 Changes in selenoprotein expression in response to the calcium
ionophore A23187in HUVEC
a) Dose-response effects ofA23187 on the [75Se]-selenoprotein expression in HUVEC
Confluent cultures of HUVEC were pre-labelled to a steady state with 0.02 MBq/ml [75Se]-
selenite for 48 hr (as described in section 4.2.2) prior to investigating the effects of A23187 on
the [75Se]-labelling of intracellular selenoproteins in HUVEC. A23187 was then added to HUVEC
to achieve final concentrations of 0.5 nM, 5 nM, 50 nM and 0.5 pM in the continued presence of
0.02 MBq/ml [75Se]-selenite. After 24 hr HUVEC were harvested and the intracellular [75Se]-
selenoproteins separated by SDS-PAGE and visualized by autoradiography as described in
section 4.2.2a.
b) The effect ofA23187 on [75Se]selenoprotein expression in HUVEC for different times
The concentration of A23187 (0.5 pM) used for this experiment was selected on the basis of the
experiment described in section 4.2.4a, which had shown optimal changes in [75Se]-labelling of
selenoproteins at this concentration.
As with PMA the effects of A23187 (0.5 pM) on the second messenger pathways in HUVEC may
be rapid, whilst the changes in selenoprotein expression may only be observable after several
hours. The time course experiments used to study the effects of PMA were therefore repeated
using A23187 as described section 4.2.2a. In the first series of experiments continuous
exposure of A23187 was studied (figure 4.05), whilst in the second series of experiments the
influence of short 'pulsed' exposure times of HUVEC to A23187 on the subsequent maximal
changes observed in the expression of selenoproteins was studied (figure 4.06). The incubation
time chosen to study the maximal changes in selenoprotein expression in response to A23187
1.e. the second series of experiments, was 35 hr not 48 hr. This was chosen as it was not always
possible to use time points in excess of 35 hr as A23187 occasionally caused cell detachment if
time periods longer than this were used.
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4.2.6 The effect of PMA and A23187 added alone or in combination on the
expression of selenoproteins
The effects of PMA (0.5 pM) and A23187 (0.5 pM), added individually or in combination on the
expression of [75Se]-selenoproteins were investigated by the inclusion of the compounds in the
culture medium of HUVEC for 35 hr in the continuous presence of 0.02 MBq/ml [75Se]-selenite.
Prior to treatment with PMA and/or A23187 HUVEC were pre-labelled with 0.02 MBq/ml [75Se]-
selenite for 48 hr. HUVEC were harvested and the intracellular [75Se]-selenoproteins were
separated by SDS-PAGE and visualized by autoradiography as described in section 4.2.2a. The
TR expression in HUVEC incubated with PMA and/or A23187 was quantified by Western blot
analysis using the method described in section 2.3.16.
4.2.7 The effects of acetylcholine, adenosine triphosphate and bradykinin on
the [75Se]-selenoprotein expression in HUVEC
The effects of acetylcholine (1 mM) and adenosine triphosphate (1 mM) on the [75Se]-
selenoprotein expression was studied by the inclusion of these compounds (made up in EBSS)
individually in confluent cultures of HUVEC in the continued presence of 0.02 MBq/ml [75Se]-
selenite. The cells had been pre-labelled to a steady state for 48 hr with 0.02 MBq/ ml [75Se]-
selenite prior to the addition of the compounds to be tested. After 48 hr HUVEC were harvested
and the intracellular [75Se]-selenoproteins were separated by SDS-PAGE and visualized by
autoradiography as previously described in section 4.2.2a.
The effect of bradykinin (1 pM) was studied by the inclusion of this compound into the culture
medium of pre-labelled HUVEC for 6 hr, 12 hr, 24 hr and 48 hr in the continued presence of 0.02
MBq/ml [75Se]-selenite. The additions were timed to ensure that all the cells for each data point
were harvested immediately after the defined incubation period but so that cells were cultured
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for the same period of time. HUVEC were harvested as described above and the intracellular
[75Se]-selenoproteins were separated by SDS-PAGE and visualized by autoradiography.
4.2.8 The effect of forskolin on the [75Se]-setenoprotein expression in HUVEC
HUVEC were pre-labelled to a steady state for 48 hr with 0.02 MBq/ml [75Se]-selenite. The effect
of forskolin on the [75Se]-selenoprotein expression was studied by the inclusion of forskolin (0.1
pM) in the culture medium in the continued presence of 0.02 MBq/ml [75Se]- selenite. This
concentration of forskolin was chosen as it induced steroidogenic responses in bovine adrenal
cells (personal communication from Mrs Moira Nicol of this department). After 48 hr HUVEC
were harvested and the intracellular [75Se]-selenoproteins were separated by SDS-PAGE and
visualized by autoradiography as previously described in sections 4.2.2a.
To control for any possible effects of ethanol, in which the forskolin was dissolved, HUVEC were
treated with 0.1% ethanol.
4.2.9 Statistical analysis
An unpaired 't' test was used to test for significance between the levels of selenoprotein
expression or activity in treated cells compared to control cells. The Students 't' test assumes
that the standard deviations (SD) are equal. In cases where there was found to be a significant
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4.3 RESULTS
4.3.1 In troduction
The 22 kDa, 24 kDa and 58 kDa bands observed on an autoradiograph of an SDS-PAGE gel
showing the [75Se]-selenoproteins expressed by HUVEC have been identified in section three as
PHGPX, cyGPX and TR respectively. Therefore these bands whether expressed by HUVEC or
other endothelial cells are referred to as these selenoproteins in the text.
4.3.2 Changes in selenoprotein expression in response to protein kinase C
activation in HUVEC
a) The effect of PMA on [75Se]-selenoprotein expression in HUVEC for different times
The effect of PMA on the expression of intracellular selenoproteins was time-dependent. The
continued presence of PMA (0.5 pM) markedly decreased the expression of TR and PHGPX. In
contrast, the expression of cyGPX was increased in the presence of PMA. The change in the
expression of the TR following exposure to PMA was first apparent after 12 hr, with the lowest
level of expression observed after 48 hr exposure (figure 4.07). At 72 hr and 96 hr of exposure,
the expression of TR started to rise but the level did not return to the level observed in the
control DMSO-treated HUVEC. The changes in expression of both the PHGPX and cyGPX were
observed at 12 hr exposure and at each subsequent time point thereafter the expression of
PHGPX continued to decrease, whilst the expression of cyGPX continued to rise.
The effects of the shorter 'pulsed' exposures to PMA (0.5 pM) are shown in figure 4.08. In
HUVEC transiently exposed to PMA for 1 min to 12 hr, a decrease in the expression of both TR
and PHGPX was measured after a 48 hr lag period following the initial exposure to PMA for 1
min. In contrast, the increased expression of cyGPX was observed after a 10 min exposure to
PMA measured after a 48 hr lag period.
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b) The effect of PMA on thioredoxin reductase and glutathione peroxidase expression in
HUVEC
Changes in TR mass and activity, cyGPX and PHGPX activities in HUVEC were measured after
a 48 hr incubation with PMA (0.5 pM) (figures 4.09-4.12).
The TR mass and activity decreased significantly (p<0.01) in the presence of PMA, whilst no
significant change in either the activity of cyGPX or PHGPX was measured despite the trend of
increased cyGPX activity observed in the presence of PMA.
c) Effects of GF109203X and PMA on the expression of [75Se]-selenoproteins in HUVEC
Treatment of pre-labelled HUVEC with PMA (0.5 pM) for 48 hr resulted in a decrease in
expression of both TR and PHGPX, whilst the expression of cyGPX was increased (figure 4.13).
Pre-incubation of the HUVEC with the protein kinase C inhibitor GF109203X 1 hr prior to the
addition of PMA (0.5 pM) partially reversed these changes in selenoprotein expression in a dose
dependent manner. The addition of the highest dose of GF109203X (5.0 pM) with PMA (0.5 pM)
allowed only a very small net change in selenoprotein expression whilst the lowest dose of
GF109203X (0.5 pM) was very much less effective at attenuating the selenoprotein response to
PMA. No change in selenoprotein expression was observed when HUVEC were incubated with
GF109203X alone at all the concentrations tested.
d) The effects of prolonged exposure and cumulative doses of PMA on [75Se]-
selenoprotein expression in HUVEC
The effect of PMA on the expression of TR, PHGPX and cyGPX after 48 hr continuous exposure
to PMA was consistent with the changes described in section a) above. At 48 hr the expression
of both TR and PHGPX was decreased whilst the expression of cyGPX was increased
compared to that observed in control cells which were not treated with PMA (figure 4.14).
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However between 48 hr and 96 hr the expression of both TR and PHGPX decreased further,
whilst the expression of cyGPX continued to increase. The changes in selenoprotein expression
described above were maximal in HUVEC to which two doses of PMA had been added, one of
which was added 48 hr after the first.
4.3.3 The effects of PMA on the selenoprotein expression in human coronary
arterial endothelial cells
Whilst the basal expression of some of the major selenoproteins measured in human coronary
artery endothelial cells (HCAEC) and HUVEC differed (as discussed in section 3.3.6), the
changes in selenoprotein expression observed in both cell types followed the same general
trend when incubated for 48 hr with PMA (0.5 pM). The expression of TR and PHGPX
decreased whilst the expression of cyGPX increased as visualised by autoradiography (figure
4.15).
Figure 4.16 shows that in both HUVEC and HCAEC which had been treated with PMA (0.5 pM)
for 48 hr, TR expression is significantly decreased (p<0.01). In HUVEC, PMA reduced the mass
of TR to approximately 35% of control cells and in HCAEC to approximately 42% of control cells.
The cyGPX activity in both HUVEC and HCAEC treated with PMA (0.5 pM) were not statistically
different from the activities measured in untreated cells, though there was a trend towards a
general increase which was more obvious in HCAEC (figure 4.17).
In HUVEC treated with PMA (0.5 pM) for 48 hr no significant effect on PHGPX activity was
observed (figure 4.18). In contrast in PMA-treated HCAEC the PHGPX activity was
approximately 37% of control values, significantly lower than HCAEC treated with DMSO
(p<0.01).
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4.3.4 The effects of PMA on the selenoprotein expression in bovine aortic
endothelial cells
Figure 4.19 shows that in HUVEC treated with PMA (0.5 pM) for 48 hr both TR and PHGPX
expression decreased whilst the expression of cyGPX increased. However, in PMA-treated
bovine aortic endothelial cells (BAEC) no noticeable changes in the selenoprotein expression as
visualized by autoradiography were observed. The labelling of the BAEC selenoproteins was
very low in this particular experiment (in contrast to figure 3.15), which could not be explained by
different labelling conditions or by protein loading errors.
Figure 4.20 shows that the TR activity of HUVEC incubated with 0.5 pM PMA for 48 hr was
significantly lower than that measured in control HUVEC. In contrast, in BAEC treated in an
identical fashion there was no difference in TR activity.
4.3.5 Changes in selenoprotein expression in response to the calcium
ionophore A23187 in HUVEC
a) Dose-response effects ofA23187 on the [7SSe]-selenoprotein expression in HUVEC
The effects of the calcium ionophore A23187 on the expression of [75Se]-selenoproteins was
dose dependent (figure 4.21). The continued presence of 0.5 pM A23187 for 24 hr significantly
increased the expression of TR. Other changes in the unidentified selenoproteins included a
small up-regulation of a 64 kDa selenoprotein whilst the expression of a 72 kDa selenoprotein
was significantly attenuated. At the lower doses of A23187 tested, no noticeable change in
selenoprotein expression was observed as visualized by autoradiography.
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b) The effect of A23187 on [7SSe]-selenoprotein expression in HUVEC for different times
As with PMA, the effects of A23187 on selenoprotein expression were time-dependent (figure
4.22). The continued presence of A23187 (0.5 pM) in the culture medium resulted in an
induction of TR first observed at 12 hr which was augmented after 24 and 35 hr exposure (figure
4.22). The response was maximal at 48 hr. In contrast, the expression of a 64 kDa selenoprotein
was increased after 24 hr and was maximal at 48 hr. A23187 appeared to increase the
expression of cyGPX whilst the expression of PHGPX was unchanged. A clear increase in the
expression of the selenoprotein with an approximate molecular mass of 15 kDa was observed in
the presence of A23187.
In some experiments where HUVEC were exposed to A23187 for 38 hr and longer, cells started
to detach from the monolayer, suggesting possible toxic effects of the ionophore. Therefore in
future experiments a total incubation time of 35 hr was chosen, as this allowed maximal
changes in selenoprotein expression to occur without any observable effect on cell attachment.
The effect of the shorter pulse times of exposure to A23187 is shown in figure 4.23. HUVEC
transiently exposed to A23187 (0.5 pM) for 1 hr showed a slight induction of TR expression. This
observed induction became more obvious with longer exposure times such that a clear increase
in the 58 kDa selenoprotein was observed at 12 hr, with maximal induction after 35 hr of
exposure.
4.3.6 The effect of PMA and A23187 added alone or in combination on the
expression of selenoproteins
Treatment of HUVEC with PMA (0.5 pM) alone significantly down-regulated the expression of
TR and PHGPX, whilst the expression of cyGPX was up-regulated as visualized by
autoradiography (figure 4.24). The addition of the calcium ionophore A23187 significantly
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increased the expression of TR and to a slightly lesser extent the expression of an unidentified
64 kDa selenoprotein. The expression of a 72 kDa selenoprotein appeared to be completely
suppressed in the presence of A23187. PMA and A23187 added in combination produced an
overall net increase in the expression of TR and a 64 kDa selenoprotein 35 hr later but the
expression of both was lower than that seen when A23187 was added alone. The addition of
PMA and A23187 however, had an additive effect on the down-regulation of PHGPX, reducing
its expression significantly more in the presence of both compounds compared to the level of
expression when PMA and A23187 were added alone. The expression of the 72 kDa
selenoprotein in the presence of both compounds was attenuated to the same degree as when
A23187 was added alone.
Quantification of the 58kDa [75Se]-labelled band (TR) using the Molecular Imager System
showed that treatment with PMA decreased the intensity of the 58 kDa band by 31.36±2.46% of
basal levels (mean ± SEM, n=3), whereas treatment with A23187 increased the intensity of the
same band by 1.69+0.40-fold over basal levels (mean ± SEM, n=3). PMA and A23187 added in
combination produced an overall increase in the intensity of the 58 kDa band by 1.40+0.26-fold
(mean ± SEM, n=3) over basal levels. Poor resolution of the [75Se]-selenoproteins meant that it
was not possible to quantitate the 22 kDa and 24 kDa [75Se]-labelled bands (PHGPX and cyGPX
respectively) in this manner.
The effects of PMA and A23187 treatment on TR were confirmed by Western blotting using
antiserum to rat TR (figure 4.25). Western blotting showed that PMA significantly (p< 0.05,
ANOVA and test of least significant difference) decreased the expression of TR from 4.36±0.63
pg/mg of protein (n=3), expressed under basal conditions, to 2.97 pg/mg of protein (n=3), a
decrease of 29.6±9.7%. In contrast treatment with A23187 significantly (p<0.01) increased TR
expression to 8.38±0.69 pg/mg of protein (n=3), a 1.96±0.13-fold increase over basal levels.
When HUVEC were treated with PMA and A23187 in combination there was a net increase in
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TR expression to 6.58±0.42 pg/mg of protein (n=3), a 1.57 ± 0.24-fold increase over basal
levels.
4.3.7 The effects of acetylcholine, adenosine triphosphate and bradykinin on
the [75Se]-selenoprotein expression in HUVEC
Treatment of HUVEC with acetylcholine (1 mM) slightly decreased the expression of all the
[75Se]-labelled selenoproteins whilst adenosine triphosphate (1 mM) had no observable effects
on the expression of any [75Se]-labelled selenoproteins (figure 4.26).
No changes in the expression of [75Se]-labelled selenoproteins were observed in HUVEC treated
with bradykinin (1 pM) for any incubation time studied (figure 4.27).
4.3.8 The effect of forskolin on the [75Se]-selenoprotein expression in HUVEC
Treatment of HUVEC with forskolin (0.1 pM) for 1 min and 48 hr had no observable effect on the






Figure 4.07. Autoradiograph of an SDS-PAGE gel showing the expression of
[75Se]-selenoproteins in HUVEC incubated in the continued presence of PMA (0.5
pM) for various times. Confluent cultures of HUVEC were pre-labelled for 48 hr with
0.02 MBq/ml [75Se]-selenite. The effect of PMA on the expression of [75Se]-
selenoproteins was studied by including either PMA (0.5 pM) or DMSO (0.05%) in the
culture medium for 1 min, 12 hr, 48 hr, 72 hr or 96 hr in the continued presence of 0.02
MBq/ml [75Se]-selenite. Lane 1, PMA, 1 min; lane 2, DMSO, 1 min; lane 3, PMA, 12 hr;
lane 4, DMSO, 12 hr; lane 5, PMA, 48 hr; lane 6, DMSO, 48 hr; lane 7, PMA 72 hr;
lane 8, DMSO, 72 hr; lane 9, PMA, 96 hr; lane 10, DMSO, 96 hr. Each lane was loaded
with 25 pg of protein. TR, Thioredoxin reductase; cyGPX, cytoplasmic glutathione
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Figure 4.08. Autoradiograph of an SDS-PAGE gel showing the expression of [75Se]-
selenoproteins in HUVEC incubated with PMA (0.5 pM) for various times. Confluent
cultures of HUVEC pre-labelled for 48 hr with 0.02 MBq/ml [75Se]-selenite were used. The
effect of PMA on the expression of [75Se]-selenoproteins was studied by including either PMA
(0.5 pM) or DMSO (0.05%) in the culture medium for 1 min, 10 min, 1 hr or 12 hr in the
continued presence of 0.02 MBq/ml [75Se]-selenite. After each time-point the medium was
removed, the cells were washed and fresh culture medium containing 0.02 MBq/ml [75Se]-
selenite without PMA or DMSO added. The cells were incubated for a total incubation time of
48 hr. Lane 1, PMA, 1 min; lane 2, DMSO, 1 min; lane 3, PMA, 10 min; lane 4, DMSO, 10 min;
lane 5, PMA, 1 hr; lane 6, DMSO, 1 hr; lane 7, PMA, 12 hr; lane 8, DMSO, 12 hr. Each lane
was loaded with 25 pg of protein. TR, thioredoxin reductase; cyGPX, cytoplasmic glutathione




Figure 4.09. Thioredoxin reductase (TR) mass in HUVEC treated with either DMSO
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Figure 4.10. Thioredoxin reductase (TR) activity in HUVEC treated with either DMSO






Figure 4.11. Cytoplasmic glutathione peroxidase (cyGPX) activity in HUVEC treated with
either DMSO (0.05%) or PMA (0.5 pM) for 48 hr. Results shown are those of the mean of 3
flasks ± SD. No significant difference in cyGPX activity between HUVEC treated with DMSO







Figure 4.12. Phospholipid hydroperoxide glutathione peroxidase (PHGPX) activity in
HUVEC treated with either DMSO (0.05%) or PMA (0.5 pM) for 48 hr. Results shown are
those of the mean of 3 flasks ± SD. No significant difference in PHGPX activity between













tsMMihi. n—if iih -
«He ■HP
Figure 4.13 Autoradiograph of an SDS-PAGE gel showing the expression of [75Se]-
selenoproteins in HUVEC incubated with the PKC inhibitor GF109203X at various doses
and/or PMA (0.5 pM). Confluent cultures of HUVEC pre-labelled for 48 hr with 0.02 MBq/ml
[75Se]-selenite were used. The effect of GF109203X and PMA on the expression of [75Se]-
selenoproteins was studied by the inclusion of different concentrations of GF109203X and PMA
(0.5 pM) in the culture medium either alone or in combination. GF109203X was added 1 hr
prior to the 48 hr PMA incubation in the continued presence of 0.02 MBq/ml [75Se]-selenite.
Lane 1, DMSO; lane 2, PMA alone (0.5 pM); lane 3, GF109203X alone (5.0 pM); lane 4,
GF109203X alone (1.0 pM); lane 5, GF109203X alone (0.5 pM); lane 6, GF109203X (5.0 pM)
and PMA (0.5 pM); lane 7, GF109203X (1.0 pM) and PMA (0.5 pM); lane 8, GF109203X (1.0
pM) and PMA (0.5 pM). Each lane was loaded with 25 pg of protein. TR, thioredoxin reductase;





Figure 4.14 Autoradiograph of an SDS-PAGE gel showing the expression of [75Se]-
selenoproteins in HUVEC incubated in the continued presence of PMA (0.5 pM) for
various times with single and cumulative doses. Confluent cultures of HUVEC pre-labelled
for 48 hr with 0.02 MBq/ml [75Se]-selenite were used. The effect of PMA on the expression of
[75Se]-selenoproteins was studied by including either PMA (0.5 pM) or DMSO (0.05%) in the
culture medium for 1 min, 48 hr, and 96 hr in the continued presence of 0.02 MBq/ml [75Se]-
selenite. The effect a cumulative dose of PMA on the expression of [75Se]-selenoproteins was
studied by adding a further dose of PMA (final concentration 1 pM) to HUVEC previously
incubated with PMA for 48 hr, followed by a further 48 hr incubation. Lane 1, PMA (0.5 pM), 1
min; lane 2, DMSO (0.05%), 1 min; lane 3, PMA (0.5 pM), 48 hr; lane 4, DMSO (0.05%), 48 hr;
lane 5, PMA (0.5 pM), 96 hr, lane 6, DMSO (0.05%), 96 hr; lane 7, PMA (10"6M), 96 hr; lane 8,
DMSO (0.10%), 96 hr. Each lane was loaded with 25 pg of protein. TR, thioredoxin reductase;
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Figure 4.15 Autoradiograph of an SDS-PAGE gel showing the expression of [75Se]-
selenoproteins in both human umbilical vein endothelial cells (HUVEC) and human
coronary artery endothelial cells (HCAEC) incubated in the continued presence of PMA
(0.5 pM) for 48 hr. Confluent cultures of HUVEC and HCAEC were pre-labelled for 48 hr with
0.02 MBq/ml [75Se]-selenite. The effect of PMA on the expression of [75Se]-selenoproteins was
studied by including either PMA (0.5 pM) or DMSO (0.05%) in the culture medium of both cell
types for 48 hr in the continued presence of 0.02 MBq/ml [75Se]-selenite. Lane 1, HUVEC,
DMSO; lane 2, HUVEC, PMA; lane 3, HCAEC, DMSO; lane 4, HCAEC, PMA; lane 5, HUVEC,
DMSO; lane 6, HUVEC, PMA; lane 7, HCAEC, DMSO; lane 8, HCAEC, PMA, lane 9, HUVEC,
DMSO, lane 10, HUVEC, PMA; lane 11, HCAEC, DMSO; lane 12, HCAEC, PMA. The samples
loaded are those from triplicate flasks of both cell types for each treatment. Each lane was
loaded with 25 pg of protein. TR, thioredoxin reductase; cyGPX, cytoplasmic glutathione
peroxidase; PHGPX, phospholipid hydroperoxide glutathione peroxidase.
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Figure 4.16. Thioredoxiri reductase (TR) mass in HUVEC and HCAEC treated with either
DMSO (0.05%) or PMA (0.5 pM) for 48 hr. Results shown are those of the mean of 3 flasks ±
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Figure 4.17. Cytoplasmic glutathione peroxidase (cyGPX) activity in HUVEC and HCAEC
treated with either DMSO (0.05%) or PMA (0.5 pM) for 48 hr. Results shown are those of the
mean of 2 or 3 flasks ± SD. No significant difference in cyGPX activity between DMSO- and
PMA-treated HUVEC or HCAEC was shown.
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Figure 4.18. Phospholipid hydroperoxide glutathione peroxidase (PHGPX) activity in
human umbilical vein endothelial cells (HUVEC) and human coronary arterial endothelial
cells (HCAEC) treated with either DMSO (0.05%) or PMA (0.5 pM) for 48 hr. Results shown
are those of the mean of 3 flasks ± SD. Results which are significantly different from DMSO-




Figure 4.19. Autoradiograph of an SDS-PAGE gel showing the expression of [75Se]-
selenoproteins in both human umbilical vein endothelial cells (HUVEC) and bovine
aortic endothelial cells (BAEC) incubated in the continued presence of PMA (0.5 pM) for
48 hr. Confluent cultures of HUVEC and BAEC were pre-labelled for 48 hr with 0.02 MBq/ml
[75Se]-selenite. The effect of PMA on the expression of [75Se]-selenoproteins was studied by
including either PMA (0.5 pM) or DMSO (0.05%) in the culture medium of both cell types for 48
hr in the continued presence of 0.02 MBq/ml [ 5Se]-selenite. Lane 1, HUVEC, DMSO; lane 2,
HUVEC, PMA; lane 3, BAEC, DMSO; lane 4, BAEC, PMA; lane 5, HUVEC, DMSO; lane 6,
HUVEC, PMA; lane 7, BAEC, DMSO; lane 8, BAEC, PMA, lane 9, HUVEC, DMSO, lane 10,
HUVEC, PMA; lane 11, BAEC, DMSO; lane 12, BAEC, PMA. The samples loaded are those
from triplicate flasks of both cell types for each treatment. Each lane was loaded with 25 pg of
protein. TR, thioredoxin reductase; cyGPX, cytoplasmic glutathione peroxidase; PHGPX,
phospholipid hydroperoxide glutathione peroxidase.
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Figure 4.20. Thioredoxin reductase activity in human umbilical vein endothelial cells
(HUVEC) and bovine aortic endothelial cells (BAEC) treated with either DMSO (0.05%) or
PMA (0.5 mM) for 48 hr. Results shown are those of the mean of 3 flasks ± SD. Results which













Figure 4.21. Autoradiograph of an SDS-PAGE gel showing the expression of [75Se]-
selenoproteins in both human umbilical vein endothelial cells (HUVEC) in the continued
presence of various doses of A23187 for 24 hr. Confluent cultures of HUVEC were pre-
labelled for 48 hr with 0.02 MBq/ml [75Se]-selenite. The effect of A23187 on the expression of
[75Se]-selenoproteins was studied by including different concentrations of A23187 in the culture
medium for 24 hr in the continued presence of 0.02 MBq/ml [75Se]-selenite. Lane 1, No
additions; lane 2, DMSO (0.05%), lanes 3 and 4, A23187 (0.5 nM); lanes 5 and 6, A23187 (5
nM); lanes 7 and 8 (50 nM); lanes 9 and 10, A23187 (0.5 pM) Each lane was loaded with 25 pg
of protein. TR, thioredoxin reductase; cyGPX, cytoplasmic glutathione peroxidase; PHGPX,




Figure 4.22. Autoradiograph of an SDS-PAGE gel showing the expression of
[75Se]-selenoproteins in human umbilical vein endothelial cells (HUVEC)
incubated in the presence of A23187 (0.5 pM) for various times. Confluent cultures
of HUVEC were pre-labelled for 48 hr with 0.02 MBq/ml [75Se]-selenite. The effect of
A23187 on the expression of [75Se]-selenoproteins was studied by including A23187
(0.5 pM) in the culture medium for 1 min, 12 hr, 24 hr 35 hr or 48 hr in the continued
presence of 0.02 MBq/ml [75Se]-selenite. Lane 1, A23187, 1 min; lane 2, DMSO, 1 min;
lane 3, A23187, 12 hr; lane 4, DMSO, 12 hr; lane 5, A23187, 24 hr; lane 6, DMSO, 24
hr; lane 7, A23187, 35 hr; lane 8, DMSO, 35 hr; lane 9, A23187, 48 hr; lane 10, DMSO,
48 hr. Each lane was loaded with 25 pg of protein. TR, thioredoxin reductase; cyGPX,
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Figure 4.23. Autoradiograph of an SDS-PAGE gel showing the expression of [75Se]-
selenoproteins in human umbilical vein endothelial cells (HUVEC) incubated in the
continued presence of A23187 (0.5 pM) for various times. Confluent cultures of HUVEC
were pre-labelled for 48 hr with 0.02 MBq/ml [75Se]-selenoproteins was studied by including
either A23187 (0.5 pM) or DMSO (0.05%) in the culture medium for 1 min, 10 min, 1 hr, 12 hr
or 48 hr in the continued presence of 0.02 MBq/ml [75Se]-selenite. After each time point the
medium was removed and the cells washed and fresh medium containing 0.02 MBq/ml [75Se]-
selenite without A23187 or DMSO added. The cells were incubated for a total time of 48 hr.
Lane 1, A23187, 1 min; lane 2, DMSO, 1 min, lane 3, A23187, 10 min; lane 4, DMSO, 10 min;
lane 5, A23187, 1 hr; lane 6, DMSO, 1 hr; lane 7, A23187, 12 hr; lane 8, DMSO, 12 hr; lane 9,
A23187, 35 hr, lane 10, DMSO, 35 hr. Each lane was loaded with 25 pg of protein. TR,






Figure 4.24. Autoradiograph of an SDS-PAGE gel showing the expression of [75Se]-
selenoproteins in human umbilical vein endothelial cells (HUVEC) labelled with [75Sej-
selenite (0.02 MBq/ml) for 35 hr in the presence and absence of various agents. Lane 1,
no additions; lane 2, A23187 (0.5 pM); lane 3, PMA (0.5 pM); lane 4, A23187 (0.5 pM) and
PMA (0.5 pM). Each lane was loaded with 25 pg of protein. TR, thioredoxin reductase; cyGPX,
cytoplasmic glutathione peroxidase; PHGPX, phospholipid hydroperoxide glutathione
peroxidase.
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Figure 4.25. Western blot of human umbilical vein endothelial cells (HUVEC) using
antiserum to thioredoxin reductase (TR). HUVEC were incubated in the presence and
absence of various agents, as specified, prior to the Western blotting of the cell lysates. Lanes
1-3, purified human TR standard (4, 2, and 1ng respectively); lane 4, HUVEC - no additions;
lane 5, HUVEC - A23187 (0.5 pM); lane 6, HUVEC - PMA (0.5 pM); lane 7, HUVEC - A23187





Figure 4.26. Autoradiograph of an SDS-PAGE gel showing the expression of [75Se]-
selenoproteins in human umbilical vein endothelial cells (HUVEC) in the continued
presence of various agents. Confluent cultures of HUVEC were pre-labelled for 48 hr with
0.02 MBq/ml [75Se]-selenite. The effects of acetylcholine (1 mM) and adenosine triphosphate (1
mM) on the expression of [75Se]-selenoproteins was studied by including each of these agents
in the culture medium for 48 hr in the continued presence of 0.02 MBq/ml [75Se]-selenite. Lane
1, no additions; lane 2, acetylcholine; lane 3, adenosine triphosphate.. Each lane was loaded
with 25 pg of protein. TR, thioredoxin reductase; cyGPX, cytoplasmic glutathione peroxidase;
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Figure 4.27. Autoradiograph of an SDS-PAGE gel showing the expression of [7SSe]-
selenoproteins in human umbilical vein endothelial cells (HUVEC) incubated in the
continued presence of bradykinin (1 pM) for various times. Confluent cultures of HUVEC
were pre-labelled for 48 hr with 0.02 MBq/ml [75Se]-selenite. The effects of bradykinin (1 pM)
on the expression of [75Se]-selenoproteins was studied by including bradykinin in the culture
medium for 6 hr, 12 hr, 24 hr and 48 hr in the continued presence of 0.02 MBq/ml [75Se]-
seienite. Lane 1, no additions; lane 2, 6 hr; lane 3, 12 hr; lane 4, 24 hr; lane 5, 48 hr. Each lane
was loaded with 25 pg of protein. TR, thioredoxin reductase; cyGPX, cytoplasmic glutathione





Figure 4.28. Autoradiograph of an SDS-PAGE gel showing the expression of [75Se]-
selenoproteins in human umbilical vein endothelial cells (HUVEC) in the continued
presence of forskolin for 48 hr. Confluent cultures of HUVEC were pre-labelled for 48 hr with
0.02 MBq/ml [75Se]-selenite. The effect of forskolin on the expression of [75Se]-selenoproteins
was studied by including forskolin (0.1 pM) in the culture medium for 48 hr in the continued
presence of 0.02 MBq/ml [75Se]-selenite. Lane 1, forskolin, 1 minute; lane 2, ethanol (0.1%), 1
minute; lane 3, forskolin, 48 hr; lane 4, ethanol (0.1%), 48 hr. Each lane was loaded with 25 pg
of protein. TR, thioredoxin reductase; cyGPX, cytoplasmic glutathione peroxidase; PHGPX,
phospholipid hydroperoxide glutathione peroxidase.
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4.4 DISCUSSION
The treatment of HUVEC with the phorbol ester PMA and/or the calcium ionophore A23187 has
clear effects on intracellular selenoprotein expression. In HUVEC exposed to PMA for times as
short as 1 minute, a down-regulation of TR and PHGPX was observed. In contrast, an up-
regulation of cyGPX was found after 10 min exposure to PMA (as visualized by
autoradiography). These changes in selenoprotein expression were only apparent after a 48 hr
lag period following these brief exposure times to PMA. The degree of change in the expression
of these major selenoproteins was similar to that observed in HUVEC which had been
continually exposed to PMA for 48 hr. These results strongly support an effect of PMA on
selenoprotein expression through the activation of PKC rather than its desensitization which has
been previously reported after prolonged PMA exposure (Emori et at., 1991; Santell, Bartfield
and Levin, 1992). It is possible that desensitization of PKC was not observed in HUVEC exposed
to PMA for times in excess of 48 hr because the initial levels of PMA were depleted. However,
our results showed that this was unlikely as the double dose of PMA had an additive effect on
the changes in selenoprotein expression observed after 96 hr (figure 4.14).
The data presented using the PKC inhibitor GF109203X provided further evidence that the
change in selenoprotein expression induced by PMA was through the activation of PKC.
Furthermore the use of this inhibitor strongly suggests that the effects of PMA on selenoprotein
expression did not result from a down-regulation of PKC since GF109203X added alone had no
observable effect on selenoprotein expression. However, in cells pre-incubated with
GF109203X, the effects of PMA on selenoprotein expression were attenuated.
Overall the results from the [75Se]-selenoprotein labelling experiments and the Western blot
analysis provide good evidence that the expression of TR, PHGPX and cyGPX is modulated
through the activation of PKC by the phorbol ester PMA. Changes in TR expression in response
211
Regulation of thioredoxin reductase and glutathione peroxidase chapter four
expression through different second pathways
to phorbol esters have also been reported in human thyrocytes and HepG2 cells but in contrast
to HUVEC PMA led to an increase in TR expression in these cells (Howie et at., 1998). Recently
Kumar and Holmgren demonstrated that a topical application of the phorbol ester 12-0-
tetradecanoylphorbol-13-acetate (8 nM) significantly induces TR activity in skin (Kumar and
Holmgren, 1999). The down-regulation of TR expression in response to PMA in HUVEC thus
contrasts with TR up-regulation reported in these other cell and tissue types. It is possible that
the same protein (in this case TR) may be differentially regulated by PKC perhaps through the
expression of different isoforms of PKC (Hug and Sarre, 1993). The responses of PHGPX and
cyGPX expression to PMA have not been reported elsewhere although treatment of HUVEC
with phorbol ester has been shown to increase cyGPX mRNA levels (Jornot and Junod, 1997).
The decreases in TR mass and activity in HUVEC in response to a 48 hr treatment with PMA
confirmed the findings from the [75Se]-selenoprotein labelling experiments. However the down-
regulation of [75Se]-labelled PHGPX and the up-regulation of [75Se]-labelled cyGPX observed in
HUVEC treated with PMA were not confirmed by the activity assays for PHGPX and cyGPX.
Although there was a trend towards increased cyGPX activity in the presence of PMA such
changes did not reach statistical significance and no change in PHGPX activity was apparent.
The reason for this discrepancy may be due to the fact that the GPX activities being measured
were very low and therefore may be at the detection limit of the assay. Thus at such levels it may
be difficult to detect the modest changes in activity which occur in response to PMA treatment.
Indeed in HCAEC, which express higher levels of PHGPX, a significant effect of PMA on
PHGPX activity could be observed. Though, it is also a possibility that the selenoprotein bands
with molecular masses of 21 kDa and 24 kDa identified in this study as being PHGPX and
cyGPX respectively were not homogenous and that other selenoproteins with identical molecular
masses were being affected by PMA. Two-dimensional gels would be required to clarify this
point.
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Despite some differences in the basal expression of selenoproteins in HCAEC and HUVEC both
cell types respond to a 48 hr incubation with PMA in a similar manner. PMA-treatment resulted
in the down-regulation of both PPIGPX and TR, whilst the expression of cyGPX was increased
as visualized by autoradiography. The HCAEC were also assayed for TR mass, PHGPX and
cyGPX activity. PMA was shown to down-regulate TR mass to a similar degree in both HUVEC
and HCAEC. In HCAEC the change is cyGPX activity in response to PMA treatment was not
significant, despite a trend for higher cyGPX activity in cells treated with PMA. The disparity
between the results from the [75Se]-iabelling experiment and the selenoenzyme activities is likely
to be due to a sensitivity problem in the activity assay discussed previously.
We have shown that in HUVEC and HCAEC, both TR and PHGPX are down-regulated through
PKC activation, whilst the expression of cyGPX is increased in response to PMA. The up-
regulation of cyGPX may not result from the direct activation of PKC but rather as a
consequence of the increased oxidative stress resulting from the down-regulation of the
antioxidant enzymes TR and PHGPX. Activation of cyGPX expression may thus occur in order
to maintain the antioxidant capacity of the cell. Indeed when hydrogen peroxide production is
stimulated in the rat thyroid during iodine deficiency, there is an associated increase in cyGPX
activity possibly to protect against the increased oxidative stress (Mitchell et at., 1996). The
pulsed time course data is in agreement with this hypothesis as the induction of cyGPX as
visualized by autoradiography appears to occur after the down-regulation of TR and PHGPX
expression. There is evidence that exposure of endothelial cells to oxidants causes a time and
dose-dependent stimulation of the phospholipase C signal transduction pathway (Shasby, Yorek
and Shasby, 1988). In inflammatory cells activation of PKC has been associated with a burst of
superoxide production (Harrison and Ohara, 1995). More recently the activation of PKC through
oxidized low-density lipoprotein has been implicated in vascular disease (Ohgushi et at., 1993).
We have shown that activation of the PKC pathway attenuates the expression of TR and
PHGPX. Since these selenoproteins may have an antioxidant function within the endothelial cell,
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down-regulation of TR and PHGPX may diminish the cells antioxidant capacity and render it
more susceptible to oxidative damage and to the development of atheroma.
The selenoprotein expression of BAEC did not appear to be regulated by PMA as visualized by
autoradiography. Also, treatment of BAEC with PMA did not modify TR activity. These results
suggest that in BAEC, any possible modification of selenoprotein expression must occur through
a signal transduction mechanism other than the phosphoinositol pathway. Differences in signal
transduction pathways have been previously reported. For example, bradykinin, a potent
stimulus for IP3 formation and Ca2+ mobilization in bovine aortic and cerebral microvascular
endothelium is only partially effective in HUVEC (Garcia and Natarajan, 1992).
The addition of the calcium ionophore A23187 increased the expression of TR 1.96 ± 0.13-fold
over basal levels in HUVEC. A similar response of TR to A23187 was reported in human
thyrocytes and HepG2 cells (Howie eta/., 1998). A23187 has a number of actions, in addition to
increasing the intracellular concentration of Ca2+. It may act as an uncoupler of oxidative
phosphorylation and as an inhibitor of mitochondrial ATPase activity (Reed and Lardy, 1972).
The action of A23187 on Ca2+ influx is a rapid response. For example, the A23187-induced
cGMP response in cultured endothelial cells reaches a plateau within 3 minutes (Schmidt, Mayer
and Kukovetz, 1989). However, in our studies the increase of TR expression in response to
A23187 was only observed when A23187 was present continuously in the culture medium for
periods in excess of 12 hr. This raises the possibility that the regulation of TR expression by
A23187 is a result of the toxic effect of A23187 rather than a calcium-signalling effect. In
agreement with this Dr Forbes Howie has found that the calcium ionophore ionomycin has no
effect on TR expression in human or sheep thyrocytes (personal communication).
Studies involving the Ca2+ regulation of TR expression are not in agreement. The claim by
Schallreuter and colleagues that purified human TR is regulated by Ca2+ at physiological levels
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has been refuted (Oblong and Powis, 1993). Oblong and Powis suggested that the ambiguity
concerning the Ca2+ regulation of TR results from Schallreuter et al. using only a partially purified
TR preparation which may contain a less stable isoform of TR or another reductase (Oblong and
Powis, 1993). Howie et al. have claimed that the up-regulation of TR in cultured human
thyrocytes was a calcium signalling effect and postulated that TR may be important in detoxifying
the high concentrations of peroxides produced during thyroid hormone synthesis (Howie et al.,
1998). Therefore the possibility exists that increased TR levels are a consequence of increased
reactive oxygen species in thyrocytes and other cell types rather than a straightforward Ca2+
response. In agreement with this hypothesis the addition of A23187 to FRTL-5 rat thyroid cell
line and to human thyroid slices produced a marked stimulation of hydrogen peroxide production
(Bjorkman and Ekholm, 1992; Corvilain et al., 1994). Indeed, our data also suggests that
calcium signalling does not regulate TR expression, but that the up-regulation of TR is likely to
be a consequence of toxicity, possibly an oxidative stress resulting from the presence of
A23187.
0
The TR7Trx system provides a powerful dithiol/disulphide oxidoreductase system which has
been shown to reduce and detoxify lipid hydroperoxides, hydrogen peroxides, and organic
hydroperoxides (Bjornstedt et al., 1995). The accumulation of such compounds in tissues exerts
deleterious effects. For example the hydroperoxide (15S)-hydroperoxy-(5Z), (8Z), 11 (Z), 13 (E)-
eicosatetraenoic acid ([15SJ-HPETE) oxidizes low-density lipoprotein to a form which under
some conditions renders the particle more toxic to the endothelium, with implications for the
development and progression of atherosclerosis (Bjornstedt et al., 1995).
In HUVEC, the A23187-induced increase in TR expression may therefore act as a detoxification
mechanism induced by the increased presence of reactive oxygen species which result from the
presence of A23187. The addition of tert-butylhydroperoxide (an oxidative agent) to HUVEC in
the continued presence of 0.02 MBq/ml [75Se]-selenite for 20 hr resulted in an increased
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labelling of the 58 kDa selenoprotein (TR) (data shown in figure 5.02, section five). In addition
A23187 treatment of BAEC has been shown to induce oxidant production as measured by
luminol-enhanced chemiluminescence (Kooy and Royall, 1994). These findings also support the
interpretation that the up-regulation of TR in response to A23187 may be a beneficial response
to oxidative stress rather than a specific induction occurring through calcium signalling.
The effect of A23187 on cyGPX and PHGPX was variable in our studies. In one experiment
(figure 4.24) PHGPX appeared to be down-regulated after A23187 treatment, but in a further two
experiments (figures 4.21 and 4.22) no clear change was observed. The reasons for this
difference are unknown, but may be accounted for by the age, selenium status, oxidant status or
the ethnic group of the individual from whom the cells were isolated.
In the unlikely event that A23187 was exerting its effects on TR expression in HUVEC through a
calcium response, it would appear that the calcium signalling branch antagonises the
phosphoinositol signalling branch of the calcium-phosphoinositol signalling pathway. There are
other examples in the endothelium where this is the case. For example, constitutive endothelial
nitric oxide synthase activity in endothelial cells is stimulated by A23187, but the subsequent
A23187-induced nitric oxide release is inhibited by PKC activation using the phorbol ester, 12-0-
tetradecanoylphorbol-13-acetate (Hirata et at., 1995). There are also examples in endothelial
cells where the two branches of the calcium-phosphoinositol signalling pathway act
synergistically. Matsubara and Ziff have shown that in HUVEC, simultaneous stimulation with
PMA and A23187 produces a large increase in superoxide anion release at submaximal
concentrations, which, when added separately, only cause a minimal response. (Matsubara and
Ziff, 1986).
Bradykinin (BK) and adenosine triphosphate (ATP) activate the calcium-phosphoinositol
signalling pathway by increasing intracellular Ca2+ in endothelial cells (Buchan and Martin, 1991;
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Busse, Trogisch and Bassenge, 1985; Colden-Stanfield et al., 1987; Natarajan, 1995). Our data
shows that the treatment of cultured HUVEC with BK and ATP induced no change in [75Se]-
labelling of any of the selenoproteins. These compounds, through an increase in intracellular
calcium, may not affect selenoprotein expression, thereby supporting a non-specific effect of
A23187. There are a number of alternative possible explanations for this lack of response.
Firstly, it is possible that the BK and ATP receptors are lost during isolation and subculture of
these cells or secondly, the receptors may be down-regulated as a result of the growth factors
present in the culture medium. These possibilities were not investigated further in any more
detail. However, no intracellular cGMP response to BK could be measured in the HUVEC used
in this study (data not shown).
The inability of acetylcholine (ACh) to promote changes in the [75Se]-labelling of selenoproteins
is likely to be the effect of the loss of muscarininc receptors during cell culture. The literature
reports that freshly isolated endothelial cells respond to ACh (Fransen, Katnik and Adams, 1998;
Hartmann, Saeed and Bing, 1987) whilst there are a number of reports showing that cultured
endothelial cells do not respond to ACh (Cocks et al., 1985; Gryglewski, Moncada and Palmer,
1986; Schmidt, Mayer and Kukovetz, 1989).
Forskolin (a diterpine compound that activates adenylate cyclase) had no effect on the [75Se]-
selenoprotein expression in HUVEC. The activation of adenylate cyclase by forskolin and
subsequent increase in cAMP levels has been previously reported in endothelial cells (Crutchley
et al., 1993; Ferro et al., 1999). These findings suggest therefore that selenoprotein expression
in HUVEC is not regulated by the adenylate cyclase signal transduction pathway, in contrast to
thyrocytes where this signalling pathway is extremely important.
In conclusion, in HUVEC and HCAEC the expression of TR, PHGPX and cyGPX is regulated by
the activation of PKC. Since oxidised LDL has been shown to activate PKC the changes in
217
Regulation of thioredoxin reductase and glutathione peroxidase chapter four
expression through different second pathways
selenoprotein expression which we observed in this study may reflect those seen in vivo in
endothelial cells exposed to reactive oxygen species. In particular TR and PHGPX are
potentially important antioxidant enzymes in the vascular endothelium and their down-regulation
could result in an increased susceptibility to oxidative damage and thus the development of
atheroma. Again the findings of this chapter demonstrate that HUVEC but not BAEC provide a
good model for HCAEC as both HUVEC and HCAEC show similar responses in selenoprotein
expression to PMA whilst in BAEC treatment with PMA induces no such changes.
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CHAPTER FIVE THE ROLE OF SELENIUM IN THE PREVENTION
OF OXIDATIVE DAMAGE
5.1 INTRODUCTION
Aerobic cells are constantly exposed to oxidative stresses from reactive oxygen species (ROS)
such as superoxide, hydroxyl radicals, hydrogen peroxide and singlet oxygen. At a cellular level
ROS are responsible for a number of different disruptive processes, including: lipid peroxidation,
protein cross-linking and degradation, cleavage of DNA, polymerization of polysaccharides and
ultimately cell mortality (Hennig and Chow, 1988; Kirkland, 1991; Pohlman and Harlan, 2000;
Schuppe-Koistinen et al., 1994; Thomas, Geiger and Girotti, 1993). Oxidative damage to the
endothelium is one of the principle mechanisms in the pathogenesis of atherosclerosis
(Gimbrone, 1995; McGorisk and Treasure, 1996; Ross, 1993). Cytoprotection against oxidative
damage is accomplished by diverse enzymatic and non-enzymatic antioxidant systems. In the
endothelial cell these systems principally consist of antioxidant vitamins, superoxide dismutase,
catalase and selenoproteins such as the glutathione peroxidases and possibly thioredoxin
reductase (TR).
Low plasma selenium levels have been associated with an increased risk of cardiovascular
disease including coronary atherosclerosis (Kok et al., 1991; Salonen et al., 1982; Suadicani,
Hein and Gyntelberg, 1992). Studies in vitro have demonstrated that selenium supplementation
confers resistance on bovine endothelial cells to oxidative damage (Ochi, Morita and Murota,
1992; Thomas, Geiger and Girotti, 1993). Ochi et al. demonstrated that sodium selenite and
ebselen (a synthetic glutathione peroxidase mimic) dramatically decreased the toxicity of the
hydroperoxide (15S)-hydroperoxy-(5Z), (8Z), 11(2), 13(£)-eicosatetraenoic acid ([15SJ-HPETE)
(which is formed in vivo by oxygenation of arachidonic acid by arachidonic acid 15-lipoxygenase)
(Bjornstedt et al., 1995) in a dose-dependent manner (10-100nM) (Ochi, Morita and Murota,
1992). These findings and further investigations manipulating the glutathione redox cycle
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suggested that (15S)-HPETE-induced cytoxicity could be attributed to a decreased glutathione
peroxidase (GPX) activity. In agreement with Ochi et at., Thomas et at. using bovine endothelial
cells, proposed that increased cytoxicity in selenium-deficient endothelial cells to both tert-
butylhydroperoxide (t-BuOOH) and photogenerated oxidized low density lipoprotein (oxLDL)
resulted from a decrease in both cytoplasmic glutathione peroxidase (cyGPX) and phospholipid
hydroperoxide glutathione peroxidase (PHGPX) activity (Thomas, Geiger and Girotti, 1993).
However, the expression of other selenoproteins with antioxidant properties such as extracellular
glutathione peroxidase, selenoprotein P and TR was not considered in either of these studies.
cyGPX catalyzes the reduction of a variety of hydroperoxides, including hydrogen peroxide,
cumene hydroperoxide, t-BuOOH, and fatty acid hydroperoxides (Flohe, 1989; Rotruck et at.,
1973). In contrast, PHGPX has been shown to catalyze the reduction of fatty acid
hydroperoxides and cholesterol hydroperoxides (Ursini, Maiorino and Gregolin, 1985). The
modification of the expression and activity of these selenoproteins in cultured cells through
selenium supplementation has been widely reported (Ricetti et at., 1994; Takahashi, Newburger
and Cohen, 1986; Thomas, Geiger and Girotti, 1993). It is therefore possible that decreased
expression and activity of these selenoproteins in selenium-deficiency may increase the
susceptibility of the endothelium to oxidative damage.
Knockout mice which are deficient in cyGPX have been developed as a model to study the role
of cyGPX in normal physiology and the pathogenesis of a number of diseases (Ho et at., 1997).
Using this model Ho et at. showed that mice deficient in cyGPX developed normally and showed
no increased sensitivity to pulmonary hyperoxia (Ho et at., 1997). In contrast, oxidative stress
induced by 30 mg/kg of paraquat, which is approximately LD2o for mice, killed all the cyGPX
knock-out mice, whereas control mice showed no signs of toxicity at this dose (de Haan et at.,
1998). The possible protective role of cyGPX in the pathogenesis of atherosclerosis has not
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been ruled out and the use of this model in future studies could help define which selenoproteins
contribute to the protective effect of selenium against oxidative damage in endothelial cells.
Data presented in this thesis have shown that TR is the dominantly expressed selenoprotein in
both HUVEC and HCAEC. Despite this, an antioxidant function for TR in the endothelium has
not been reported. TR can reduce and detoxify lipid hydroperoxides and organic hydroperoxides
(Bjornstedt et al., 1995). For example, the hydroperoxide (15S)-HPETE oxidizes low density
lipoprotein to a form that under some conditions renders it more toxic to the endothelium, with
implications for the pathogenesis of atherogenesis (Bjornstedt et al., 1995). TR can detoxify
(15S)-HPETE and other lipid hydroperoxides (Bjornstedt et al., 1995).
An important mediator of oxidative damage to the endothelium in vivo is oxLDL (Nielson, 1999;
Steinberg, 1991; Witzum and Steinberg, 1991). OxLDL is not a single homogenous entity,
instead it consists of many oxidation products that form from both the peroxidation and
fragmentation of the lipid components of LDL, and the modification and oxidation of the
apoprotein B (Rosenfeld, 1991; Witzum and Steinberg, 1991). Studies using oxLDL are
confounded by the considerable variation in the products formed between different preparations.
It appears that the products formed are dependent on several factors including; the cell type
used to initiate oxidation, the metal ion concentration in the medium as well as the composition
of the medium, the incubation conditions and the inherent susceptibility of the native LDL to be
oxidised in the peroxidation conditions used for different studies (Esterbauer and Jurgens, 1993;
Kuzuya et al., 1991; Witzum and Steinberg, 1991). Therefore the toxic composition of any one
batch of oxLDL made using LDL isolated from different sources, even when using constant
conditions, is known to vary, which can make interpretation of results difficult. t-BuOOH has
been previously used as a membrane permeable oxidative stress inducing reagent (Elliot, Doan
and Henschke, 1995; Schupe, Moldeus and Cotgreave, 1992; Thomas, Geiger and Girotti,
1993). This is the agent adopted for the studies in this chapter. Although it could be argued that
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t-BuOOH is not physiological agent, unlike oxLDL it is not subject to between-batch variation to
the same extent.
Organic selenium such as selenomethionine and selenocysteine provide the main source of
selenium ingested in the normal human diet. However inorganic forms of selenium such as
sodium selenite are often used in experimental diets and as supplements (Daniels, 1996). In
man, tracer studies have shown that selenomethionine is incorporated more efficiently into body
tissues and has a longer half-life than selenite (Griffiths, Stewart and Robinson, 1976). The
properties of selenomethionine result from the ability of selenomethionine to be substituted into
proteins at methionine residues (Behne et at., 1991). It is possible that sodium selenite is a more
bioactive form of the trace element selenium. Studies comparing the efficacy of sodium selenite
and selenomethionine in the prevention of oxidative damage to endothelial cells have not been
previously performed.
Differences in the expression of intracellular selenoproteins occur between endothelial cells
isolated from different vascular beds. Also, there are clear species differences in selenoprotein
expression in the endothelium (chapter three). It is therefore possible that the antioxidant
systems of endothelial cells may vary between cells isolated from different vascular beds and
different species.
This study aims to:
• determine the effects of t-BuOOH on [75Se]-selenoprotein expression in HUVEC
• examine the ability of sodium selenite supplementation to protect HUVEC, HCAEC and
BAEC from cytotoxicity resulting from t-BuOOH treatment
• associate any observed protective effects with changes in the expression and activity of TR
and the activity of cyGPX and PHGPX
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• assess the direct effect of sodium selenite in the protection of HUVEC against oxidative
damage resulting from t-BuOOH treatment
• to compare the potency of inorganic sodium selenite with organic selenomethionine on the
protection of HUVEC against oxidative damage resulting from t-BuOOH treatment.
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5.2 MATERIALS AND METHODS
5.2.1 Introduction
To study the ability of selenium to protect endothelial cells against oxidative damage from tert-
butylhydroperoxide (t-BuOOH), HUVEC, HCAEC and BAEC were isolated, cultured and
maintained as described in sections 2.3.2, 2.3.5 and 2.3.8, respectively. Prior to each
experiment the cells were sub-cultured and seeded according to a specific protocol using M199
medium to which were added the supplements used in EGM-2 (i.e. FBS (2%), hydrocortisone
(0.04%), ascorbic acid (0.1%), long R insulin-like growth factor-1 (0.1%), heparin (0.1%), human
fibroblast growth factor (0.4%), human recombinant vascular endothelial growth factor (0.1%),
human recombinant epidermal growth factor (0.1%) and gentamicin sulphate/ amphotericin B
(0.1%)). The selenium content of the M199 medium containing these supplements was
determined by acid digestion followed by fluorimetric analysis, as described in section 2.3.11.
M199 medium containing all the above listed supplements had a selenium concentration of 4.73
nM, and was classified as effectively selenium-deficient medium.
Selenium-sufficient medium refers to a culture medium with a selenium concentration of
approximately 48 nM. It comprises of a basal medium, with added selenium, and contains the
same supplements as the selenium-deficient medium described above.
5.2.2 The effect of t-BuOOH on the expression of [75Se]-selenoproteins in
HUVEC
For these experiments HUVEC derived from the same primary cell isolation were seeded into
both 12 well plates (seeding density 10000 cell/cm2) and T75 flasks (seeding density 3000
cells/cm2) and maintained in selenium-sufficient medium (48 nM).
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a) The effect of different concentrations of t-BuOOH on cell viability
To determine a sub-toxic concentration of t-BuOOH, triplicate wells of confluent wells of HUVEC,
which had been cultured in selenium-sufficient medium, were incubated with defined
concentrations of t-BuOOH (0, 50, 60, 70, 80, 90, 100, 500 pM) for 48 hr. After this incubation
period, both the culture medium and cells were harvested and analysed for LDH activity as
described in section 2.3.21.
b) The effect of a sub-toxic dose of t-BuOOH on the expression of [75Se]-selenoproteins
Confluent cultures of HUVEC in T75 flasks, which had been cultured in selenium-sufficient
medium, were pre-labelled to a steady state with 0.02 MBq/ml [75Se]-selenite for 48 hr (as
described in section 3.2.2) prior to investigating the effects of a sub-toxic dose of t-BuOOH (as
determined from the experiment described in section 'a' above). The effect of t-BuOOH on the
[75Se]-labelled selenoproteins was studied by the inclusion of t-BuOOH (90 pM) in the culture
medium for 48 hr in the continued presence of 0.02 MBq/ml [75Se]-selenite.
After 48 hr, HUVEC were harvested into 20 ml EBSS by scraping and centrifuged at 2000 g for
10 min at 4°C. The resulting cell pellet was resuspended in 200pl 60 mM Tris buffer, pH 7.8,
containing 1 mM EDTA and 1 mM dithiothreitol (Tris buffer). The cells were lysed by sonication
on ice using the Soniprep 150.
Protein concentrations were measured using the Bradford assay (section 2.3.12). The samples
were then diluted to a common protein concentration with Tris buffer and prepared for
separation by SDS-PAGE as described in section 2.3.13.
The [75Se]-labelled selenoproteins present in 25 pg protein were separated by SDS-PAGE
(section 2.3.13). The resulting gel was dried and the [75Se]-labelled selenoproteins visualized by
autoradiography using Kodak X-OMAT XAR-5 film (section 2.3.14).
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5.2.3 The effect of different doses of t-BuOOH on LDH activity in HUVEC
cultured in selenium-deficient medium
HUVEC were sub-cultured and seeded into 12 well plates with selenium-deficient medium. The
effect of different doses of t-BuOOH (0, 75, 150, 300 pM) on HUVEC viability was determined
using triplicate wells of confluent HUVEC. After 20 hr incubation in the presence of t-BuOOH
both the medium and cells were harvested and analysed for LDH activity (section 2.3.21).
5.2.4 The ability of sodium selenite to protect against oxidative damage from t-
BuOOH in HUVEC
To investigate the possible protective effect of sodium selenite against oxidative damage,
HUVEC were sub-cultured into 12 well plates at a density of approximately 10000 cells/cm2
using selenium-deficient medium to which different concentrations of sodium selenite had been
added. After three days the culture medium was removed and replaced with fresh medium
containing the same respective concentration of sodium selenite.
Due to clear variability in the susceptibility of different preparations of HUVEC to be killed by t-
BuOOH it was necessary to determine a concentration of t-BuOOH which would be significantly
toxic to a particular preparation of HUVEC. This was done before each main experiment and
required an additional 12 well plate of HUVEC seeded in selenium-deficient medium.
Concentrations of t-BuOOH ranging from 0-300 pM were added to the cells and after 20 hr
exposure to t-BuOOH the HUVEC were observed under the light microscope. The
concentrations of t-BuOOH chosen for the subsequent experiment spanned the range of
concentrations which were found to cause significant cell death as observed under the light
microscope.
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The remaining HUVEC when fully confluent (between 5 to 6 days) were used to monitor the
effects of sodium selenite at preventing cell death in the presence of two or three concentrations
of t-BuOOH. After 20 hr of exposure to t-BuOOH both the medium and cells were harvested and
analysed for LDH activity as described in section 2.3.21.
5.2.5 Assessment of the direct effect of sodium selenite in the protection of
HUVEC against oxidative damage from t-BuOOH
To determine whether sodium selenite can exert a direct antioxidant effect against t-BuOOH in
HUVEC, rather than through modification of selenoprotein expression, the following procedure
was adopted. Briefly, HUVEC were cultured in selenium-deficient medium until confluent and
then supplemented with different concentrations of sodium selenite (0, 5, 10, 40, 160 nM)
simultaneously with the addition of t-BuOOH (100 pM). In contrast, HUVEC, were sub-cultured in
selenium-deficient medium, were supplemented with different concentrations of sodium selenite
(0, 5, 10, 40, 160 nM) prior to treatment with t-BuOOH.
HUVEC were sub-cultured into 12 well plates at a density of approximately 10000 cells/cm2 in
selenium-deficient medium. When the cells were fully confluent (between 5 to 6 days) the culture
medium was removed and replaced with fresh medium containing sodium selenite (0, 5, 10, 40,
160 nM) to which t-BuOOH (100 pM) was added. Control cells received no t-BuOOH or sodium
selenite supplementation. After 20 hr both the medium and cells were harvested and analysed
for LDH activity as described in section 2.3.21.
In parallel, HUVEC derived from the same primary cell preparation were sub-cultured at a
density of approximately 10000 cells/cm2 in selenium-deficient medium containing defined
concentrations of sodium selenite (0, 5, 10, 40, 160 nM). When the cells were fully confluent
(between 5 to 6 days) the culture medium was removed and replaced with fresh medium
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containing sodium selenite (0, 5, 10, 40, 160 nM) to which t-BuOOH (100 pM) was added. Again
control cells received no t-BuOOH or sodium selenite supplementation.
After 20 hr treatment with t-BuOOH the medium and cells from the experiments were harvested
and analysed for LDH activity as described in section 2.2.21.
The above procedure was carried out on two different preparations of HUVEC.
5.2.6 The ability of sodium selenite to protect against oxidative damage from t-
BuOOH in HCAEC
The procedures used to study the protective effect of sodium selenite against oxidative damage
from t-BuOOH in HCAEC were as described for HUVEC (section 5.2.4).
Unfortunately, due to a limited supply of HCAEC, it was not possible to repeat these experiments
on different preparations of cells. However the experiment was repeated on the same
preparation of cells but at a different passage to show that the effects observed were
reproducible.
5.2.7 The ability of sodium selenite to protect against oxidative damage from t-
BuOOH in BAEC
The procedures used to study the protective effect of sodium selenite against oxidative damage
from t-BuOOH in BAEC were as described previously for HUVEC (section 5.2.4).
Again due to a limited supply of BAEC this experiment was repeated on the same preparation of
cells at a later passage.
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5.2.8 The effect of sodium selenite supplementation on intracellular
selenoprotein expression and activity in different vascular endothelial cells
Measurements of TR mass and activity, cyGPX and PHGPX activity, were run in parallel with the
cell viability determinations. HUVEC, HCAEC and BAEC were sub-cultured as described above
(sections 5.2.4, 5.2.6 and 5.2.7) and a proportion of the cells were seeded at a density of
approximately 3000 cells/cm2 into T75 flasks. The cells were cultured and maintained in
selenium-deficient medium containing sodium selenite concentrations which corresponded to
those used for each of the cell viability experiments. The cultured medium was removed and
replaced with fresh medium containing sodium selenite on every other day. Upon reaching full
confluence (approximately 9 to 12 days) the cells were harvested, lysed in 0.125 M potassium
phosphate buffer, pH 7.4, and sonicated on ice. The HUVEC lysates were then subsequently
frozen at -70°C until assayed. TR mass and activity, cyGPX and PHGPX activity were
determined as described in sections 2.3.17, 2.3.18, 2.3.19 and 2.3.20, respectively.
It was not possible to determine TR expression in BAEC due to the lack of cross-reactivity of the
antibody to human TR with the bovine protein. The cyGPX and PHGPX activity were not
measured in all experiments due to a shortage of cells.
5.2.9 A comparison of the protective effect of sodium selenite and
selenomethionine against oxidative damage from t-BuOOH in HUVEC
HUVEC were sub-cultured into 12 well plates at a density of approximately 10000 cells/cm2 in
selenium-deficient medium to which different concentrations of either sodium selenite or
selenomethionine had been added (0, 10, 40, 160, 320, 640 nM). On the third day after sub¬
culture the medium was removed and replaced with fresh medium containing the same
respective dose of sodium selenite or selenomethionine. Upon reaching confluence (between 5
to 6 days) the culture medium was removed and replaced with fresh medium which contained
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either sodium selenite or selenomethionine to which different concentrations of t-BuOOH had
been added (0, 100, 200 pM). After 20 hr incubation with t-BuOOH both the medium and cells
were harvested and analysed for LDH activity as described in section 2.3.21.
5.2.10 Statistical analysis
One-way analysis of variance (ANOVA) was used to test for significant differences in % LDH
activity retained in response to t-BuOOH between cells cultured in selenium-sufficient media and
cells cultured in selenium-deficient media. In the cases where the difference was significant
(p<0.05) a Tukey-Kramer multiple comparisons post test was used to test for significant
differences in % LDH retained in response to t-BuOOH for sodium selenite concentrations.
These statistical tests were also used to investigate significant differences between levels of
selenoprotein expression and activity in cells cultured in different concentrations of sodium
selenite.
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5.3 RESULTS
5.3.1 The effect of t-BuOOH on the expression of [75Se]-selenoproteins in
HUVEC
a) The effect of different concentrations of t-BuOOH on cell viability
The changes in %LDH activity retained by HUVEC incubated for 48 hr with different
concentrations of t-BuOOH (0, 50, 60, 70, 80, 90, 100 and 500 pM) are shown in figure 5.01.
Concentrations of 90 pM t-BuOOH and above significantly decreased the %LDH activity retained
by HUVEC (p<0.001). The concentration of t-BuOOH chosen to study the effects of this
compound on the expression of intracellular [75Se]-selenoproteins was 90 pM. This
concentration produced a small, albeit significant, toxic effect.
b) The effect of a sub-toxic dose of t-BuOOH on the expression of [75Se]-selenoproteins
Treatment of HUVEC with 90 pM t-BuOOH for 20 hr significantly up-regulated the expression of
the 58kDa selenoprotein identified as TR (figure 5.02). No other changes in expression of
intracellular [75Se]-labelled selenoproteins were observed.
5.3.2 The effect of different doses of t-BuOOH on LDH activity in HUVEC
cultured in selenium-deficient medium
The cell viability of HUVEC, cultured in selenium-deficient medium, was decreased in a dose-
dependent manner in response to treatment with t-BuOOH (figure 5.03). The cytotoxic effect
was initially observed at 75 pM. Concentrations of 150 pM and 300 pM t-BuOOH decreased the
% LDH activity retained to its lowest levels of 11.25 ± 1.05% and 18.87 ±0.70% (mean ± SD,
n=3), respectively.
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5.3.3 The ability of sodium seienite to protect against oxidative damage from t-
BuOOH in HUVEC
The protective effect of sodium seienite against oxidative damage resulting from t-BuOOH
exposure was established in four different preparations of HUVEC.
a) Protection by seienite added at concentrations up to 1000 nM
Figure 5.04 shows that HUVEC cultured in the presence of all the concentrations of sodium
seienite tested (40, 200, 1000 nM) were significantly less sensitive to the cytotoxic effects of t-
BuOOH (100 pM) compared to HUVEC cultured in selenium-deficient medium. The maximal
protective effect of sodium seienite was observed at 200 nM sodium seienite though 40 nM
sodium seienite conferred almost full protection against 100 pM t-BuOOH (p<0.001).
TR activity and mass and cyGPX and PHGPX activity were determined in the same preparation
of HUVEC as the cell viability experiment shown in figure 5.04. Figures 5.05 a and b show that
both TR activity and mass were significantly increased in HUVEC cultured in the presence of 40
nM sodium seienite (by 2.2-fold and 3.0-fold, respectively) compared to HUVEC cultured in
selenium-deficient medium (p<0.05). The TR activity was maximal in HUVEC cultured in 40 nM
sodium seienite although with all concentrations of sodium seienite tested the TR activity was
higher than basal activity. At 1000 nM sodium seienite, TR expression was maximally increased
by 2.9-fold over basal. Figure 5.05 c shows that cyGPX activity was significantly increased in
HUVEC grown in increasing concentrations of sodium seienite (p<0.01). The maximal increase
in cyGPX activity was a 5.4-fold (n=3) response to 1000 nM sodium seienite. Figure 5.05 d
shows that PHGPX activity is increased in a dose-dependent manner to sodium seienite, with
the increase significant at 200 nM and 1000 nM sodium seienite (p< 0.05).
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b) Protection by selenite added at concentrations between 0-160 nM
In the following experiment HUVEC were cultured in a more limited range of sodium selenite
concentrations (10, 40, 160 nM) than used in the previous experiment in order to more
accurately define a level of sodium selenite at which protection against t-BuOOH could be
observed. These concentrations of sodium selenite were also more physiological than those
used in the previous experiment. Different concentrations of t-BuOOH (100, 200, 300 pM) were
also used, again in an attempt to more closely define the protective effect of sodium selenite.
Figure 5.06 shows that HUVEC cultured in 10 nM sodium selenite appear to be slightly less
sensitive to the cytotoxic effects of 100 pM t-BuOOH compared to those cells cultured in
selenium-deficient medium. This protective effect was only significant and maximal in HUVEC
cultured in 40 nM and 160 nM sodium selenite. In HUVEC exposed to 200 pM and 300 pM t-
BuOOH no protection was afforded by sodium selenite at any concentration tested (10, 40, 160
nM). It was observed, however, that in HUVEC exposed to these higher concentrations of t-
BuOOH (200 and 300 pM) the % LDH activity retained by the cell significantly decreased with
increasing sodium selenite concentrations (200 pM, p< 0.01; 300 pM, p<0.05).
TR activity and mass and cyGPX and PHGPX activity were determined in these HUVEC cultured
in different concentrations of sodium selenite (0, 10, 40, 160 nM). TR activity and mass and
cyGPX activity for all concentrations of sodium selenite were higher than levels measured in
selenium-deficient cells and this effect was maximal at 40 nM sodium selenite in all cases, with
n-fold increases of 2.5, 1.5, and 5.3, respectively (n=3; figures 5.07 a, b and c.). PHGPX activity
was also increased significantly in HUVEC cultured in 10 nM and 160 nM sodium selenite
(p<0.05). The increase was maximal in HUVEC grown in the presence of 10 nM sodium selenite
which expressed a 3.7-fold increase in PHGPX activity over cells cultured in selenium-deficient
medium (n=3).
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Figure 5.08 shows the protective effect of different doses of sodium selenite (0, 1, 5, 10, 40 nM)
against cytoxicity from t-BuOOH (0, 100, 200 pM) in a third HUVEC preparation. A significant
protective effect against 100 pM t-BuOOH was observed in HUVEC cultured in 5 nM sodium
selenite compared to selenium-deficient cells (p<0.001). The sensitivity to 100 pM t-BuOOH was
decreased further at 10 nM and protection was maximal at 40 nM sodium selenite resulting in
93.4% LDH activity retained. Again, sodium selenite did not exhibit a protective effect against
200 pM t-BuOOH. However, as observed previously, the sensitivity, as measured by % LDH
retained, to this concentration of t-BuOOH was significantly augmented at all concentrations of
sodium selenite (p<0.05). In addition, in HUVEC exposed to 100 pM t-BuOOH at 1 nM sodium
selenite (a concentration at which no protection was observed) the % LDH retention was
significantly attenuated (p< 0.001).
The TR activity and mass was measured in the third experiment and both increased in response
to sodium selenite in a dose-dependent manner. As observed previously the increase was
maximal in HUVEC grown in the presence of 40 nM sodium selenite which expressed a 3.9-fold
and 2.0-fold increase in TR activity and TR mass respectively, over cells which were cultured in
selenium-deficient medium (n=3; figure 5.09).
Figure 5.10 shows the protective effect of different doses of sodium selenite (0, 1, 5, 10, 40, 160
nM) against cytoxicity from different concentrations of t-BuOOH (0, 100, 200 pM) in the fourth
HUVEC preparation. A near maximal, highly significant protective effect was observed at 10 nM
sodium selenite against 100 pM t-BuOOH (p<0.001). The decreased sensitivity to 100 pM t-
BuOOH was maintained in HUVEC cultured in 40 nM and 160 nM sodium selenite. Again it was
observed that sodium selenite did not exhibit a protective effect against 200 pM t-BuOOH at any
concentration, and as previously recorded, the sensitivity to this dose of t-BuOOH was
significantly increased at all concentrations of sodium selenite (p<0.001) in a dose-dependent
manner. HUVEC cultured in 5 nM sodium selenite and then exposed to 100 pM t-BuOOH (a
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sodium selenite concentration at which no protection was observed) the % LDH retention was
significantly attenuated (p< 0.001).
Both the TR activity and mass were measured in the fourth HUVEC preparation and both
increased in response to sodium selenite in a dose-dependent manner. On this occasion the
increase in TR activity was maximal in HUVEC grown in the presence of 160 nM sodium selenite
which expressed a 6.4-fold increase in TR activity over cells cultured in selenium-deficient
medium. TR mass was maximal in HUVEC cultured in 40 nM sodium selenite which expressed
a 3.7-fold increase (n=3; figure 5.11) compared to selenium-deficient medium.
5.3.4 Assessment of the direct effect of sodium selenite in the protection of
HUVEC against oxidative damage from t-BuOOH
Figure 5.12 shows the effects of sodium selenite on the % LDH retention in HUVEC. The
selenite was added either prior to or at the same time as t-BuOOH (100 pM) treatment. In
HUVEC to which different concentrations of sodium selenite (0, 5, 10, 40, 160 nM) were added
at the same time as t-BuOOH treatment no protection was afforded to the HUVEC. In contrast,
HUVEC which had been pre-cultured in sodium selenite were significantly protected against 100
pM t-BuOOH at 40 nM and 160 nM sodium selenite concentrations (p<0.001).
These effects were paralleled in a further experiment which used the same protocol but with
HUVEC from a different preparation (data not shown).
5.3.5 The ability of sodium selenite to protect against oxidative damage from t-
BuOOH in HCAEC
The protective effect of sodium selenite against cytotoxicity from t-BuOOH observed in HUVEC
was also evident in HCAEC. Figure 5.13 clearly demonstrates that the sensitivity of HCAEC to
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100 pM t-BuOOH is significantly decreased in cells cultured in concentrations of sodium selenite
of 10 nM and above (p<0.001). The protective effect of sodium selenite was sub-maximal at 10
nM sodium selenite. At 40 nM and 160 nM sodium selenite, the decreased sensitivity to 100 pM
t-BuOOH was maximal with % LDH activity retained measured at 94.7 ± 0.4% and 95.1 ± 0.8%
respectively (mean ± SD, n=3). HCAEC treated with 150 pM and 200 pM t-BuOOH responded in
the same manner as observed in HUVEC, showing a significant reduction in % LDH retention in
cells cultured in increasing concentrations of sodium selenite (150 pM, p< 0.05; 200 pM,
p<0.001).
TR activity and mass and cyGPX and PHGPX activity were determined in these HCAEC cultured
in different concentrations of sodium selenite (0, 1, 5, 10, 40, 160 nM) (figure 5.14). TR activity
and mass significantly increased in response to sodium selenite concentrations of 5 nM sodium
selenite and above compared to HCAEC cultured in selenium-deficient medium (p<0.001). The
increases in TR activity and mass were maximal in HUVEC grown in 160 nM sodium selenite
which produced a 4.1-fold and 1.9-fold increase, respectively (n=3). CyGPX activity also
increased dose-dependently with sodium selenite. The augmented activity was significant at 10
nM sodium selenite (p<0.05) and maximal at 160 nM which increased activity 4.0-fold over levels
measured in cells cultured in selenium-deficient medium. In contrast PHGPX activity was shown
not to be significantly different from basal levels in HCAEC cultured in sodium selenite at all
concentrations tested. However there was a trend towards a small increase in at 40 nM and 160
nM sodium selenite.
The experiment was repeated in the same preparation of HCAEC of a later passage with a
similar protective effect against 100 pM t-BuOOH observed (figure 5.15). However, the effect
was close to maximal at 5 nM sodium selenite resulting in a 80.9 ±3.5% retention of % LDH
activity (mean ± SD, n=3). Again, the HCAEC treated with 200 pM t-BuOOH showed a
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significantly attenuated % LDH retention in response to sodium selenite concentrations of 5 nM
and above (p< 0.01).
TR activity and mass and cyGPX and PHGPX activity were measured in these HCAEC cultured
in different concentrations of sodium selenite (0, 1, 5, 10, 40 nM) (figure 5.16). The TR activity
and mass increased in an almost identical dose-dependent manner to sodium selenite as
observed in the previous HCAEC. In contrast, the cyGPX activity in these cells showed no
significant changes with added sodium selenite, although there was a trend towards increased
activity in response to sodium selenite concentrations of 5 nM and above. PHGPX activity
increased in a dose-dependent manner to increasing concentrations of sodium selenite with a
significant response to 10 nM and 40 nM sodium selenite (p<0.05).
Thus the only selenoprotein which changed in activity at 5nM sodium selenite, a dose which
gave full protection against 100 pM t-BuOOH was TR.
5.3.6 The ability of sodium selenite to protect against oxidative damage from t-
BuOOH in BAEC
Figure 5.17 shows the protective effect of different concentrations of sodium selenite (0, 1, 5, 10,
40, 160 nM) against cytoxicity from different concentrations of t-BuOOH (100 and 200 pM) in
cultured BAEC. At concentrations of 10 nM sodium selenite and below no protective effect
against t-BuOOH (100 pM) was found, though cells cultured in 40 nM and 160 nM sodium
selenite showed a moderate level of protection with 46.9 ± 26.9% and 35.8± 5.4 % LDH
retention, respectively (mean ± SD, n=3). No significant differences were observed in cell
damage for BAEC cultured in sodium selenite at any concentration and then treated with 200 pM
t-BuOOH. Thus full protection was not afforded by any concentration of sodium selenite tested.
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This experiment was repeated on the same preparation of BAEC of a later passage with similar
results (figure 5.18).
TR activity was measured in response to increasing concentrations of sodium selenite in the two
different passages of BAEC which in the cytoxicity experiments had shown a similar protective
profile against 100 pM t-BuOOH. Figure 5.19 shows the changes in TR activity in BAEC parallel
the % LDH retention data represented in figure 5.17. BAEC cultured in 40 nM and 160 nM
sodium selenite significantly increased the activity of TR (p<0.05) from 0 mU/mg protein to 0.594
± 0.121 mU/mg protein and 0.484 ± 0.174 mU/mg protein, respectively. In contrast in the
subsequent experiment for which the cytoxicity data was illustrated in figure 5.18, TR activity
was significantly augmented in BAEC cultured in sodium selenite concentrations of 5 nM and
above (figure 5.20; p<0.001). The maximal increase in TR activity was measured in BAEC
cultured in 40 nM sodium selenite whereby TR activity was 1.1-fold higher than measured in
cells cultured in the absence of sodium selenite.
At each concentration of sodium selenite TR activity was significantly higher in HUVEC
compared to BAEC.
5.3.7 A comparison of the protective effect of sodium selenite and
selenomethionine against oxidative damage from t-BuOOH in HUVEC
Selenomethionine was less potent at protecting HUVEC against damage from t-BuOOH (100
pM) then sodium selenite. Figure 5.21 shows a comparison of the protective effects of various
concentrations of sodium selenite and selenomethionine (0, 10, 40, 160, 320, 640 nM) against
oxidative damage from t-BuOOH (100 and 200 pM).
HUVEC cultured in the presence of all the concentrations of sodium selenite tested (10, 40, 160,
320, 640 nM) were significantly less sensitive to the cytotoxic effects of 100 pM t-BuOOH
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compared to HUVEC cultured in selenium-deficient medium (figure 5.21). Also, at all
concentrations of sodium selenite tested the protective effect was near maximal with LDH
activity retention at approximately 90.0%. As observed in previous experiments in section 5.3.3,
sodium selenite did not exhibit a protective effect against 200 pM t-BuOOH, though the
sensitivity to this dose of t-BuOOH was significantly augmented at ail concentrations of sodium
selenite tested (p<0.05).
In contrast in the same preparation of HUVEC, cultured in the presence of selenomethionine
(10, 40, 160, 320, 640 nM), no indication of a protective effect against damage from either dose
of t-BuOOH (100 and 200 pM) was observed. At each concentration of either sodium selenite or
selenomethionine tested a significant difference between the % LDH response to 100 pM t-
BuOOH was found (p<0.001) between selenite and selenomethionine-treated cells .
The second experiment comparing the protective effects of sodium selenite with
selenomethionine was carried out using exactly the same procedure on a different preparation of
HUVEC but using a different stock of selenomethionine. This experiment again demonstrated
that selenomethionine was less potent at protecting HUVEC against damage from t-BuOOH
(100 pM) than sodium seienite (figure 5.22). However on this occasion the sensitivity to 100 pM
t-BuOOH was significantly attenuated at 640 nM selenomethionine resulting in a LDH activity
retention of 82.1 ± 5.4% (mean ± SD, n=3). At this concentration no significant difference
between the protective effect of sodium selenite and selenomethionine was found.
The other contrasting features of these two experiments include the different sodium selenite
concentrations at which a significant protective effect against 100 pM t-BuOOH was observed. In
the first experiment 10 nM sodium selenite produced a significant protective effect against 100
pM t-BuOOH whilst in the second 40 nM sodium selenite produced a significant response. Also
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the increase in sensitivity to 200 pM t-BuOOH observed was shown to be significant in the
second experiment with the exception of 160 nM selenomethionine (p<0.05).
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Figure 5.01. %LDH activity retained in HUVEC incubated with various concentrations of
tert-butylhydroperoxide (t-BuOOH) for 48 hr. Confluent cultures of HUVEC grown in
selenium-sufficient medium were incubated in various concentrations of t-BuOOH (0, 50, 60,
70, 80, 90, 100, 500 pM) for 48 hr. Results shown are the mean of triplicate wells ± SD. Results





Figure 5.02. Autoradiograph of an SDS-PAGE gel showing the expression of [75Se]-
selenoproteins in human umbilical vein endothelial cells (HUVEC) incubated in the
continued presence of tert-butylhydroperoxide (t-BuOOH). Confluent cultures of HUVEC
were pre-labelled for 48 hr with 0.02 MBq/ml [75Se]-selenite. The effects of t-BuOOH (90 pM)
on the expression of [75Se]-selenoproteins was studied by including t-BuOOH in the culture
medium for 48 hr in the continued presence of 0.02 MBq/ml [75Se]-selenite. Lanes 1 and 2, no
additions; lanes 3 and 4, t-BuOOH (90 pM). Each lane was loaded with 25 pg of protein. TR,
thioredoxin reductase; cyGPX, cytoplasmic glutathione peroxidase; phospholipid hydroperoxide
glutathione peroxidase, PHGPX.
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Figure 5.03. %LDH activity retained in HUVEC incubated with various concentrations of
tert-butylhydroperoxide (t-BuOOH) for 20 hr. Confluent cultures of HUVEC grown in
selenium-deficient medium were incubated in various concentrations of t-BuOOH (0, 75, 150,
300 gM) for 20 hr. Results shown are the mean of triplicate wells ± SD. Results^which are




Figure5.04.Theeffectofsodiumelenitet ns ivityHUVECtert-butylhydroperoxide(t-B OOH)ind c dc lldamag . HUVECweresub-culturedintoelenium-defici ntmedi mcontainingdiff r no centrat o ss len te(0,402 0,1 0nM).A confluenceHUVECwereincubatedthabsenpres f-BuOOH(100M).Aft r2h llvi bi ityss ssedbydet rmining% LDHactivityretained.Resultsshownrthmeaofriplic tew l±SDs lhichignificantlyd ffe e tf msel niu -deficie tc r denotedasfollows:-p<0.001.OnfurexperimentsnHUVEC.
[sodiumselenite]nM






















bidOpMt-BuOOH ■100pMt-BuOOH 11200pMt-BuOOH □300pMt-BuOOH
Figure5.06.Theeffectofsodiumel nitet nsitivityHUVECtert-butylhydroperoxide( -BuOOH)-i duc dc lldamage. HUVECweresub-culturedintoelenium-deficientmedi mcontainingdiff rentonc ntrat onss len t(0,1460nM).Ac nflu ce HUVECwereincubatednthpresenceofdiff r ntconc nt ationst-BuOOH(0,1 0,23 M).Aft rllvi bilityasassessedby determiningthe%LDHactiv tyr tained.Resultsshownrmeaoftriplic tew l±SD.hichignif ca tlyd ffe e tf o selenium-deficientcellsardenot dsfollows:-p<0.00l"\O rxperimentsus gHUVEC.
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Figure5.07.Theexpressionandctivityofthrsele oprotei siHUVECc l ur dselenium- eficientm diumonta ningdiff concentrationsfsodiumel nite.HUVECwersub-cul uredins lenium-deficientm d mco tainingdiff rc centrat o sso iu selenite(0,14600nM).AconfluenceHUVECwerharv st da dthssayf ;)t i r doxinred c ase(TR)ct vity;bTm s cytoplasmicglutathioneperoxidas(c GPX)ac v ty;d)phosph lipidhydr erox deglut thioneperoxidas(PHGPX)acti ty.R ulsh wn themeariofriplic teflasks±SD.Re ul swhichresignificantlydiff rentromeleni m-deficientc lad not dfoll ws:-p<0.05*.p<1 p<0.001***.Oneoff urexperimentsusi gHUVEC.
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Figure5.08.Theffectofsodiumelenitet ns ivityHUVECtert-butylhydroperoxide( -B OOH)ind cc lldamag . HUVECweresub-culturedintoselenium-deficientmedi mconta ningdiff reconcent ationsil n t(0,1540nM).Aflu nce HUVECwereincubat dthepres nceofdiff r ntconc nt ations-BuOOH(0,1 0,2 M).Aft r0llvi bi itysassessedby determiningthe%LDHactiv tyretained.R sultsshownrmeaoftriplic tew l±SD.lh chignif ca tlyd ffere tf o selenium-deficientc llsardenot dsfollows:-p<0.001O rxperimentsus gHUVEC.
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Figure 5.09. Thioredoxin reductase (TR) activity and mass in HUVEC cultured in
selenium-deficient medium containing different concentrations of sodium selenite.
HUVEC were sub-cultured into selenium-deficient medium containing different
concentrations of sodium selenite (0, 1, 5, 10, 40 nM). At confluence HUVEC were
harvested and assayed for; a) TR activity; b) TR mass. Results are shown as triplicate flasks
± SD. Results which are significantly different from selenium-deficient cells are denoted as















Figure5.10.Theeffectsofsodiumel ni et ns ivityHUVECtert-butylhydroperoxide(t B OOH)ind c dc lldamag . HUVECweresub-culturedintoelenium-deficientmedi mcontainingdiff r no centrat o ss len te(0,15,10,46M).A confluenceHUVECweretreat dithdiffer tnc ntrationsft-BuOOH(0,100,20pM).Aft rh ,llviabi ityasassessedbyd t m ng the%LDHactivityretainedbycells.Resultsshownrmeaoftriplic tew l±SDlh chignificantlyd ff ref om selenium-deficientcellsardenot dsfollows:-p<0.001*".O rxperimentsus gHUVEC.
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Figure 5.11. Thioredoxin reductase (TR) activity and mass in HUVEC cultured in
selenium-deficient medium containing different concentrations of sodium. HUVEC
were sub-cultured into selenium-deficient medium containing different concentrations of
sodium selenite (0, 1, 5, 10, 40, 160 nM). At confluence HUVEC were harvested and
assayed for; a) TR activity and b) TR mass. Results are shown as triplicate flasks ± SD.
Results which are significantly different from selenium-deficient cells are denoted as
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Figure5.12.Theeffectsofsodiumel nitets ns ivityHUVECtert-butylhydroperoxide( -B OOH)aeith rprio- BuOOHtreatmentorthsa eims-BuOOHtr t .HUVECwers b-cul uredintoei h relenium-deficientedi mconta ning differentconcentrationsfsodiumlen te(0,51 ,40,60M)rselenium-deficientm diumw thoad itions.Aco flu ceth iu removedfromallHUVECndplacwithmediumco tainings ielen tencen rations(0,51460M)t-BuOOH10f r 20hr.Controlcellsreceivedt-BuOOHrsel niumupplementation.R sultshownahm aftrip ic ew l±SD.l sh ch significantlydifferentfromsel nium-deficientcellsaenot dsfollows:-p<0.001***.
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Figure5.14.Theexpressionandctivityofthrsele oprotei shumacoronarya t rndo h l lc lls(HCAEC)ltured selenium-deficientmediumcontai ingdiff r nc ncentrationsso il n te.HCAECwersub-culturedinselenium-deficie t mediumcontainingdiff re toncentrationsfs ilenite(0,15460M).Aco fl e ceHCAECw rharv stedthass y) thioredoxinreductase(TR)activ ty;b)Tma scytoplasmicglut thio ep roxidas(c GPX)ac ivity;dphosph lipidhydroperoxidegl tat on peroxidase(PHGPX)activity.Resulreshownsthme ftripl c tfl sks±SDR ul swhichrsign ficantlyd ff tfr msel iu - deficientcellsarnotedsfollows:-p<0.05*,p<.0 1** .Nos gnificantdiff nceiPHGPXactivitybetw eHUVECcul ureddiffer concentrationsfsodiumelen tewashow .O etexp rime tsus gHCAEC.
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Figure5.16.Theexpressionandctivityofthrselenoproteinsihumaco onarrnd th l alll(HCAEC)cult ed selenium-deficientmediumconta ningdiff rentoncentr tionsdil ni e.HCAECw rub-cult r dintos l i - f i t mediumcontainingdiff rentconcentrationsfs iel n te(0,15460nM).Aflu ncHCAECw eharv steda dthssay fora)thi redoxinreductase(TR)ctivity;bTmasscytoplasmicglutathionep r xidc GPX)dphos h lip dhydrop roxide glutathioneperoxidas(PHGPX)ac iv ty.Resulresh wstmeaofri lic tefl k±SD.wh chignif cantlydiff rentm selenium-deficientc llsardenot dsfollows:-p<0.05*,p<.0 1*"*.Nsig ificantiff reni yGPXctivi ybetHCAECultur differentconcentrationsfsodiumel nitewashow .Ot oexpe imentusi gHCAEC
Figure5.17.Theeffectsofsodiumel nitet ns ivityfb vaor icndothelialc lls(BAEC)tert-b tylhydroperoxide- BuOOH)inducedcelldamage.AECwers b-culturedintoselenium-d ficientdi mcon ainingdiff rc nc ntrat o ssodiumlen te(0,
1,50,460nM).AtconfluenceBAECweretreat di hdiffer ntconc n ationsft-BuOOH( ,1 0,2pM).erh llv abi ityw assessedbydeterminingthe%LDHact vityretainedc lls.R sultshpwrtm aoft iplic tew lls±SDR ulhichre significantlydifferentfromsel ium-deficientcellsadenot dsfoll ws:-p<0.05*,0.01*.Onft oexp rim ntsgBAEC.
Figure5.18.Theffectsofsodiumel nitet nsi ivityb viao ticendoth lialc ll(BAEC)tert-buty hyd operoxide- BuOOH)inducedcelldamage.AECw rsub- ulturedtoselenium-deficientdi mcontainingiff r toncent ationsilen t(0,
1,50,460nM).AtconfluenceBAECweretreat di hdiffer ntc c ntrationsf-BuOOH( ,5p ).ft r2h llviabi itys assessedbydeterminingth%LDHctiv tyr tainec lls.R ultshownrmeaoftriplic tew l±SD.s lh cha significantlydifferentfromel nium-deficie tcellsadenot dsfoll ws:-p<0.001***.Ot oxperimentsu i gBAEC
Figure 5.19. Thioredoxin reductase (TR) activity in bovine aortic endothelial cells (BAEC)
Cultured in selenium-deficient medium containing different concentrations of sodium
selenite. BAEC were sub-cultured into selenium-deficient medium containing different
concentrations of sodium selenite (0, 1, 5, 10, 40, 160 nM). At confluence BAEC were
harvested and then assayed for TR activity. Results shown are the mean of triplicate flasks ±
SD. Results which are significantly different from selenium-deficient cells are denoted as
follows:- p<0.05*, p<0.01**. One of two experiments using BAEC.
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Figure 5.20. Thioredoxin reductase (TR) activity in bovine aortic endothelial cells (BAEC)
cultured in selenium-deficient medium containing different concentrations of sodium
selenite. BAEC were sub-cultured into selenium-deficient medium containing different
concentrations of sodium selenite (0, 1, 5, 10, 40, 160 nM). At confluence BAEC were
harvested and then assayed for TR activity. Results shown are the mean of triplicate flasks ±
SD. Results which are significantly different from selenium-deficient cells are denoted as
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Figure5.22.Acompa isonftheeffectssodiumel niteandselenom th onine%LDHr ten iiHUVECubjectoxi t v stressfromtert-butylhydroperoxide(t-BuOOH).HUVECw reb-cultureintelenium-d ficientme i mc nta ningdiff ec centratio s eithersodiumelenite(0,10,40,60,3264nM)relenomethionine44 n ).Aco fluencethHUVECwr at di h differentconcentrationsft-BuOOH(0,1 0,2pM)fh .Mediuma dllsw rearv stedalyset rmi eh%LDHvity retained.Resultsshownartmeaoftriplic ew l±SD.lthichignificantlyd ffere tf oms lenium-d ficientc ln ts follows:-p<0.001**Significantdifferencesbet eensodiumelenitea dl nomethio iner ulrindica dy. 1.O ft experimentscomparings diumeleniteandel nomethio ine.
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5.3 DISCUSSION
Studies in vitro have demonstrated that sodium selenite affords resistance to endothelial cells
against oxidative damage (Ochi, Morita and Murota, 1992; Thomas, Geiger and Girotti, 1993).
The results presented here show that HUVEC cultured in selenium-deficient medium
supplemented with sodium selenite (5-40 nM) are significantly protected from the toxic effects of
100 pM t-BuOOH. The protective effect of sodium selenite was observed in all HUVEC tested,
though there was some variability in the concentration of sodium selenite which afforded the
maximal protective response. For example, with one preparation of HUVEC the lowest
concentration of sodium selenite that afforded a significant protective effect against 100 pM t-
BuOOH was 40 nM whereas in another preparation a significant effect was observed as low as 5
nM sodium selenite. Thus HUVEC from different preparations display a variable susceptibility to
t-BuOOH toxicity. These differences are likely to reflect the variability in endogenous antioxidant
defence mechanisms derived from genetic and environmental heterogeneity of these cultured
cells. The enzymatic antioxidant defences of the endothelium include selenoproteins, catalase
and superoxide dismutase, which all work in concert to maintain the cells redox potential
(Michiels, Toussaint and Remade, 1990; Vercellotti et al., 1988). The varied susceptibility to
toxic agents between different isolates of HUVEC and BAEC and passage number within the
same isolate has been previously reported (Harlan et al., 1984).
The ability of sodium selenite to protect against oxidative damage from t-BuOOH exhibited in
HUVEC was markedly similar to that observed in HCAEC. These findings provide further
evidence to support the use of HUVEC as a suitable alternative to HCAEC in the study of the
role of selenium in atherosclerosis. In two experiments carried out on the same preparation of
HCAEC at different passages, 5 nM and 10 nM sodium selenite, respectively, produced
significant protective effects against the cytoxicity from 100 pM t-BuOOH. The difference in
susceptibility of these two passages of cells may reflect differences in endogenous antioxidant
defense mechanisms which can notably change with the age of cultured cells (Harlan et al.,
263
The role of selenium in the prevention of oxidative damage chapter five
1984) or with the state of confluence (Miss M Lewin, personal communication). Ideally the
protective effect of sodium selenite supplementation should have been studied on a number of
HCAEC preparations, but our supply of these cells was limited.
The findings shown here suggest that the protective effect of sodium selenite against oxidative
damage from 100 pM t-BuOOH is more potent in HUVEC and HCAEC compared to BAEC.
Whilst concentrations of between 5 nM and 40 nM sodium selenite afforded maximal protective
effects against t-BuOOH in the HUVEC and HCAEC studied, concentrations of 40 nM and 160
nM sodium selenite protected BAEC only sub-maximally. However, only one preparation of
bovine cells were studied here. Differences in the susceptibility to cytotoxic agents resulting from
both intra- and inter-species variation has been previously reported (Harlan et at., 1984). To
clarify this, experiments need to be repeated using several preparations of BAEC.
Thomas et at. have previously investigated the role of selenoproteins in cytoprotection against 0-
500 pM t-BuOOH damage in BAEC (Thomas, Geiger and Girotti, 1993). They demonstrated that
BAEC cultured in 60 nM sodium selenite were significantly protected against concentrations of t-
BuOOH of up to 500 pM. These findings are very much in contrast to our own which found that
concentrations of sodium selenite up to 160 nM only sub-maximally protected cells against 100
pM t-BuOOH (as indicated by 50% LDH activity retained compared to control cells) and did not
protect at all against higher concentrations of t-BuOOH (200 pM). The clear differences
observed between the findings of this study and those of Thomas et at. may be possibly
explained by the different culture media used. Despite the low selenium status of both media the
different formulations of each may potentially alter the overall antioxidant status of the cell. The
most likely explanation for these differences probably results from the different preparations of
BAEC used. For example, the endothelial cells would have been isolated from different cattle, of
different breeds and age, using possibly different methods of isolation.
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The difference in susceptibility of selenium-deficient and selenium-sufficient endothelial cells to
t-BuOOH was associated with the modification of selenoprotein expression and activity. Our
findings show that t-BuOOH is not directly detoxified by sodium selenite in the culture medium
(figure 5.12) and that selenoprotein expression and activity can be modified by selenium-
supplementation of endothelial cells (figures; 5.05, 5.07, 5.09, 5.11, 5.14, 5.16, 5.19 and 5.20).
The modification of selenoprotein expression and activity through selenium-supplementation in
cell culture systems is widely reported. Berggren et at. demonstrated that supplementation of
HT-29 human colon cancer cells with sodium selenite produced a time and dose-dependent
increase in intracellular thioredoxin reductase (TR) activity and protein levels (Berggren et al.,
1997). Selenium supplementation also enhances also cytoplasmic glutathione peroxidase
(cyGPX) and phospholipid hydroperoxide glutathione peroxidase (PHGPX) activity in endothelial
cells (Ricetti eta!., 1994; Thomas, Geigerand Girotti, 1993).
Our attempts to associate changes in TR activity and mass and cyGPX and PHGPX activity in
HUVEC supplemented with sodium selenite with the protection against 100pM t-BuOOH
observed in selenium-supplemented cells were not fully conclusive. This study demonstrates
that HUVEC cultured to confluence in selenium-deficient medium supplemented with different
concentrations of sodium selenite exhibit a dose-dependent increase in both TR activity and
mass. This effect was generally consistent in all of the preparations of HUVEC studied. The
increase in TR activity and mass consistently occurred at 5 nM sodium selenite. This increase
was significant (p<0.001) in all but one experiment where 40 nM sodium selenite was the
concentration at which TR activity was significantly increased. The concentrations of sodium
selenite which resulted in significant changes in TR activity and mass were similar to those
which afforded a significant protective effect against t-BuOOH.
cyGPX and PHGPX activities were only measured in two of the HUVEC preparations in which
cytoxicity experiments were carried out. Both cyGPX and PHGPX activity exhibited a trend to
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increased activity in response to increasing concentrations of sodium selenite although the
PHGPX response was not always significant. The absolute values of PHGPX activity assay were
generally very small, which may account for poor replication within the assay. The activity of
PHGPX needs to be investigated further using an assay system with greater sensitivity.
Short term selenium-deficiency (20 days) in rats results in a 50% decrease in lung CuZn
superoxide dismutase activity which is not the result of a diet-induced deficiency of either copper
or zinc (Coursin and Cihla, 1996). Therefore the possibility that selenium-deficient cells are more
susceptible to oxidative damage because of a selenium-deficiency-induced decrease in
superoxide dismutase activity cannot be excluded at this stage.
In summary, it is likely that in the range of 5-40 nM sodium selenite (at which protection against
t-BuOOH is generally observed in HUVEC) the activity of TR, cyGPX and PHGPX all change. It
is therefore difficult to determine the relative importance of each of these selenoenzymes in the
protection of HUVEC against t-BuOOH.
As with HUVEC, the cytoxicity of 100 pM t-BuOOH in HCAEC cultured in different
concentrations of sodium selenite could be inversely related to the expression of TR, cyGPX and
PHGPX. In HCAEC cultured in selenium-deficient medium supplemented with sodium selenite,
dose-dependent increases in TR activity and mass were demonstrated. The activity of cyGPX
and PHGPX were either significantly increased or showed a trend towards an increase in
HCAEC cultured in increasing concentrations of sodium selenite. The concentrations of sodium
selenite which increased TR activity and mass and cyGPX activity (i.e. 10, 40 and 160 nM) also
produced a significant protection of HCAEC against 100 pM t-BuOOH.
No TR activity was measurable in BAEC cultured in selenium-deficient medium whereas in both
HUVEC and HCAEC levels of between 1-7 mU/ mg protein were measured under these
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conditions (table 5.01). Although cyGPX and PHGPX were not measured in this particular
preparation of BAEC, we have shown previously that cyGPX and PHGPX activities measured in
BAEC grown in selenium-sufficient medium did not differ significantly from those measured in
HUVEC also grown in selenium-sufficient medium (figures 3.17 and 3.18). This data implies that
the difference in the protective effect of sodium selenite observed between BAEC and HUVEC
may be related to the significantly lower TR activity found in BAEC.
Table 5.01: Thioredoxin reductase activity measured in human and bovine endothelial cells
cultured in selenium-deficient medium. Results shown are the means of triplicate flasks.
CELL TYPE TR ACTIVITY (mU/mg protein)
HUVEC 3.65 2.42 1.36 1.92
HCAEC 6.40 7.21
BAEC 0 0
The findings reported in this chapter are important in that they suggest that, in addition to the
GPX's, TR may also be important in the protection of endothelial cells against oxidative damage,
although, the physiological significance is as yet unclear since t-BuOOH is not an endogenous
mediator of oxidative damage in the endothelium. Future studies will need to assess the effect of
selenium-supplementation on the protection of cultured endothelial cells against oxLDL, an
important endogenous mediator of endothelial cytoxicity and atherogenesis (Nielson, 1999;
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Steinberg, 1991; Witzum and Steinberg, 1991). Thomas et al. have studied the role of
selenoproteins in the protection of endothelial cells against damage from oxLDL, attributing the
protective effect of selenium to the GPX's. The data from this study questions the relevance of
their findings to humans as we have highlighted distinct differences between the endothelial cells
isolated from the two different species.
Studies by Claise et al. compared the cytotoxic effect of oxLDL on both HUVEC and the
endothelial cell line EAhy926 (Claise et al., 1997). EAhy926 cells were found to be significantly
more susceptible to damage from oxLDL than HUVEC, the latter being unaffected by oxLDL
concentrations of up to 200 pg/ml. The higher susceptibility of EAhy926 cells to oxLDL
cytotoxicity was attributed to the lower antioxidant defenses of these cells compared to HUVEC,
particularly as regards the cyGPX activity which was 8% of that of HUVEC. Our studies also
found a lower cyGPX activity in EAhy926 cells. The cyGPX activity in our cells was only 27% of
that found in HUVEC which may be accounted for by differences in selenium bioavailability in the
culture media used for each cell type (see section 3.4). Despite these differences TR activity and
mass and PHGPX activity were shown not to be significantly different. Claise's group did not
measure the activities of either TR or PHGPX. Therefore, if EAhy926 cells are more susceptible
to damage from oxLDL as reported by Claise et al. our data would argue against a protective
role for TR and PHGPX. Recently data from this laboratory has shown no significant difference
in susceptibility to t-BuOOH-induced damage, between HUVEC and EAhy926 cells (Miss M
Lewin, personal communication). This would suggest that cyGPX activity is not important in the
protection of EAhy926 cells against damage from t-BuOOH.
The pro-oxidant status of sodium selenite at pM concentrations is well documented in both in
vivo and in vitro studies (Dougherty and Hoekstra, 1982; Stewart eta/., 1999; Yan and Spallholz,
1993). However there is no data published to date on the ability of sodium selenite to induce cell
toxicity at nM concentrations. Our findings show a dose-dependent increase in sensitivity to 200
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pM t-BuOOH when both HUVEC and HCAEC were cultured with increasing concentrations of
sodium selenite. This response is likely to be a consequence of sodium selenite acting as a pro-
oxidant, whereby the antioxidant capabilities of the cells are insufficient to protect against the
oxidative stress resulting from the combined insults of both t-BuOOH and sodium selenite.
In the study by Rafferty et al. the chemical form of selenium added to cells was shown to be an
important factor in determining the ability of selenium to afford protection from ultraviolet B
radiation in skin cells (Rafferty et al., 1998). Our results are in agreement with the findings of this
study, demonstrating that sodium selenite is more potent than selenomethionine in conferring
protection against t-BuOOH in cultured HUVEC. This difference possibly reflects the different
abilities of each compound to modify selenoprotein status. Indeed Berggren et al. have
previously shown that L-selenomethionine favoured a smaller change in TR activity, than sodium
selenite in HT-29 human colon cancer cells (Berggren et al., 1997). Therefore inorganic forms of
selenium such as sodium selenite may provide a more bioactive form of the selenium
supplementation than organic forms such as selenomethionine. An alternative explanation is
that L-methionine present in the culture (15 mg/L) may compete with the selenomethionine for
its selenium. In rats utilization of dietary selenomethionine was shown to be inversely correlated
to methionine uptake (Waschulewski and Sunde, 1988). Consequently the possibility exists that
there is less selenomethionine uptake by the cell resulting in a lesser effect. This possibility
could be further investigated with the use of a methionine-free M199 medium.
Previous studies have suggested that the GPX's are the important selenoproteins which protect
endothelial cells against harmful hydroperoxides which cause oxidative damage (Claise et al.,
1997; Hara, 1998; Ochi, Morita and Murota, 1992; Thomas, Geiger and Girotti, 1993). To date
no such studies have suggested that TR may be important in this regard. Our results argue that
TR maybe important in antioxidant protection. In both HUVEC and HCAEC, the concentrations
of sodium selenite which afford a protective effect against the cytoxicity of t-BuOOH are those
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which significantly increase TR activity and mass. Also, the incubation of HUVEC with t-BuOOH
(90 pM) increases the expression of TR without affecting the expression of the other
selenoproteins such as cyGPX or PHGPX.
The relative importance of TR, cyGPX and PHGPX in the protection of endothelial cells against
oxidative damage from t-BuOOH is unknown at present. Previous literature suggests that, in
BAEC, cyGPX is expressed at much higher relative amounts than PHGPX and is more potent at
reducing t-BuOOH (Thomas, Geiger and Girotti, 1993). A comparison of the apparent rate
constants for peroxide substrates indicated that PHGPX was approximately one tenth as active
as cyGPX against t-BuOOH (Maiorino, Gregolin and Ursini, 1990). Kinetic data is consistent with
cyGPX and PHGPX having potentially different roles. In the aqueous phase the reaction of
cyGPX with peroxidases is favoured over PHGPX. However, our studies have shown that the 22
kDa selenoprotein (which we characterized as PHGPX) has a much higher relative abundance
than cyGPX in BAEC (figure 3.15).
Future studies might include assessing the ability of cells to resist oxidative stress after cells are
treated with specific antibodies to TR or other candidate antioxidant selenoproteins.
LDH retention, which quantitates cell death, was used as a measure of cell viability in this thesis.
Ideally, LDH retention should be used in tandem with an alternative measurement of cell viability
in order to validate the results. The trypan blue exclusion assay, MTT and neutral red assay etc.
have all been previously used to quantitate cytoxicity. The more sensitive markers of cell
viability, such as the metabolic activity of the cell, provide an appropriate test to use in
conjunction with LDH retention.
In conclusion, the protective effect of sodium selenite observed in human endothelial cells is
likely to be through the modification of selenoprotein expression rather than a direct antioxidant
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effect of sodium selenite. The findings of this study have shown that, in addition to the GPX's,
TR may also have an important antioxidant function in the human endothelium, a possibility
which has not been previously considered. Our studies were not able to conclusively establish
the relative importance of each of the selenoproteins in the protection of the human endothelium
against oxidative damage though it is likely that TR, cyGPX and PHGPX all contribute. Under
pathological conditions it is possible that one particular selenoprotein however may become
more important. Our studies have highlighted the lack of suitability of BAEC as a model for the
study of selenoprotein expression and protection from oxidative stress.
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CHAPTER SIX CONCLUDING REMARKS
Atherosclerosis is the principle cause of morbidity and mortality of man in Western society. Low
plasma selenium levels have been associated with an increased risk of cardiovascular disease
including coronary atherosclerosis (Kok et a!., 1991; Salonen et ai, 1982; Suadicani, Hein and
Gyntelberg, 1992). Damage to the endothelium by reactive oxygen species has been shown to
favour atherogenesis. Cell culture studies have demonstrated that selenium supplementation
confers resistance to bovine endothelial cells from damage by reactive oxygen species possibly
through the expression of different antioxidant selenoproteins (Ochi, Morita and Murota, 1992;
Thomas, Geiger and Girotti, 1993). This protection has been attributed to the expression of
intracellular glutathione peroxidases, though the expression of other selenoproteins with
antioxidant properties, such as extracellular glutathione peroxidase, selenoprotein P and TR was
not considered in these studies.
The main objective of this thesis was to identify the selenoproteins expressed by endothelial cells
and to study the modification of their expression through selenium supply and activation of second
messenger systems. The ability of sodium selenite and selenomethionine supplementation to
protect cultured endothelial cells against oxidative damage was also studied in order to establish
their possible anti-atherosclerotic function.
The work in this thesis has provided evidence to demonstrate the following:-
1. There are distinct differences in [75Se]-selenoprotein expression between cells isolated from
different tissues and endothelial cells isolated from different species. In contrast, the
differences in [75Se]-selenoprotein expression observed in endothelial cells isolated from
different human vascular beds and in the human endothelial cell line EAhy926 were less
pronounced.
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2. Whilst no extracellular selenoproteins were secreted by HUVEC, four major and several minor
intracellular selenoproteins were [75Se]-labelled. Of the major bands, the 22 kDa, 24 kDa and
58 kDa selenoproteins were identified as PHGPX, cyGPX and TR respectively, whilst the
fourth major band with a molecular mass of 15 kDa selenoprotein was not identified. TR was
the predominantly expressed selenoprotein in HUVEC accounting for approximately 43% of
the total intracellular [75Se]-labelled selenoproteins.
3. This study has demonstrated that HUVEC, and possibly the human endothelial cell line
EAhy926, could provide a suitable alternative to HCAEC as a cell culture model for the study of
selenium expression in human atherosclerotic disease. In contrast, the distinct differences
observed in selenoprotein expression by endothelial cells isolated from the bovine and porcine
aorta compared to HCAEC suggest that in neither BAEC nor PAEC would provide a suitable
cell culture model for such studies.
4. Selenoprotein expression has been shown to be regulated through specific second messenger
signalling pathways (Beech et at., 1995; Howie et at., 1998; Howie et at., 1995). In HUVEC we
have shown that the phorbol ester PMA, through the activation of PKC, down-regulates the
expression of both TR and PHGPX. In contrast, the expression of cyGPX is increased, which
may be mediated by the decreased intracellular anti-oxidant capacity resulting from the down-
regulation of TR and PHGPX. Since oxLDL has been shown to activate PKC, it is possible that
oxLDL may down-regulate the expression of TR and PHGPX in the endothelium which could
result in an increased susceptibility to oxidative damage and thus the development of
atheroma.
5. The calcium ionophore A23187 was also shown to modify selenoprotein expression. However
these effects are likely to be the result of a toxic effect of A23187 rather than the activation of
the calcium signalling pathway.
273
Concluding remarks chapter six
6. The ability of sodium selenite to protect against oxidative damage from t-BuOOH was
demonstrated in both HUVEC and HCAEC and is likely to be through the modification of
selenoprotein expression rather than a direct antioxidant effect. The relative importance of TR,
cyGPX and PHGPX in the protection of endothelial cells against oxidative stress was not
established.
7. Selenomethionine was considerably less potent than sodium selenite at inducing protection
against oxidative damage from t-BuOOH in HUVEC.
The limitations of the statistical analysis used in this thesis needs to be considered. Both the
unpaired't' test and the ANOVA are parametric tests which assume normal distribution. It was not
possible to test whether this was the case, through the use of a normality test, as the sample size
was too small. The use of parametric tests on small samples is not powerful and if the population
is not Gaussian, the P value can be misleading. Therefore although some p-values give a strong
indication that the differences are significant ideally the sample size should be increased.
The protection afforded by sodium selenite against the toxic effects of t-BuOOH may not be widely
applicable, as in addition to being a non-physiological oxidative agent, it is also a cyGPX
substrate. As such, the upregulation of cyGPX may be a response to an increase in substrate
availability. However, previous studies have demonstrated a protective effect of selenium against
oxidative damage from UV radiation and menadione treatment in human skin cells. Further
studies of interest would be to establish the relative importance of each antioxidant selenoprotein
in the protection of endothelial cells against oxidative stress from oxLDL, (15S)-HPETE and
possibly menadione. TR has not been previously implicated in the protection of endothelial cells
against oxidative stress. Human endothelial cells express high levels of TR, which can be
modified by selenium supply, PKC activation and oxidative stress. Thus TR may be central to the
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P1 65 THIOREDOXIN REDUCTASE EXPRESSION IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS
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Damage to the endothelium by reactive oxygen species, free radicals, oxidised lipids and lipoproteins favours
atherosclerosis. Such damage can be prevented by selenium (Se) which is thought to exert its actions through the
expression of intracellular and extracellular selenoproteins. The family of glutathione peroxidases (GPX) may
have antioxidant roles in the endothelium but other intracellular and extracellular selenoproteins with antioxidant
actions may also be important.
We studied the selenoproteins expressed in vitro in cultured human umbilical vein endothelial cells (HUVECS).
HUVECS were labelled with 7 Se-selenite and the labelled selenoproteins separated using SDS-PAGE. No
extracellular selenoproteins were secreted by HUVECS. The intracellular selenoprotein profile of 75Se-
labelled HUVECS was quite distinct from that observed in other tissues. A single selenoprotein with a
molecular mass of 58kDa accounted for approximately 36% of the intracellular 75Se-labelled proteins in
HUVECS and this was identified by western blotting as thioredoxin reductase (TR). Treatment with the
calcium ionophore A23187 (0.5xl0"6M) increased TR expression 8.45-fold over basal, whilst the phorbol ester
phorbol-12-myristate 13- acetate (O.SxlCT^M) decreased TR expression 3-fold compared to basal.
HUVECS express high levels of TR and this expression is under the regulation of the calcium /
phosphoinositol signalling cascade. In vitro this selenoenzyme appears to be more potent than the GPX's at
detoxifying hydrogen peroxide and harmful lipid hydroperoxides. TR expression may be an important factor in
the known ability of Se to protect HUVECS from oxidative damage.
This study was supported by the British Heart Foundation (Grant No. PG/96017).
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Thioredoxin reductase is the major selenoprotein expressed in human
umbilical-vein endothelial cells and is regulated by protein kinase C
Sue M. ANEMA*1, Simon W. WALKER*, A. Forbes HOWIE*, John R. ARTHURt, Fergus NICOLt and Geoff J. BECKETT*
•Department of Clinical Biochemistry, University of Edinburgh, The Royal Infirmary, Edinburgh EH3 9YW, U.K., and tRowett Research Institute, Bucksburn,
Aberdeen AB21 9SB, U.K.
Damage to the endothelium by reactive oxygen species favours
atherogenesis. Such damage can be prevented by selenium, which
is thought to exert its actions through the expression of seleno¬
proteins. The family of glutathione peroxidases (GPXs) may
have antioxidant roles in the endothelium but other intracellular
and extracellular selenoproteins with antioxidant actions may
also be important. The selenoproteins expressed by cultured
human umbilical-vein endothelial cells (HUVECs) were labelled
with [75Se]selenite and separated using SDS/PAGE. HUVECs
secreted no extracellular selenoproteins. There were distinct
differences between the intracellular selenoprotein profile of 7r,Se-
labelled HUVECs and those of other tissues. A single seleno¬
protein with a molecular mass of 58 kDa accounted for approx.
43 % of the intracellular 75Se-labelled proteins in HUVECs. This
protein was identified by Western blotting as the redox-active
lipid-hydroperoxide-detoxifying selenoprotein, thioredoxin re¬
ductase (TR). TR expression in HUVECs was down-regulated
by transiently exposing cells to the phorbol ester PMA for
periods as short as 1 min. However, there was a delay of 48 h
after PMA exposure before maximal down-regulation ofTR was
observed. The protein kinase C (PKC) inhibitor bisindolyl-
maleimide I hydrochloride had no effect on TR expression when
added alone, but the agent prevented the down-regulation ofTR
expression seen with PMA. The calcium ionophore A23187
increased TR expression in HUVECs after a 12-h exposure, but
the maximal effect was only observed after a 35-h exposure.
These findings suggest that TR may be an important factor in the
known ability of Se to protect HUVECs from peroxidative
damage. Furthermore, the results also suggest that TR expression
can be negatively regulated through PKC. It is possible that TR
expression may be positively regulated by the calcium-signalling
cascade, although TR induction by A23187 may be due to
toxicity.
Key words: atherogenesis, endothelium, oxidative damage, sel¬
enium.
INTRODUCTION
The endothelium of the vascular system regulates vessel tone,
smooth-muscle proliferation and blood coagulability. Damage
to the endothelium by reactive oxygen species, free radicals and
oxidized lipids and lipoproteins favours atherogenesis [1]. Sel¬
enium is essential for the expression of several peroxidase and
redox enzyme systems, which protect cells from oxidative stress
and, as shown in vitro, selenium supplementation can protect
human endothelial cells (ECs) from oxidative injury [2]. A
possible mechanism for this protection is through the selenium-
containing glutathione peroxidase (GPX) enzyme family [2],
Indeed, treatment of human ECs with selenium enhances GPX
activity [3,4], Furthermore, the activity of GPX in human ECs is
induced by « — 3 polyunsaturated fatty acids, which may have a
role in the prevention of vascular disease [5].
Selenium exerts many of its effects through the expression of
both extracellular and intracellular selenoproteins [6]. At least 30
such selenoproteins have been identified by SDS/PAGE of 7r'Se-
labelled tissue, but only approx. 12 have been characterized by
purification and cloning. The intracellular selenoproteins identi¬
fied to date that are most likely to protect against oxidative
damage include cytoplasmic GPX (cyGPX), phospholipid hydro¬
peroxide GPX (PHGPX) and thioredoxin reductase (TR).
Extracellular selenoproteins, including extracellular GPX
(EGPX) and selenoprotein P, are secreted by many tissues and
may also have an antioxidant action. It is not known if ECs
synthesize and secrete these extracellular selenoproteins,
although selenoprotein P is associated with vascular ECs in
brain, capillary ECs in the renal glomeruli and ECs of the liver
[7].
The expression of some selenoenzymes is regulated through
second-messenger systems. For example, in human thyrocytes
and in the human fetal liver cell line, HepG2, the expression of
TR is greatly increased by the addition of the calcium ionophore
A23187 and PMA [8]. In contrast, EGPX secretion is inhibited
by A23187, whereas PMA has little or no effect [9]. These
observations have led to the suggestion that the Ca2+/
phosphoinositol signalling cascade may be an important modu¬
lator of selenoprotein expression in certain tissues [8]. Such
studies have not been performed in ECs, although phorbol ester
has been reported to increase cyGPX mRNA levels in human
umbilical-vein endothelial cells (HUVECs) [10].
Labelling with [75Se]selenite demonstrates clear tissue
differences in the pattern of selenoprotein expression [11] but
little information of this nature is available for ECs. Although
studies in vitro have found that selenite supplementation confers
resistance on ECs to oxidative injury, the mechanisms by which
selenium acts are not clear [2]. Resistance to oxidative damage
may arise from increased expression of cyGPX and PHGPX [2],
but the expression of other selenoproteins with antioxidant
properties, such as TR, EGPX and selenoprotein P, was not
investigated. Here we describe experiments performed to examine
the range of intracellular and extracellular selenoproteins labelled
Abbreviations used: HUVECs, human umbilical-vein endothelial cells; TR, thioredoxin reductase; PKC, protein kinase C; EC, endothelial cell; GPX,
glutathione peroxidase; cyGPX, cytoplasmicGPX; PHGPX, phospholipid hydroperoxide GPX; EGPX, extracellularGPX; EBS, Earle's balanced salt solution;
GF109203X, bisindolylmaleimide I hydrochloride; (15S)-HPETE, (15S)-hydroperoxy-(5Z),(8Z),11(Z),13(£)-eicosatetraenoic acid; EGM-2, endothelial-cell
growth medium 2; DMEM, Dulbecco's modified Eagle's medium.
1 To whom correspondence should be addressed (e-mail sue@srv1.med.ed.ac.uk).
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by [7r,Se]selenite and report on the effects that PMA and A23187
exert on the expression of TR.
EXPERIMENTAL
Materials
Endothelial-cell growth medium 2 (EGM-2) bullet-kit and
endothelial-cell basal medium (EBM-2) were both supplied by
BioWhittaker UK (Wokingham, Berks., U.K.). Earle's balanced
salt solution (EBS), Ml99, Dulbecco's modified Eagle's medium
(DMEM)/Ham's F-12 nutrient mix, fetal bovine serum, glut-
amine, penicillin, streptomycin, amphotericin B and Ca2+- and
Mg2+-free Hanks balanced salt solution were obtained from Life
Technologies (Paisley, Scotland, U.K.). Collagenase was pur¬
chased from Worthington Biochemicals via Lome Laboratories
(Twyford, Berks., U.K.). [7r'Se]Selenite (specific radioactivity,
16 MBq/nmol) was obtained from the Reactor Center, Univer¬
sity of Missouri (Columbia, MO, U.S.A.). Low-range SDS/
PAGE molecular-mass standards were purchased from Bio-Rad
(Hemel Hempstead, Herts., U.K.). EDTA was supplied by
Boehringer Mannheim UK (Lewes, East Sussex, U.K.). Glycerol
and poly(ethylene glycol) were both purchased from Merck
(Lutterworth, Leics., U.K.). Antisera to human and rat TR were
raised in rabbits to TR purified from rat liver and human placenta
as described previously [8,12], Bisindolylmaleimide I hydrochlor¬
ide (GF109203X) was supplied by Calbiochem Novabiochem
UK (Nottingham, U.K.). Antisera to rat PHGPX were raised
in rabbits to PHGPX purified from rat liver. Antiserum to human
cyGPX was obtained from The Binding Site (Birmingham,
U.K.). Sigma (Poole, Dorset, U.K.) supplied all other reagents.
Isolation and culture of HUVECs and human thyrocytes
Human umbilical cords (>100 mm in length) were obtained at
normal deliveries or Caesarean sections from non-smoking
women. Immediately after delivery, the cords were placed into
sterile EBS containing penicillin (100 units/ml), streptomycin
(100 //g/ml) and amphotericin B (2.5 //g/rnl) at 4 °C. ECs were
isolated within 20 h of delivery using a method adapted from
that described previously by Jaffe et al. [13]. Briefly, the umbilical
vein was cannulated with a Venflon (17 gauge, 45 mm) and
the vein was washed with 100 ml of EBS (pre-warmed to 37 °C).
One end of the vein was clamped shut and the opposite end
infused with 0.07% (w/v) collagenase in EBS (5-15 ml). The
cord was then incubated at 37 °C in an atmosphere of 5 %
C02/95 % air. After 10 min the cord was removed and massaged
gently, and the contents of the umbilical vein were flushed out
with 30 ml of Ca2+- and Mg2+-free Hanks balanced salt solution.
The resulting cell suspension was collected, centrifuged at 450^
for 10 min and the pellet washed once with EGM-2 containing
penicillin (100 units/ml), streptomycin (100//g/ml) and amph¬
otericin B (2.5 ytg/ml). The cells were resuspended in 15 ml of
EGM-2, plated out into one 75-cm2 flask and cultured at 37 °C
in an atmosphere of 5 % CO,2/95 % air.
After 24 h, and then on alternate days, the culture medium was
changed and replaced with a further 15 ml of EGM-2. Cells
reached confluence in 3-7 days, and were then subcultured as
required, seeding at a density of approx. 3000 cells/cm2.
HUVECs were identified by their cobblestone appearance under
phase-contrast microscopy and by the presence of factor-VHI-
related antigen detected by a specific antibody using immuno-
fluorescent microscopy.
Human thyrocytes were isolated as described previously using
thyroid tissue (surplus to routine histopathological examination)
obtained from a patient with Graves' disease [14,15].
Maintenance of HepG2 cell line
HepG2 cells, a human fetal liver-derived cell line, were obtained
from the European Collection ofCell Cultures (Salisbury, Wilts.,
U.K.) and maintained in DMEM/Ham's F-12 nutrient mix plus
L-glutamine and 15 mM Hepes containing 5 % (v/v) fetal bovine
serum. The cells were cultured in 75-cm2 culture flasks and
incubated at 37 °C in an atmosphere of 5 % C02/95 % air.
Monitoring selenoprotein expression
Intracellular and extracellular selenoproteins expressed by
HUVECs were detected by labelling cells with [75Se]selenite
as described previously for thyrocytes [9], Labelling with
[7r'Se]selenite provides a reliable, precise and sensitive method for
assessing the expression of selenoproteins, where the incor¬
poration of 7r'Se is directed to specific selenocysteine residues by
a UGA codon. However, equilibration ofexogenous [75Se]selenite
with the endogenous pool of selenium and selenoproteins can
take in excess of 27 h [16] and therefore cells are usually labelled
for between 32 and 48 h to ensure that a steady state of labelling
has been achieved. If it is required to examine changes in
selenoprotein expression over short time periods it is essential to
use cells pre-labelled with [7r'Se]selenite. In the time-course
experiments described in this article, cells pre-labelled for 48 h
with [7r'Se]selenite were used. The mass of exogenous selenium
present in the culture medium was maintained at adequate levels
over the labelling period by using media containing selenite at a
concentration of 30 nM.
Therefore, to investigate intracellular selenoprotein expression
in the steady state, confluent cultures of HUVECs or other cell
types were incubated for 48 h with EGM-2 (which contains
30 nM selenite) in the presence of 0.02 MBq/ml [75Se]selenite.
After labelling, the culture medium was removed and the cells
were washed three times with EBS and harvested into 20 ml of
EBS by scraping followed by centrifugation at 2000 ^ for 10 min.
The cells were resuspended in 1 ml of 60 mM Tris buffer, pH 7.8,
containing 1 mM EDTA and 1 mM dithiothreitol and lysed by
sonication at 4 °C.
After dilution to a common final protein concentration, the
HUVECs were diluted 2:1 with 'boiling mix' (35 mM SDS/
1.4 mM glycerol/0.3 mM 2-mercaptoethanol/15 mM Bromo-
phenol Blue) and heat-treated at 90 °C for 10 min.
To monitor the extracellular selenoprotein expression,
HUVEC cultures were incubated for 48 h in the presence of
0.02 MBq/ml [7r'Se]selenite. The culture medium was changed
from EGM-2 to protein-free EBM-2 for the last 18 h of the
incubation period, but the [75Se]selenite concentration was main¬
tained throughout.
After the final 18-h labelling period, the culture medium was
removed, centrifuged at 2000 g for 20 min and dialysed over 2
days to remove the unbound [7r'Se]selenite. Dialysis was against
2 litres of 60 mM Tris buffer, pH 7.8, containing 1 mM EDTA
and 1 mM dithiothreitol at 4 °C (which was changed four times
over the 2-day period). The dialysed solution was then concen¬
trated by placing the dialysis sac into a saturated solution of
poly(ethylene glycol) prepared in the dialysis buffer. The protein
content of the dialysed medium was then measured and the
medium treated with boiling mix as described above.
The [75Se]selenoproteins present in 25 /tg of protein in the
HUVECs and in 12.5 /ig of protein in the culture medium were
separated by SDS/PAGE on a 12% gel, the resulting gel was
dried and the 7r'Se-labelled selenoproteins were visualized by
autoradiography using Kodak X-OMAT XAR-5 film.
The gels were scanned using a Bio-Rad model GS-525 Mol¬
ecular Imager System to create a digitized image. The radio-
© 1999 Biochemical Society
Thioredoxin reductase in human umbilical-vein endothelial cells 113
activity in each band was quantified using the Bio-Rad Molecular
Analyst/PC image-analysis software. The data were presented as
a percentage of the total intracellular "Se-labelled proteins
expressed. Quantification ofTR in the Western blots was carried
out on an EpsonGT-9500 scanner using Phoretix software.
The intracellular selenoproteins expressed by human thyro-
cytes and HepG2 cells were determined in an identical fashion
to the HUVECs.
To investigate the changes in selenoprotein expression that
occurred over time in response to various agents, HUVECs pre-
labelled to a steady state with [75Se]selenite (0.02 MBq/ml) for
48 h were used. Monitoring of selenoprotein expression in these
cells was then carried out as described above. These experiments
are described in detail below.
Western-blot analysis
Proteins (20//.g per sample) resolved by SDS/PAGE were
transferred to Immobilon P membranes that were then blocked
using 10% (v/v) horse serum in 0.025 M Tris buffer/0.5M NaCl
(pH 7.5) containing 0.05% (v/v) Tween before being probed
with affinity-purified anti-rat TR antibody at a final dilution of
1:500. Chemiluminescence was used to visualize the immuno-
reactive proteins [8].
Previous studies that we have performed with this antiserum
and the purified 58-kDa selenoprotein isolated from 7r'Se-labelled
HepG2 cells confirmed that the antiserum reacted with TR and
not another protein of similar molecular mass [8]. Western
blotting for PHGPX was performed as for TR, using an antibody
raised to rat testes PHGPX.
Changes in expression of the 58-kDa selenoprotein in HUVECs
following exposure to PMA and A23187 for different times
Selenoprotein expression in cells can be modified by PMA and
A23187 [8,9], Whereas these agents may produce a rapid effect
on signalling systems in the cell, the changes in selenoprotein
expression that they elicit may only be observable after several
hours. The following experiments were performed to determine
(i) the time at which maximal changes in the expression of the 58-
kDa selenoprotein occur when HUVECs are exposed continually
to PMA and A23187 and (ii) the influence of short 'pulsed'
exposure times to PMA and A23187 on the subsequent maximal
changes observed in the expression of the 58-kDa selenoprotein.
To investigate (i) above, confluent cultures of HUVECs were
pre-labelled to a steady state for 48 h in the presence of EGM-2
containing 0.02 MBq/ml [75Se]selenite. The culture medium was
then removed and replaced with a further 15 ml of medium
containing 0.02 M Bq/rnl [7r,Se]selenite to ensure that nutrient
and selenium supply were not exhausted. The effect of PMA
(0.5 x 10~"M) or A23187 (0.5 x 10"'' M) on the expression of the
58-kDa selenoprotein was studied by including the compounds
in the culture medium for 1 rnin, 12 h, 24 h, 48 h, 72 h or 96 h in
the continuing presence of 0.02 MBq/ml [75Se]selenite. The
timing of the additions were made to ensure that the cells for
each data point were harvested immediately at the end of the
drug-incubation period and at the same overall time point (i.e.
after a total culture time of 146 h, which includes the 48-h pre¬
incubation interval). After harvesting the HUVECs, the intra¬
cellular [7r'Se]selenoproteins were monitored as described
above.
The concentrations of PMA and A23187 were selected on the
basis of previous studies, which had shown optimal effects of
these agents on the expression of the 58-kDa selenoprotein
(results not shown).
To address (ii) above, confluent cultures of HUVECs were
used that had been pre-labelled to a steady state with [75Se]selenite
(0.02 MBq/ml) for 48 h. The addition of PMA (0.5 x 10~B M) or
A23187 (0.5 x 10~6 M) was then made to these pre-labelled cells
for 1 min, lOmin, 1 h or 12 h in the continued presence of
["Sejselenite (0.02 MBq/ml). Additions were made at the same
time and after each time point the culture medium was removed
and the cells were washed. Fresh culture medium containing
[7r'Se]selenite (0.02 MBq/ml) but without PMA or A23187 was
then added and the cells were incubated for a total incubation
time of either 48 h in the case of PMA or 35 h in the case of
A23187. These total incubation times were selected because the
experiments performed in (i) above showed that they gave
maximal changes in the expression of the 58-kDa selenoprotein.
Cells were then harvested and the expression of the 58-kDa
selenoprotein was monitored by autoradiography.
To control for any possible effects of DMSO, in which the
PMA and A23187 were dissolved, HUVECs were also incubated
with 0.05 % DMSO at each time point.
Effects of PMA and A23187 added alone and in combination on
the expression of the 58-kDa selenoprotein
The effects of PMA (0.5 x 10"K M) and A23187 (0.5 x 10"" M),
added individually or in combination, on the expression of the
58-kDa selenoprotein in HUVECs were investigated by the
inclusion of the compounds in the culture medium while the cells
were being labelled with [75Se]selenite for 35 h, as described
above. These conditions were chosen because they produced the
maximum changes in expression of the 58-kDa selenoprotein in
the presence of A23187. It was not possible to use time points in
excess of 35 h for these experiments as A23187 occasionally
caused some cell detachment if time periods were longer than
this. Pre-labelled cells were not used for this experiment, as the
incubation time (35 h) was sufficient to ensure steady-state
labelling of the selenoproteins.
Effects of GF109203X and PMA on expression of the 58-kDa
selenoprotein
Using cells pre-labelled to a steady state for 48 h with [75Se]selenite
(0.02 MBq/ml), the effect of the specific protein kinase C (PKC)
inhibitor GF109203X (4.5 x 10"' M) on the 58-kDa selenoprotein
expressed by HUVECs was studied in the presence and absence
of PMA (0.5 x 10"BM). After pre-labelling for 48 h, the culture
medium was removed from HUVECs and replaced with fresh
medium containing 0.02 MBq/ml [75Se]selenite. The GF109203X
(4.5 x 10"7M) was added to the culture medium 1 h prior to any
PMA additions. Previous studies have shown that PKC activity
is inhibited using these conditions [17]. After the PMA (0.5 x
10"6 M) addition, the HUVECs were incubated for a further 48 h
before the cells were harvested for detection of selenoprotein
expression by autoradiography.
Determination of protein
The protein content of the sonicated cells and extracellular
proteins was determined using the Bradford dye-binding method
using BSA standards [18],
RESULTS
Selenoproteins expressed by cell types
There were distinct differences in the ratios of the various
intracellular selenoproteins expressed between the cell types
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Figure 3 Autoradiograph of an SDS/PAGE gel showing the expression of
the 58-kDa selenoprotein in HUVECs incubated in the continued presence
of PMA (0.5 x 10'6 M) for various times
Confluent cultures of HUVECs pre-labelled for 48 h with 0.02 MBq/ml [75Se]selenite were used.
The effect of PMA on the expression of the 58-kDa selenoprotein was studied by including either
PMA (0.5 x 10~6 M) or DMSO (0.05%) in the culture medium for 1 min, 12 h, 48 h, 72 h or
96 h in the continued presence of 0.02 MBq/ml [75Se]selenite. Lane 1, PMA, 1 min; lane 2,
DMSO, 1 min; lane 3, PMA, 12 h; lane 4, DMSO, 12 h; lane 5, PMA, 48 h; lane 6, DMSO,
48 h; lane 7, PMA, 72 h; lane 8, DMSO, 72 h; lane 9, PMA, 96 h; lane 10, DMSO, 96 h. Each






Figure 1 Autoradiograph of an SDS/PAGE gel showing various human cell
types grown under basal conditions labelled with [75Se]selenite
(0.02 MBq/ml) for 48 h
Lane A, HUVECs; lane B, human thyrocytes; lane C, HepG2 cells. Each lane was loaded with
25 /i.g of protein.
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Figure 4 Autoradiograph of an SDS/PAGE gel showing the expression of
the 58-kDa selenoprotein in HUVECs incubated with PMA (0.5 x 10 s M) for
various times
Confluent cultures of HUVECs pre-labelled for 48 h with 0.02 MBq/ml [75Se]selenite were used.
The effect of PMA on the expression of the 58-kDa selenoprotein was studied by including either
PMA (0.5 x 10"6 M) or DMSO (0.05%) in the culture medium for 1 min, 10 min, 1 h or 12 h
in the continued presence of 0.02 MBq/ml [75Se]selenite. After each time point the medium was
removed, the cells were washed and fresh culture medium containing 0.02 MBq/ml [75Se]selenite
without PMA or DMSO was added. The cells were incubated lor a total incubation time of 48 h.
Lane 1, PMA, 1 min; lane 2, DMSO, 1 min; lane 3, PMA, 10 min; lane 4, DMSO, 10 min; lane
5, PMA, 1 h; lane 6, DMSO, 1 h; lane 7, PMA, 12 h; lane 8, DMSO, 12 h. Each lane was




Figure 2 Western blot of HUVECs using antiserum to TR
Cells were incubated for 35 h in the presence and absence of various agents, as specified, prior
to the Western blotting of cell lysates. Lanes 1-3, purified human TR standard (4, 2 and 1 ng
respectively); lane 4, no additions; lane 5, calcium ionophore A23187 (0.5 x 10~6 M); lane 6,
PMA (0.5 x 10"6 M); lane 7, A23187 (0.5 x 10~6 M) with PMA (0.5 x 10"6 M).
studied (Figure 1). In HUVEC preparations a single seleno¬
protein with a molecular mass of 58.1 + 1.0 kDa (mean + S.E.M.,
n = 5) dominated the selenoprotein profile accounting for
42.9+1.4% (n = 3) of the total intracellular ,r'Se-labellcd
proteins. Two other selenoproteins showed quite pronounced
labelling with [7r'Se]selenite, with calculated molecular masses of
21.7 + 0.5 (n — 5) and 24.4 + 0.5 kDa (n = 5). These two seleno¬
proteins accounted for 14.6+1.0% (n = 3) and 15.1+2.8%
(it = 3) of the intracellular 7r,Se-labelled selenoproteins, re¬
spectively. Western blotting identified the 21.7-kDa selenoprotein
as PHGPX (results not shown). Western blotting was also
attempted using antiserum to cyGPX but no immunoreactive
band was observed.
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In the human thyrocytes and HepG2 cells the 7r'Se-labelled 58-
kDa selenoprotein was not as prominent as that observed in the
75Se-labelled HUVECs (Figure 1). No significant 7r,Se-labelling
of any extracellular proteins was detected (results not shown).
Identification of the 58-kDa selenoprotein by Western blotting
Using antiserum to rat TR, the 58-kDa selenoprotein expressed
by HUVECs was identified by Western blotting as TR. HUVECs
expressed high concentrations of TR under basal conditions
(4.36 + 0.63 //g/mg, n = 3; Figure 2). TR concentrations in
HepG2 cells were approximately one-tenth of those found in
HUVECs. The Western blot was insufficiently sensitive to detect
TR in the thyrocytes grown in the basal state.
Time-dependent changes in expression of the 58-kDa
selenoprotein in HUVECs following exposure to PMA and A23187
for different times
The effects of both PMA and A23187 on the expression of the 58-
kDa selenoprotein were time-dependent. The continued presence
of PMA (0.5 x 10~6 M) significantly decreased the expression of
the 58-kDa selenoprotein. The down-regulation of this protein
was first apparent at 12 h, with the lowest level of expression seen
at 48 h (Figure 3). After 72 and 96 h of exposure, the expression
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Figure 5 Autoradiograph of an SDS/PAGE gel showing the expression of
the 58-kDa selenoprotein in HUVECs incubated with A23187 (0.5 x 10~6 M)
for various times
Confluent cultures of HUVECs were pre-labelled for 48 h with 0.02 MBq/ml [75Se]selenite. The
effect of A23187 on the expression of the 58-kDa selenoprotein was studied by including either
A23187 (0.5 x 10~6 M) or DMS0 (0.05%) in the culture medium for 1 min, 10 min, 1 h, 12 h
or 35 h in the continued presence of 0.02 MBq/ml [75Se]selenite. After each time point the
medium was removed, Ihe cells were washed and fresh culture medium containing 0.02 MBq/ml
[75Se]selenite without A23187 or DMS0 was added. The cells were incubated for a total
incubation time of 35 h. Lane 1, A23187,1 min; lane 2, DMSO, 1 min; lane 3, A23187,10 min;
lane 4, DMSO, 10 min; lane 5, A23187, 1 h; lane 6, DMSO, 1 h; lane 7, A23187,12 h; lane
8, DMSO, 12 h; lane 9, A23187, 35 h; lane 10, DMSO, 35 h. Into each lane, 25/eg of protein
was loaded.
of the 58-kDa selenoprotein started to rise but the level did not
return to the basal levels observed in the control DMSO-treated
HUVECs.
The continued presence ofA23187 (0.5 x 10_li M) in the culture
medium resulted in a significant induction of the 58-kDa ™Se-
labelled selenoprotein at 24 and 38 h (results not shown).
However, in some experiments, where HUVECs were exposed to
A23187 for 38 h and longer, cells started to detach from the
monolayer, suggesting possible toxic effects of the ionophore.
For all further experiments, a total incubation period of 35 h was
therefore chosen, as this allowed maximal induction of the 58-
kDa selenoprotein without any observable cell detachment.
Controls containing DMSO showed no significant change in
expression of the 58-kDa selenoprotein over the duration of the
experiments.
The effects of the shorter pulse times of exposure to PMA and
A23187 are shown in Figures 4 and 5. In HUVECs transiently
exposed to PMA (0.5 x ICC8 M) for 1 min-12 h, a decrease in the
expression of the 58-kDa selenoprotein was measured 48 h after
the initial exposure to PMA (Figure 4).
HUVECs exposed to A23187 (0.5 x lO"8 M) for 1 h showed a
slightly increased expression of the 58-kDa selenoprotein 35 h
later (Figure 5). The observed induction of this 58-kDa seleno¬
protein by A23187 was increased with exposure time such that
clear increases were observed after 12 h, with maximal induction
after 35 h of exposure.
Effects of PMA and A23187, added alone and in combination, on
the expression of the 58-kDa selenoprotein
The addition of PMA down-regulated the expression of the 58-
kDa [75Se]selenoprotein in HUVECs, whereas the addition of the
calcium ionophore A23187 alone significantly induced its ex¬
pression, as visualized by autoradiography (Figure 6). PMA and
A23187 added in combination produced an overall net increase
in the expression of the 58-kDa protein but the expression was
lower than that seen when A23187 was added alone.
Quantification of the 7r,Se-labelled 58-kDa selenoprotein using
the Molecular Imager System showed that treatment with PMA
decreased the expression of the 58-kDa band by between 43.5
and 50.7 % of basal levels (n = 2), whereas treatment with
A23187 increased the expression of the same band by 2.39-2.60-
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Figure 6 Autoradiograph of an SDS/PAGE gel of HUVECs labelled with
[75Se]selenite (0.02 MBq/ml) for 35 h in the presence and absence of
various agents
Lane A, no additions; lane B, calcium ionophore A23187 (0.5x1(T6M); lane C, PMA
(0.5 x 10"6 M); lane D, A23187 (0.5 x 1(T6 M) with PMA (0.5 x 10"6 M). Each lane was
loaded with 25 //g ol protein.
combination produced an overall increase in expression of
between 1.44- and 1.64-fold over basal levels (n = 2).
The effects of PMA and A23187 on the expression of the 58-
kDa selenoprotein were confirmed by Western blotting using the
anti-TR antibody (Figure 2). Western-blot analysis showed that
PMA significantly (P < 0.05, analysis of variance and test of
least significant difference) decreased TR expression in HUVECs
from 4.36 + 0.63//g/mg of protein (mean± S.E.M., n = 3),
expressed under basal conditions, to 2.97 ±0.27 //g/mg ofprotein
(/; = 3), a decrease of 29.6 + 9.7%. In contrast, A23187 signifi¬
cantly (P < 0.01) increased TR expression to 8.38 + 0.69 //g/mg
of protein (n = 3), a 1.96 + 0.13-fold increase over basal levels.
When HUVECs were treated with PMA and A23187 in com¬
bination there was a net increase in TR expression to
6.58 + 0.42 //g/mg of protein (n = 3), a 1.57 + 0.24-fold increase
over basal levels.
The addition of PMA and A23187 also had effects on some of
the other 75Se-labelled selenoproteins in HUVECs. For example,
treatment with PMA decreased the labelling of the 64- and 72-
kDa [75Se]selenoproteins. However, in the presence of A23187,
7r,Se-labelling of the 64-kDa selenoprotein increased, whereas
that of the 72-kDa selenoprotein was significantly attenuated.
Both PMA and A23187 down-regulated the expression of the 22-
kDa selenoprotein. The expression of the 24-kDa selenoprotein
was increased by PMA, whereas A23187 had no effect on the
expression of this selenoprotein (Figure 6).
© 1999 Biochemical Society
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Figure 7 Autoradiograph of an SDS/PAGE gel showing the expression of
the 58-kDa selenoprotein in HUVECs incubated with the PKC inhibitor
GF109203X (7.5 x 1(T7 M) and/or PMA (0.5 x HP6 M)
Confluent cultures of HUVECs pre-labelled for 48 h with 0.02 MBq/ml [75Se]selenite were used.
The effect of GF109203X and PMA on the expression of the 58-kDa selenoprotein was studied
by including GF109203X and PMA in the culture medium alone or in combination. GF109203X
was added 1 h prior to the 48-h PMA incubation in the continued presence of 0.02 MBq/ml
[75Se]selenite. Lanes 1 and 2, DMSO; lanes 3 and 4, GF109203X alone; lanes 5 and 6,
GF109203X and PMA; lanes 7 and 8, PMA alone. Each lane was loaded with 25 /tg of protein.
Effects of GF109203X and PMA on the expression of the 58-kDa
selenoprotein
Treatment of HUVECs with PMA (0.5 xlO-6 M) for 48 h
decreased the expression of the 58-kDa selenoprotein, as shown
in the previous experiments. Pre-incubation of HUVECs with
the PKC inhibitor GF109203X (4.5 x 10"7M) for 1 h prior to the
PMA addition attenuated the down-regulation of the 58-kDa
[7r'Se]selenite-labelled selenoprotein produced by PMA (Figure
7). No change in the expression of the 58-kDa selenoprotein was
observed when HUVECs were incubated with GF109203X alone.
DISCUSSION
HUVECs exhibit an intracellular selenoprotein profile that is
quite distinct from the other cells studied. We have found that
HUVECs show dominant expression of a [75Se]selenoprotein
with a molecular mass of 58 kDa (Figure 1). Using Western
blotting with antiserum characterized previously [8], we have
demonstrated that this 58-kDa selenoprotein is TR (Figure 2).
The expression of TR in HepG2 cells was found to be only
approx. one-tenth of that found in HUVECs. In human thyro-
cytes, its expression was so low that it could not be detected by
Western blotting, but 75Se-labelling experiments suggested that
TR expression in thyrocytes was approx. half of that seen in
HepG2 cells (Figure 1). These different patterns of expression
presumably underlie the requirement for different selenoproteins
to contribute to the specific functions of the different cell types.
TR is an FAD-containing homodimeric selenoenzyme, which,
together with thioredoxin as a substrate and NADPH as a
cofactor, forms a powerful dithiol-disulphide oxidoreductase
system that has multiple roles. The TR/thioredoxin system has
been associated with a number of cellular processes, including
regulation of cell growth and the modification of the activity of
transcription factors and receptors [19-21], TR expression is
regulated in cancer cells through selenium supply, which stabilizes
TR mRNA [21],
In addition, TR can reduce and detoxify lipid hydroperoxides,
hydrogen peroxides and organic hydroperoxides [22]. The ac¬
cumulation of these compounds in tissues exerts deleterious
effects. For example the hydroperoxide (155)-hydroperoxy-
(5Z),(8Z),1 l(Z),13(E)-eicosatetraenoic acid [(155)-HPETE]
oxidizes low-density lipoprotein to a form that under some
conditions renders the particle more toxic to the endothelium,
with implications in the pathogenesis of atherosclerosis [22]. TR
also appears to be more potent than the GPX system at
detoxifying (15S)-HPETE and other lipid hydroperoxides [22],
The data we have presented here show that the expression of
TR is far greater in HUVECs than the expression of the
selenoproteins with molecular masses of 22 and 24 kDa (Figure
1). The 22-kDa band was identified as PHGPX using Western-
blot analysis (results not shown). It was not possible to visualize
an immunoreactive band in HUVECs using antisera to cyGPX.
However, other groups have shown that HUVECs express
cyGPX [10] and exhibit GPX activity [2,3,5]. The molecular mass
of cyGPX has been reported to be in the range of 21-26 kDa
[23,24], which corresponds to the 24-kDa selenoprotein band we
have found in HUVECs. These observations suggest that the 24-
kDa selenoprotein expressed by HUVECs is cyGPX.
Thomas et al. [2] have suggested that selenite confers resistance
on ECs to oxidative injury by increasing expression of cyGPX
and PHGPX [2]. Whereas it is likely that these selenoperoxidases
do have an important role in preventing oxidative injury to the
ECs, our observations concerning TR expression raise the
possibility that this reductase may be more important than
the peroxidases in the protection of the endothelium against
oxidative damage. The molecular mass of TR appears greater
in HUVECs than that of PHGPX (22-kDa selenoprotein) and
cyGPX (24-kDa selenoprotein) (Figure 1) and TR can detoxify
many lipid hydroperoxides more efficiently than the GPXs [22].
TR may also have effects on other antioxidant systems in ECs;
it can induce manganese superoxide dismutase [25] and regenerate
ascorbate from dehydroascorbate [26].
We have shown that the addition of the phorbol ester PMA
and the calcium ionophore A23187 have significant effects on the
expression of TR. Exposure of HUVECs to PMA for times as
short as 1 min decreased TR expression by approx. 30%.
However, changes in TR expression were only seen 48 h after the
short exposure to PMA. A similar degree of down-regulation of
TR was seen when the exposure time of HUVECs to PMA was
as long as 48 h. However, if cells were exposed to PMA for times
in excess of 48 h the effect of the PMA on TR expression was
diminished. These observations suggest that the down-regulation
ofTR by PMA arises by activation of PKC rather than resulting
from desensitization of PKC. However, if PMA was present for
times in excess of 48 h it seems likely that PKC desensitization
does occur, as reported previously in studies using long-term
exposures to PMA [27,28],
Our experiments using the PKC inhibitor GF109203X
produced further evidence that increased TR expression in
response to PMA is not the result of desensitization of PKC.
GF109203X added alone had no effect on TR expression but
when added with PMA the PKC inhibitor attenuated the effect
of PMA on down-regulating TR. Overall, our results suggest
that TR expression in HUVECs can be down-regulated by
activation of PKC by PMA. This contrasts with human thyro¬
cytes and HepG2 cells where PMA produces an increase in TR
expression [8].
The addition of A23187 increased the expression of TR
1.96 ±0.13-fold over basal levels in HUVECs (Figure 2). Similar
effects of the ionophore on TR expression have also been reported
in human thyrocytes and HepG2 cells [8]. A23187 increases
intracellular calcium levels but it may also act as an uncoupler of
oxidative phosphorylation and as an inhibitor of mitochondrial
ATPase activity. The A23187-induced cGMP response in ECs
occurs rapidly following treatment with A23187 and reaches a
plateau within 3 min [29], However, our studies have shown that
clear increases in the expression of TR only occur when A23187
is present in the culture medium for periods in excess of 12 h.
This suggests that regulation of TR in the presence of A23187 in
HUVECs may not be the result of calcium signalling but rather
the result of a stress effect produced by A23187 on the HUVECs.
© 1999 Biochemical Society
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If A23187 was acting through a calcium response it would
appear that, in HUVECs, the two branches of the Ca2+/
phosphinositol signalling pathway are acting antagonistically.
There are other examples in ECs where this is also the case. For
example, constitutive nitric oxide synthase activity in ECs is
stimulated by A23187, but the subsequent A23187-induced nitrite
release is inhibited by PKC activation by the phorbol ester PMA
[30].
The activation of PKC through oxidized low-density lipo¬
protein has been implicated in vascular disease [31] and we have
shown that PKC activation may also give rise to a decrease in TR
expression. Since TR may have an antioxidant function within
the EC, down-regulation ofTR by this mechanism may diminish
the antioxidant capacity of ECs and render the cell prone to
oxidative damage and to the development of atheroma.
In our culture system, HUVECs do not secrete extracellular
selenoproteins. This contrasts with human thyrocytes, which
secrete a 24-kDa selenoprotein identified as EGPX [9]. The
vascular endothelium thus appears to make no contribution to
the circulating pool of EGPX or selenoprotein P, another
extracellular selenoprotein that may have antioxidant properties
[32]. Thus it would seem that the selenoprotein P found bound to
ECs is unlikely to have originated from synthesis within these
cells, but rather that it is synthesized in other tissues such as
kidney and released into plasma [7].
In conclusion, HUVECs, unlike other human cell types
examined, express high levels of TR, a selenoprotein that has the
potential to detoxify hydrogen peroxide and lipid hydroperoxides
[22], regenerate ascorbate [26], promote superoxide dismutase
activity, maintain cell redox state and influence the activity of the
transcription factors of a number of important genes [19-21]. TR
may thus be an important factor in the known ability of selenium
to protect HUVECs from oxidative damage.
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